



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2022/01/24
(87) Date publication PCT/PCT Publication Date: 2023/03/30
(85) Entrée phase nationale/National Entry: 2024/03/21
(86) N° demande PCT/PCT Application No.: US 2022/013513
(87) N° publication PCT/PCT Publication No.: 2023/048759
(30) Priorités/Priorities: 2021/09/22 (US63/247,169);
2022/01/07 (US63/297,397)

(51) Cl.Int./Int.Cl. *C07K 14/005* (2006.01),
A61K 47/10 (2017.01), *A61K 47/20* (2006.01),
A61K 47/26 (2006.01), *A61P 31/14* (2006.01),
C12N 15/86 (2006.01)
(71) Demandeur/Applicant:
HDT BIO CORP., US
(72) Inventeurs/Inventors:
REED, STEVEN GREGORY, US;
CARTER, DARRICK ALBERT, US;
KHANDHAR, AMIT PRAFUL, US;
DUTHIE, MALCOLM S., US;
BERGLUND, LARS PETER ASKEL, US;
ERASMUS, JESSE, US; ...

(54) Titre : COMPOSITIONS DE VACCIN A ARN SRAS-COV-2 ET PROCEDES D'UTILISATION
(54) Title: SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE




FIG. 1

(57) Abrégé/Abstract:

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Methods of using the compositions as a COVID-19 vaccine for the treatment of a coronavirus infection are also provided.

(72) **Inventeurs(suite)/Inventors(continued):** BERUBE, BRYAN, US; ARCHER, JACOB FREEMAN, US

(74) **Agent:** GOWLING WLG (CANADA) LLP

Date Submitted: 2024/03/21

CA App. No.: 3232719

Abstract:

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Methods of using the compositions as a COVID-19 vaccine for the treatment of a coronavirus infection are also provided.

SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE

CROSS-REFERENCE

[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63/247,169, filed September 22, 2021, and U.S. Provisional Patent Application No. 63/297,397, filed January 7, 2022, the contents of each of which is incorporated herein by reference in their entirety.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

[0002] This invention was made with government support under contracts 75N93020C00052 and 75N93019C00037 awarded by the National Institute of Allergy and Infectious Diseases, Division of Microbiology and Infectious Diseases. The government has certain rights in the invention.

SEQUENCE LISTING

[0003] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on January 21, 2021, is named 201953-713601_SL.txt and is 372,976 bytes in size.

BACKGROUND

[0004] COVID-19 is an infectious respiratory illness caused by the severe acute respiratory syndrome–corona virus 2 (SARS-CoV-2), which has spread across the world. Commercially available mRNA vaccines provide some protection against COVID-19 disease in individuals infected with SARS-CoV-2, the virus is still highly transmissible and can cause a wide array of symptoms even in vaccinated individuals that become infected. Furthermore, SARS-CoV-2 is known to mutate and the effectiveness of vaccines against current and new variants of SARS-CoV-2 are still being determined. Thus, there is a great need for vaccine compositions that are highly effective against SARS-CoV-2 infections.

BRIEF SUMMARY

[0005] Provided herein are compositions, wherein the compositions comprise a lipid carrier, wherein the lipid carrier comprises: liquid oil; and surfactants, wherein the surfactants comprise: a cationic lipid; a hydrophilic surfactant; and a hydrophobic surfactant; and at least one nucleic

acid, wherein the at least one nucleic acid comprises a sequence at least 85% identical to SEQ ID NOS: 1 to 7, optionally SEQ ID NOS: 1 to 8.

[0006] Further provided herein are compositions, wherein the compositions comprise a lipid carrier, wherein the lipid carrier comprises: liquid oil; and surfactants, wherein the surfactants comprise: a cationic lipid; a hydrophilic surfactant; and a hydrophobic surfactant; and at least one nucleic acid, wherein the nucleic acid comprises a sequence encoding for a SARS-CoV-2 omicron variant spike protein antigen sequence or functional variant thereof.

[0007] Further provided herein are compositions, wherein the compositions comprise a lipid carrier, wherein the lipid carrier comprises: liquid oil; and surfactants, wherein the surfactants comprise: a cationic lipid; a hydrophilic surfactant; and a hydrophobic surfactant; and at least one nucleic acid, wherein the nucleic acid comprises a sequence encoding for a S2 region, optionally a stem helix region, of SARS-CoV-2 spike protein antigen sequence or functional variant thereof.

[0008] Further provided herein are compositions, wherein the compositions comprise a lipid carrier, wherein the lipid carrier comprises: liquid oil; an inorganic nanoparticle, wherein the inorganic nanoparticle comprises iron oxide present in an amount of about 0.2 mg/ml 12 nm iron oxide; and surfactants, wherein the surfactants comprise a cationic lipid; and at least one nucleic acid, wherein the nucleic acid comprises a sequence encoding for a SARS-CoV-2 spike protein antigen sequence or functional variant thereof.

[0009] Further provided herein are compositions, wherein the compositions comprise a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising: about 30 mg/mL DOTAP chloride; about 37.5 mg/mL squalene; about 37 mg/ml sorbitan monostearate; about 37 mg/ml polysorbate 80; about 10 mM sodium citrate; and about 0.2 mg Fe/ml 12 nm oleic acid-coated iron oxide nanoparticles; and at least one nucleic acid, wherein the at least one nucleic acid comprises a sequence encoding for a SARS-CoV-2 spike protein antigen sequence or functional variant thereof.

[0010] Further provided herein are compositions, wherein the compositions comprise a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising: DOTAP chloride present in an amount of about 0.75 mg; squalene present in an amount of about 0.94 mg; sorbitan monostearate present in an amount of about 0.93 mg; polysorbate 80 present in an amount of about 0.93 mg; citric acid monohydrate present in an amount of about 1.05 mg; oleic acid-coated iron oxide nanoparticles present in an amount of about 0.005 mg; and at least one nucleic acid,

wherein the at least one nucleic acid comprises a sequence encoding for a SARS-CoV-2 spike protein antigen sequence or functional variant thereof.

[0011] Further provided herein are compositions, wherein the compositions comprise: a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids, and at least one nucleic acid sequence, wherein the nucleic acid sequence comprises a sequence which encodes an antigen, wherein the antigen is a SARS-CoV-2 spike protein. Further provided herein are vaccines comprising: a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids, and at least one nucleic acid sequence, wherein the nucleic acid sequence comprises a sequence which encodes an antigen, wherein the antigen is a SARS-CoV-2 spike protein.

[0012] Further provided herein are methods of generating an immune response in a subject, the methods comprising: administering to a subject a composition provided herein thereby generating an immune response to an antigen.

[0013] Further provided herein are methods of reducing the severity of a SARS-CoV-2 infection, the methods comprising: administering prior to infection a composition provided herein.

[0014] Further provided herein are methods of augmenting an immune response in a subject, the method comprising: administering to a subject the composition provided herein, thereby augmenting an immune response to an antigen.

[0015] Further provided herein are methods of treating a coronavirus infection, the method comprising: administering to a subject the composition provided herein, thereby treating the coronavirus infection.

[0016] Further provided herein are methods of immunoprotecting a subject, the methods comprise administering to a subject a composition or a vaccine provided herein.

[0017] Further provided herein are compositions for immunoprotecting a subject, the compositions comprise: a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids, and at least one nucleic acid sequence, wherein the nucleic acid sequence comprises a sequence which encodes an antigen, wherein the antigen is a SARS-CoV-2 spike protein.

[0018] Provided herein are dried compositions, the dried compositions comprising: a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids, at least one nucleic acid sequence, wherein the

nucleic acid sequence comprises a sequence which encodes an antigen, wherein the antigen is a SARS-CoV-2 spike protein, and at least one cryoprotectant.

[0019] Further provided herein are methods for preparing a lyophilized composition, the methods comprising: obtaining a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids, incorporating at least one nucleic acid into the lipid carrier to form a lipid carrier- nucleic acid complex, adding at least one cryoprotectant to the lipid carrier-nucleic acid complex to form a formulation, and lyophilizing the formulation to form a lyophilized composition.

[0020] Further provided herein are methods for preparing a spray-dried composition, the methods comprising: obtaining a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids, incorporating at least one nucleic acid into the lipid carrier to form a lipid carrier- nucleic acid complex, adding at least one cryoprotectant to the lipid carrier-nucleic acid complex to form a formulation, and spray drying the formulation to form a spray-dried composition.

[0021] Further provided herein are methods for reconstituting a lyophilized composition, the methods comprising: (a) obtaining a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles, and one or more lipids; (b) incorporating at least one nucleic acid into the said lipid carrier to form a lipid carrier-nucleic acid complex, adding at least one cryoprotectant to the lipid carrier-nucleic acid complex to form a formulation; (c) lyophilizing the formulation to form a lyophilized composition, and reconstituting the lyophilized composition in a suitable diluent.

[0022] Further provided herein are methods for reconstituting a spray-dried composition, the methods comprising: (a) obtaining a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles, and one or more lipids; (b) incorporating at least one nucleic acid into the said lipid carrier to form a lipid carrier-nucleic acid complex; (c) adding at least one cryoprotectant to the lipid carrier-nucleic acid complex to form a formulation; (d) spray drying the formulation to form a spray-dried composition; and (e) reconstituting the spray-dried composition in a suitable diluent.

[0023] Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the compositions comprise: (a) a sorbitan fatty acid ester; (b) an ethoxylated sorbitan ester; (c) a cationic lipid; (d) an immune stimulant; and (e) at least one RNA molecule.

[0024] Further provided herein are compositions for prophylaxis of SARS-CoV-2 wherein the compositions comprise: (a) sorbitan monostearate (*e.g.*, SPAN® 60); (b) polysorbate 80 (*e.g.*, TWEEN® 80); (c) DOTAP; (d) an immune stimulant; and (e) at least one RNA molecule.

[0025] Further provided herein are dried compositions comprising: a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, and one or more lipids; at least one nucleic acid that comprises a sequence which encodes a sequence capable of expressing an antigen, optionally wherein the antigen is a SARS-CoV-2 spike protein or a functional variant thereof; and at least one sugar present in amount of (i) at least about 50% by weight of the dried composition, or (ii) present in an amount of least 50 mg.

[0026] Further provided are compositions, wherein the composition comprises: a first nucleic acid comprising a sequence encoding for an RNA-dependent RNA polymerase; and a second nucleic acid comprising a sequence encoding for a SARS-CoV-2 antigen sequence.

[0027] Further provided are compositions, wherein the composition comprises: a first nucleic acid comprising a sequence encoding for an RNA-dependent RNA polymerase; and a second nucleic acid sequence encoding for a SARS-CoV-2 antigen spike sequence.

[0028] Further provided are compositions, wherein the composition comprises: a first nucleic acid comprising sequence encoding for an RNA-dependent RNA polymerase; and a second nucleic acid comprising sequence encoding for a SARS-CoV-2 omicron antigen sequence.

[0029] Further provided here are compositions, wherein the compositions comprise: a first nucleic acid comprising sequence encoding for an RNA-dependent RNA polymerase; and a second nucleic acid comprising sequence encoding for a SARS-CoV-2 spike S2 sequence region, optionally a stem helix region.

[0030] Further provided herein are kits comprising a composition provided herein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0031] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

[0032] **FIGURE 1** shows repRNA constructs disclosed herein. Schematic representations of the SARS-CoV-2 spike are shown with the signal peptide (sp), S1 and S2 domains,

transmembrane domain (TM), and cytoplasmic domain (CD) indicated. The repRNAs are identified as **SEQ ID NO: 1** encoding the A.1 spike, B.1 spike, **SEQ ID NO: 2** encoding the A.1. pre-fusion stabilized spike, B.1 pre-fusion stabilized spike, **SEQ ID NO: 5** encoding the B.1.1.7 pre-fusion stabilized spike; and **SEQ ID NO: 4** encoding the B.1.351 pre-fusion stabilized spike. Mutations are shown relative to the A.1 strain (**SEQ ID NO: 1**).

[0033] **FIGURE 2** shows the effect of spike modifications on binding antibody responses in mice. C57BL/6 mice (n = 5/group) were immunized with lipid carrier-formulated repRNA encoding the wild-type (WT), the prefusion-stabilized (PreF), the furin cleavage site-deleted (Fur_{mut}), or a combination of the PreF and Fur_{mut} modifications of the full-length spike of A.1 lineage SARS-CoV-2. Vaccinations were administered on days 0 and 28, and serum collected on days 14, 28, and 38 assayed for anti-spike binding IgG by enzyme linked immunosorbent assay.

[0034] **FIGURES 3A-3C** show schematic representations of exemplary nanoparticle (NP) carriers. **FIG. 3A** shows an oil-in-water emulsion. **FIG. 3B** shows a nanostructured lipid carrier (NLC). **FIG. 3C** shows a nanoparticle having an inorganic nanoparticle in liquid oil.

[0035] **FIGURES. 4A-4B** show the increased protein production induced by the Miglyol lipid carrier formulation, NP-3. **FIG. 4A** shows the first assay. **FIG. 4B** shows the second assay.

[0036] **FIGURES 5A-5B** show the decreased immune response induced by the Miglyol lipid carrier formulation, NP-3. **FIG. 5A** shows the first assay. **FIG. 5B** shows the second assay.

[0037] **FIGURES 6A-6B** show the correlation between enhanced protein production and low TNF (*e.g.*, TNF alpha) stimulation observed with NP-3 as a result of the first and second assays. **FIG. 6A** shows the first assay. **FIG. 6B** shows the second assay.

[0038] **FIGURES 7A-7F** show SEAP levels in BALB/c mice injected intramuscularly with various embodiments of lipid carrier formulations described herein. **FIG. 7A** shows SEAP levels on day 4 post-injection. **FIG. 7B** shows SEAP levels on day 6 post-injection. **FIG. 7C** shows SEAP levels on day 8 post-injection. **FIG. 7D** shows SEAP levels on day 4 post-injection. **FIG. 7E** shows SEAP levels on day 6 post-injection. **FIG. 7F** shows SEAP levels on day 8 post-injection. X-axis: Condition, Y-axis: Relative light units (RLU).

[0039] **FIGURE 8** is a bar chart with measurements of Z-average measurement and polydispersity index (PDI) on the Y-axis and group number on the X-axis for conditions 1 to 14.

[0040] **FIGURES 9A-9B** show dot charts showing anti-D614G IgG levels for conditions 1 to 14. **FIG. 9A** shows a dot chart with IgG (μg/ml) on the Y-axis, group number on the X-axis for conditions 1 to 14. Measurements were recorded at day 14 for anti-D614G (1:40 dilution)

IgG responses. **FIG. 9B** shows a dot chart with IgG ($\mu\text{g/ml}$) on the Y-axis, group number on the X-axis for conditions 1 to 14. Measurements were recorded at day 28 for anti-D614G (1:200 dilution) IgG responses.

[0041] **FIGURE 10** shows a dot chart at day 28 with anti-D614G (1:200 dilution) IgG ($\mu\text{g/ml}$) measurements on the Y-axis and indications of storage conditions on the X-axis.

[0042] Various aspects now will be described more fully hereinafter. Such aspects may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey its scope to those skilled in the art.

DETAILED DESCRIPTION OF THE INVENTION

[0043] Provided herein are compositions, kits, methods, and uses thereof for inducing an immune response to a coronavirus. Briefly, further described herein are (1) nanoparticle carrier systems; (2) nucleic acids encoding for coronavirus antigens and RNA polymerases; (3) combination compositions; (4) thermally stable, dried, and lyophilized SARS-CoV-2 RNA vaccines; (5) pharmaceutical compositions; (6) dosing; (7) administration; (8) therapeutic applications; and (9) kits.

Definitions

[0044] All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, and/or ordinary meanings of the defined terms.

[0045] All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document. All references disclosed herein, including patent references and non-patent references, are hereby incorporated by reference in their entirety as if each was incorporated individually. However, where a patent, patent application, or publication containing express definitions is incorporated by reference, those express definitions should be understood to apply to the incorporated patent, patent application, or publication in which they are found, and not necessarily to the text of this application, in particular the claims of this application, in which instance, the definitions provided herein are meant to supersede.

[0046] The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.”

[0047] The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and/or B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

[0048] As used herein in the specification and in the claims, “or” should be understood to have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (*i.e.*, “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.

[0049] As used herein, “optional” or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not.

[0050] As used herein, the term “about” or “approximately” means a range of up to $\pm 20\%$, of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated, the term “about” is implicit and in this context means within an acceptable error range for the particular value.

[0051] The term “effective amount” or “therapeutically effective amount” refers to an amount that is sufficient to achieve or at least partially achieve the desired effect.

Nanoparticle Carrier Systems

[0052] Provided herein are various compositions comprising a nanoparticle or a plurality of nanoparticles. Nanoparticles also referred to herein as carriers or abbreviated as NPs. Nanoparticles provided herein may be an organic, inorganic, or a combination of inorganic and organic materials that are less than about 1 micrometer (μm) in diameter. In some embodiments, nanoparticles provided herein are used as a delivery system for a bioactive agent provided herein.

[0053] Various nanoparticles and formulations of nanoparticles (i.e., nanoemulsions) are employed. Exemplary nanoparticles are illustrated in **FIGS. 3A-3C**. Nanoparticles provided herein can include but are not limited to: oil in water emulsions, nanostructured lipid carriers (NLCs), cationic nanoemulsions (CNEs), vesicular phospholipid gels (VPG), polymeric nanoparticles, cationic lipid nanoparticles, liposomes, gold nanoparticles, solid lipid protein nanoparticles, polyethylenimine nanoparticles (LNPs or SLNs), mixed phase core NLCs, ionizable lipid carriers, magnetic carriers, polyethylene glycol (PEG)-functionalized carriers, cholesterol-functionalized carriers, polylactic acid (PLA)-functionalized carriers, and polylactic-co-glycolic acid (PLGA)-functionalized lipid carriers.

[0054] Oil in water emulsions, as illustrated in **FIG. 3A** (not to scale), are stable, immiscible fluids containing an oil droplet dispersed in water or aqueous phase. **FIG. 3B** (not to scale) illustrates a nanostructured lipid carrier (NLCs) which can comprise a blend of solid organic lipids (e.g., trimyristin) and liquid oil (e.g., squalene). In NLCs, the solid lipid is dispersed in the liquid oil. The entire nanodroplet is dispersed in the aqueous (water) phase. In some embodiments, the nanoparticle comprises inorganic nanoparticles, as illustrated in **FIG. 3C** (not to scale), as solid inorganic nanoparticles (e.g., iron oxide nanoparticles) dispersed in liquid oil. The entire nanodroplet is then dispersed as a colloid in the aqueous (water) phase. In some embodiments, the nanoparticles provided herein are dispersed in an aqueous solution. Non-limiting examples of aqueous solutions include water (e.g., sterilized, distilled, deionized, ultra-pure, RNase-free, etc.), saline solutions (e.g., Krebs's, Ascaris, Dent's, Tet's saline), or 1% (w/v) dimethyl sulfoxide (DMSO) in water.

[0055] In some embodiments, the nanoparticles provided herein comprise a hydrophilic surface. In some embodiments, the hydrophilic surface comprises a cationic lipid. In some embodiments, the hydrophilic surface comprises an ionizable lipid. In some embodiments, the

nanoparticle comprises a membrane. In some embodiments, the membrane comprises a cationic lipid. In some embodiments, the nanoparticles provided herein comprise a cationic lipid. Exemplary cationic lipids for inclusion in the hydrophilic surface include, without limitation: 1,2-dioleoyloxy-3 (trimethylammonium)propane (DOTAP), 3 β -[N— (N',N'-dimethylaminoethane) carbamoyl]cholesterol (DC Cholesterol), dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl 3-trimethylammoniumpropane(DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), N-[1-(2,3-dioleoyloxy)propyl]N,N,N-trimethylammonium, chloride (DOTMA), N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), and 1,2- dilinoleyloxy-3-dimethylaminopropane (DLinDMA), 1,1'-((2-(4-(2-((2-(bis(2-hydroxy-dodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), 306Oi10, tetrakis(8-methylnonyl) 3,3',3'',3'''-(((methylazanediyl) bis(propane-3,1 diyl))bis(azanetriyl))tetrapropionate, 9A1P9, decyl (2-(dioctylammonio)ethyl) phosphate; A2-Iso5-2DC18, ethyl 5,5-di((Z)-heptadec-8-en-1-yl)-1-(3-(pyrrolidin-1-yl)propyl)-2,5-dihydro-1H-imidazole-2-carboxylate; ALC-0315, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); ALC-0159, 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide; β -sitosterol, (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5R)-5-ethyl-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; BAME-O16B, bis(2-(dodecylsulfanyl)ethyl) 3,3'-((3-methyl-9-oxo-10-oxa-13,14-dithia-3,6-diazahexacosyl)azanediyl)dipropionate; BHEM-Cholesterol, 2-((((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)amino)-N,N-bis(2-hydroxyethyl)-N-methylethan-1-aminium bromide; cKK-E12, 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione; DC-Cholesterol, 3 β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol; DLin-MC3-DMA, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino) butanoate; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOSPA, 2,3-dioleoyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; ePC, ethylphosphatidylcholine; FTT5, hexa(octan-3-yl) 9,9',9'',9''',9''''-(((benzene-1,3,5-tricarbonyl)tris(azanediyl)) tris (propane-3,1-diyl)) tris(azanetriyl))hexanonanoate; Lipid H (SM-102), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-

6-(undecyloxy)hexyl)amino) octanoate; OF-Deg-Lin, (((3,6-dioxopiperazine-2,5-diyl)bis(butane-4,1-diyl))bis(azanetriyl))tetrakis(ethane-2,1-diyl) (9Z,9'Z,9''Z,9'''Z,12Z,12'Z,12''Z,12'''Z)-tetrakis (octadeca-9,12-dienoate); PEG2000-DMG, (R)-2,3-bis(myristoyloxy)propyl-1-(methoxy poly(ethylene glycol)2000) carbamate; TT3, or N1,N3,N5-tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide. Other examples for suitable classes of lipids include, but are not limited to, the phosphatidylcholines (PCs), phosphatidylethanolamines (PEs), phosphatidylglycerol (PGs); and PEGylated lipids including PEGylated version of any of the above lipids (*e.g.*, DSPE-PEGs). In some embodiments, the nanoparticle provided herein comprises DOTAP.

[0056] In some embodiments, the nanoparticle provided herein comprises an oil. In some embodiments, the oil is in liquid phase. Non-limiting examples of oils that can be used include α -tocopherol, coconut oil, dihydroisqualene (DHIS), farnesene, grapeseed oil, lauroyl polyoxylglyceride, mineral oil, monoacylglycerol, palmkernel oil, olive oil, paraffin oil, peanut oil, propolis, squalene, squalane, solanesol, soy lecithin, soybean oil, sunflower oil, a triglyceride, or vitamin E. In some embodiments, the nanoparticle provided herein comprises a triglyceride. Exemplary triglycerides include but are not limited to: capric triglycerides, caprylic triglycerides, a caprylic and capric triglycerides, triglyceride esters, and myristic acid triglycerins.

[0057] In some embodiments, the nanoparticles provided herein comprise a liquid organic material and a solid inorganic material. In some embodiments, the nanoparticle provided herein comprises an inorganic particle. In some embodiments, the inorganic particle is a solid inorganic particle. In some embodiments, the nanoparticle provided herein comprises the inorganic particle within the hydrophobic core.

[0058] In some embodiments, the nanoparticle provided herein comprises a metal. In some embodiments, the nanoparticle provided herein comprises a metal within the hydrophobic core. The metal can be without limitation, a metal salt such as a transition metal salt, a metal oxide such as a transition metal oxide, a metal hydroxide such as a transition metal hydroxide, a metal phosphate such as a transition metal phosphate, or a metalloid (*e.g.*, silicon and silicon-based compounds or alloys). In some embodiments, the nanoparticle provided herein comprises aluminum oxide (Al_2O_3), aluminum oxyhydroxide, iron oxide (Fe_3O_4 , Fe_2O_3 , FeO , or combinations thereof), titanium dioxide, silicon dioxide (SiO_2), aluminum hydroxyphosphate ($\text{Al}(\text{OH})_x(\text{PO}_4)_y$), calcium phosphate ($\text{Ca}_3(\text{PO}_4)_2$), calcium hydroxyapatite ($\text{Ca}_{10}(\text{PO}_4)_6(\text{OH})_2$), iron gluconate, or iron sulfate. The inorganic particles may be formed from one or more same or

different metals (any metals including transition metal). In some embodiments, the inorganic particle is a transition metal oxide. In some embodiments, the transition metal is magnetite (Fe_3O_4), maghemite ($\gamma\text{-Fe}_2\text{O}_3$), wüstite (FeO), or hematite (alpha (α)- Fe_2O_3). In some embodiments, the metal is aluminum hydroxide or aluminum oxyhydroxide, and a phosphate-terminated lipid or a surfactant, such as oleic acid, oleylamine, SDS, TOPO or DSPA is used to coat the inorganic solid nanoparticle before it is mixed with the liquid oil to form the hydrophobic core. In some embodiments, the metal can comprise a paramagnetic, a superparamagnetic, a ferrimagnetic or a ferromagnetic compound. In some embodiments, the metal is a superparamagnetic iron oxide (Fe_3O_4).

[0059] In some embodiments, the nanoparticle provided herein comprises a cationic lipid, an oil, and an inorganic particle. In some embodiments, the nanoparticle provided herein comprises DOTAP; squalene and/or glyceryl trimyristate-dynasan; and iron oxide. In some embodiments, the nanoparticle provided herein further comprises a surfactant. Thus, in some embodiments, the nanoparticles provided herein comprise a cationic lipid, an oil, an inorganic particle, and a surfactant.

[0060] Surfactants are compounds that lower the surface tension between two liquids or between a liquid and a solid component of the nanoparticles provided herein. Surfactants can be hydrophobic, hydrophilic, or amphiphilic. In some embodiments, the nanoparticle provided herein comprises a hydrophobic surfactant. Exemplary hydrophobic surfactants that can be employed include but are not limited to: sorbitan monolaurate (SPAN® 20), sorbitan monopalmitate (SPAN® 40), sorbitan monostearate (SPAN® 60), sorbitan tristearate (SPAN® 65), sorbitan monooleate (SPAN® 80), and sorbitan trioleate (SPAN® 85). Suitable hydrophobic surfactants include those having a hydrophilic-lipophilic balance (HLB) value of 10 or less, for instance, 5 or less, from 1 to 5, or from 4 to 5. For instance, the hydrophobic surfactant can be a sorbitan ester having an HLB value from 1 to 5, or from 4 to 5.

[0061] In some embodiments, the nanoparticle provided herein comprises a hydrophilic surfactant, also called an emulsifier. In some embodiments, the nanoparticle provided herein comprises polysorbate. Polysorbates are oily liquids derived from ethoxylated sorbitan (a derivative of sorbitol) esterified with fatty acids. Exemplary hydrophilic surfactants that can be employed include but are not limited to: polysorbates such as TWEEN®, Kolliphor, Scattics, Alkest, or Canarcel; polyoxyethylene sorbitan ester (polysorbate); polysorbate 80 (polyoxyethylene sorbitan monooleate, or TWEEN® 80); polysorbate 60 (polyoxyethylene sorbitan monostearate, or TWEEN® 60); polysorbate 40 (polyoxyethylene sorbitan

monopalmitate, or TWEEN® 40); and polysorbate 20 (polyoxyethylene sorbitan monolaurate, or TWEEN® 20). In one embodiment, the hydrophilic surfactant is polysorbate 80.

[0062] Nanoparticles provided herein comprises a hydrophobic core surrounded by a lipid membrane (*e.g.*, a cationic lipid such as DOTAP). In some embodiments, the hydrophobic core comprises: one or more inorganic particles; a phosphate-terminated lipid; and a surfactant.

[0063] Inorganic solid nanoparticles described herein may be surface modified before mixing with the liquid oil. For instance, if the surface of the inorganic solid nanoparticle is hydrophilic, the inorganic solid nanoparticle may be coated with hydrophobic molecules (or surfactants) to facilitate the miscibility of the inorganic solid nanoparticle with the liquid oil in the “oil” phase of the nanoemulsion particle. In some embodiments, the inorganic particle is coated with a capping ligand, the phosphate-terminated lipid, and/or the surfactant. In some embodiments the hydrophobic core comprises a phosphate-terminated lipid. Exemplary phosphate-terminated lipids that can be employed include but are not limited to: trioctylphosphine oxide (TOPO) or distearyl phosphatidic acid (DSPA). In some embodiments, the hydrophobic core comprises a surfactant such as a phosphorous-terminated surfactant, a carboxylate-terminated surfactant, a sulfate-terminated surfactant, or an amine-terminated surfactant. Typical carboxylate-terminated surfactants include oleic acid. Typical amine terminated surfactants include oleylamine. In some embodiments, the surfactant is distearyl phosphatidic acid (DSPA), oleic acid, oleylamine or sodium dodecyl sulfate (SDS). In some embodiments, the inorganic solid nanoparticle is a metal oxide such as an iron oxide, and a surfactant, such as oleic acid, oleylamine, SDS, DSPA, or TOPO, is used to coat the inorganic solid nanoparticle before it is mixed with the liquid oil to form the hydrophobic core.

[0064] In some embodiments, the hydrophobic core comprises: one or more inorganic particles containing at least one metal hydroxide or oxyhydroxide particle optionally coated with a phosphate- terminated lipid, a phosphorous-terminated surfactant, a carboxylate- terminated surfactant, a sulfate-terminated surfactant, or an amine-terminated surfactant; and a liquid oil containing naturally occurring or synthetic squalene; a cationic lipid comprising DOTAP; a hydrophobic surfactant comprising a sorbitan ester selected from the group consisting of: sorbitan monostearate, sorbitan monooleate, and sorbitan trioleate; and a hydrophilic surfactant comprising a polysorbate.

[0065] In some embodiments, the hydrophobic core comprises: one or more inorganic nanoparticles containing aluminum hydroxide or aluminum oxyhydroxide nanoparticles optionally coated with TOPO, and a liquid oil containing naturally occurring or synthetic

squalene; the cationic lipid DOTAP; a hydrophobic surfactant comprising sorbitan monostearate; and a hydrophilic surfactant comprising polysorbate 80.

[0066] In some embodiments, the hydrophobic core consists of: one or more inorganic particles containing at least one metal hydroxide or oxyhydroxide particle optionally coated with a phosphate-terminated lipid, a phosphorous-terminated surfactant, a carboxylate-terminated surfactant, a sulfate-terminated surfactant, or an amine-terminated surfactant; and a liquid oil containing naturally occurring or synthetic squalene; a cationic lipid comprising DOTAP; a hydrophobic surfactant comprising a sorbitan ester selected from the group consisting of: sorbitan monostearate, sorbitan monooleate, and sorbitan trioleate; and a hydrophilic surfactant comprising a polysorbate. In some embodiments, the hydrophobic core consists of: one or more inorganic nanoparticles containing aluminum hydroxide or aluminum oxyhydroxide nanoparticles optionally coated with TOPO, and a liquid oil containing naturally occurring or synthetic squalene; the cationic lipid DOTAP; a hydrophobic surfactant comprising sorbitan monostearate; and a hydrophilic surfactant comprising polysorbate 80. In some embodiments, the nanoparticle provided herein can comprise from about 0.2% to about 40% w/v squalene, from about 0.001% to about 10% w/v iron oxide nanoparticles, from about 0.2% to about 10 % w/v DOTAP, from about 0.25% to about 5% w/v sorbitan monostearate, and from about 0.5% to about 10% w/v polysorbate 80. In some embodiments the nanoparticle provided herein from about 2% to about 6% w/v squalene, from about 0.01% to about 1% w/v iron oxide nanoparticles, from about 0.2% to about 1 % w/v DOTAP, from about 0.25% to about 1% w/v sorbitan monostearate, and from about 0.5%) to about 5% w/v polysorbate 80. In some embodiments, the nanoparticle provided herein can comprise from about 0.2% to about 40% w/v squalene, from about 0.001% to about 10% w/v aluminum hydroxide or aluminum oxyhydroxide nanoparticles, from about 0.2% to about 10 % w/v DOTAP, from about 0.25% to about 5% w/v sorbitan monostearate, and from about 0.5% to about 10% w/v polysorbate 80. In some embodiments, the nanoparticle provided herein can comprise from about 2% to about 6% w/v squalene, from about 0.01% to about 1% w/v aluminum hydroxide or aluminum oxyhydroxide nanoparticles, from about 0.2% to about 1 % w/v DOTAP, from about 0.25% to about 1% w/v sorbitan monostearate, and from about 0.5%) to about 5% w/v polysorbate 80.

[0067] In some embodiments, a composition described herein comprises at least one nanoparticle formulation as described in Table 1. In some embodiments, a composition described herein comprises any one of NP-1 to NP-30. In some embodiments, a composition described herein comprises any one of NP-1 to NP-31. In some embodiments, the nanoparticles

provided herein are admixed with a nucleic acid provided herein. In some embodiments, nanoparticles provided herein are made by homogenization and ultrasonication techniques.

Table 1. Nanoparticle Formulations.

Name	Cationic Lipid(s) %(w/v) or mg/ml	Oil(s) %(w/v) or mg/ml	Surfactant(s) %(w/v) or mg/ml	Additional Ingredients %(w/v), mg/ml, or mM
NP-1	30 mg/ml 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) chloride	37.5 mg/ml squalene	37 mg/ml sorbitan monostearate, (2R)-2-[(2R,3R,4S)-3,4-Dihydroxyoxolan-2-yl]-2-hydroxyethyl octadecenoate, C ₂₄ H ₄₆ O ₆ (SPAN® 60) 37 mg/ml polyoxyethylene (20) sorbitan monooleate, C ₆₄ H ₁₂₄ O ₂₆ Polysorbate 80 (TWEEN® 80)	0.2 mg Fe/ml 12 nm oleic acid-coated iron oxide nanoparticles 10 mM sodium citrate dihydrate.
NP-2	30 mg/ml 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) chloride	37.5 mg/ml squalene	37 mg/ml sorbitan monostearate (2R)-2-[(2R,3R,4S)-3,4-Dihydroxyoxolan-2-yl]-2-hydroxyethyl octadecenoate C ₂₄ H ₄₆ O ₆ (SPAN® 60) 37 mg/ml polyoxyethylene (20) sorbitan monooleate, C ₆₄ H ₁₂₄ O ₂₆ , Polysorbate 80 (TWEEN® 80)	1 mg Fe/ml 15 nm oleic acid-coated iron oxide nanoparticles 10 mM sodium citrate dihydrate
NP-3	30 mg/ml 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) chloride	37.5 mg/ml Miglyol 812 N (triglyceride ester of saturated coconut/palmkernel oil derived caprylic	37 mg/ml sorbitan monostearate, (2R)-2-[(2R,3R,4S)-3,4-Dihydroxyoxolan-2-yl]-2-	0.2 mg Fe/ml 15 nm oleic acid-coated iron oxide nanoparticles 10 mM sodium citrate dihydrate

		and capric fatty acids and plant derived glyccrol)	hydroxyethyl octadecenoate $C_{24}H_{46}O_6$ (SPAN® 60) 37 mg/ml polyoxyethylene (20) sorbitan monooleate, $C_{64}H_{124}O_{26}$ Polysorbate 80 (TWEEN® 80)	
NP-4	30 mg/ml 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) chloride	37.5 mg/ml Miglyol 812 N (triglyceride ester of saturated coconut/palmkernel oil derived caprylic and capric fatty acids and plant derived glyccrol)	37 mg/ml sorbitan monostearate, (2R)-2-[(2R,3R,4S)-3,4-Dihydroxyoxolan-2-yl]-2-hydroxyethyl octadecenoate, $C_{24}H_{46}O_6$ (SPAN® 60) 37 mg/ml polyoxyethylene (20) sorbitan monooleate, $C_{64}H_{124}O_{26}$, Polysorbate 80 (TWEEN® 80)	1 mg Fe/ml 15 nm oleic acid-coated iron oxide nanoparticles 10 mM sodium citrate dihydrate.
NP-5	30 mg/ml DOTAP chloride	37.5 mg/ml squalene	37 mg/ml sorbitan monostearate (SPAN® 60) 37 mg/ml polysorbate 80 (TWEEN® 80)	1 mg/ml trioctylphosphine oxide (TOPO)-coated aluminum hydroxide (Alhydrogel® 2%) particles 10 mM sodium citrate dihydrate
NP-6	30 mg/ml DOTAP chloride	37.5 mg/ml Solanesol (Cayman chemicals)	37 mg/ml sorbitan monostearate (SPAN® 60) 37 mg/ml polysorbate 80 (TWEEN® 80)	0.2 mg Fe/ml oleic acid-coated iron oxide nanoparticles 10 mM sodium citrate
NP-7	30 mg/ml DOTAP chloride	37.5 mg/ml squalene 2.4 mg/ml Dynasan 114	37 mg/ml sorbitan monostearate (SPAN® 60)	10 mM sodium citrate

			37 mg/ml polysorbate 80 (TWEEN® 80)	
NP-8	4 mg/ml DOTAP chloride	43 mg/ml squalene	5 mg/ml sorbitan trioleate (SPAN® 85) 5 mg/ml polysorbate 80 (TWEEN® 80)	10 mM sodium citrate
NP-9	7.5 mg/ml 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) chloride	9.4 mg/ml squalene ((6E,10E,14E,18E)-2,6,10,15,19,23-Hexamethyltetracos-2,6,10,14,18,22-hexaene, C ₃₀ H ₅₀) 0.63 mg/ml glyceryl trimyristate-dynasan (DYNASAN 114®)	9.3 mg/ml sorbitan monostearate (2R)-2-[(2R,3R,4S)-3,4-Dihydroxyoxolan-2-yl]-2-hydroxyethyl octadecenoate, C ₂₄ H ₄₆ O ₆ (SPAN® 60) 9.3 mg/ml polyoxyethylene (20) sorbitan monooleate, C ₆₄ H ₁₂₄ O ₂₆ , Polysorbate 80 (TWEEN® 80)	0.05 mg/ml 15 nanometer superparamagnetic iron oxide (Fe ₃ O ₄) 10 mM sodium citrate dihydrate
NP-10	0.4% DOTAP	0.25% glyceryl trimyristate-dynasan (DYNASAN 114®) 4.75% Squalene	0.5% sorbitan monostearate (SPAN® 60) 0.5% polysorbate 80 (TWEEN® 80)	
NP-11	3.0% DOTAP	0.25% glyceryl trimyristate-dynasan (DYNASAN 114®) 3.75% Squalene	3.7% sorbitan monostearate (SPAN® 60) 3.7% polysorbate 80 (TWEEN® 80)	
NP-12	0.4% DOTAP	4.3% Squalene	0.5% sorbitan trioleate (SPAN® 85) 0.5% polysorbate 80 (TWEEN® 80)	
NP-13	0.4% DOTAP	0.25% glyceryl trimyristate-dynasan (DYNASAN 114®) 4.08% squalene	2.0% polysorbate 80 (TWEEN® 80)	
NP-14	0.4% DOTAP	0.25% glyceryl trimyristate-dynasan (DYNASAN 114®)	0.5% sorbitan trioleate (SPAN® 85)	

		4.08% squalene	2.0% polysorbate 80 (TWEEN® 80)	
NP-15	0.4% DOTAP	0.25% glyceryl trimyristate-dynasan (DYNASAN 114®) 4.08% squalene	0.25% sorbitan trioleate (SPAN® 85) 2.0% polysorbate 80 (TWEEN® 80)	
NP-16	0.4% DOTAP	5% squalene	0.5% sorbitan trioleate (SPAN® 85) 2.0% polysorbate 80 (TWEEN® 80)	
NP-17	0.4% DOTAP	5% squalene	0.5% sorbitan monostearate (SPAN® 60) 2% polysorbate 80 (TWEEN® 80)	
NP-18	0.4% DOTAP	0.25% glyceryl trimyristate-dynasan (DYNASAN 114®) 4.08% squalene	2% sorbitan trioleate (SPAN® 85) 2% polysorbate 80 (TWEEN® 80)	
NP-19	0.4% DOTAP	0.25% glyceryl trimyristate-dynasan (DYNASAN 114®) 4.75% Squalene	0.5% sorbitan monostearate (SPAN® 60) 0.5% polysorbate 80 (TWEEN® 80)	1% aluminum hydroxide
NP-20	3.0% DOTAP	0.25% glyceryl trimyristate-dynasan (DYNASAN 114®) 3.75% Squalene	3.7% sorbitan monostearate (SPAN® 60) 3.7% polysorbate 80 (TWEEN® 80)	1% aluminum hydroxide
NP-21	0.4% DOTAP	4.3% Squalene	0.5% sorbitan trioleate (SPAN® 85) 0.5% polysorbate 80 (TWEEN® 80)	1% aluminum hydroxide
NP-22	0.4% DOTAP	0.25% glyceryl trimyristate-dynasan (DYNASAN 114®) 4.08% squalene	2.0% polysorbate 80 (TWEEN® 80)	1% aluminum hydroxide
NP-23	0.4% DOTAP	0.25% glyceryl trimyristate-dynasan (DYNASAN 114®) 4.08% squalene	0.5% sorbitan trioleate (SPAN® 85)	1% aluminum hydroxide

			2.0% polysorbate 80 (TWEEN® 80)	
NP-24	0.4% DOTAP	0.25% glyceryl trimyristate-dynasan (DYNASAN 114®) 4.08% squalene	0.25% sorbitan trioleate (SPAN® 85) 2.0% polysorbate 80 (TWEEN® 80)	1% aluminum hydroxide
NP-25	0.4% DOTAP	5% squalene	0.5% sorbitan trioleate (SPAN® 85) 2.0% polysorbate 80 (TWEEN® 80)	1% aluminum hydroxide
NP-26	0.4% DOTAP	5% squalene	0.5% sorbitan monostearate (SPAN® 60) 2% polysorbate 80 (TWEEN® 80)	1% aluminum hydroxide
NP-27	0.4% DOTAP	0.25% glyceryl trimyristate-dynasan (DYNASAN 114®) 4.08% squalene	2% sorbitan trioleate (SPAN® 85) 2% polysorbate 80 (TWEEN® 80)	1% aluminum hydroxide
NP-28	0.5-5.0 mg/ml DOTAP	0.2-10% (v/v) squalene	0.01-2.5% (v/v) polysorbate 80 (TWEEN® 80)	
NP-29	0.4% (w/w) DOTAP	4.3% (w/w) squalene	0.5% (w/w) sorbitan trioleate (SPAN® 85) 0.5% (w/w) polysorbate 80 (TWEEN® 80)	
NP-30	30 mg/ml DOTAP chloride	37.5 mg/ml squalene	37 mg/ml sorbitan monostearate (SPAN® 60) 37 mg/ml polysorbate 80 (TWEEN® 80)	10 mM sodium citrate
NP-31	30 mg/ml DOTAP chloride	37.5 mg/ml squalene	37 mg/ml sorbitan monostearate (SPAN® 60) 37 mg/ml polysorbate 80 (TWEEN® 80)	0.4 mg Fe/ml 5 nm oleic acid-coated iron oxide nanoparticles

				10 mM sodium citrate dihydrate
--	--	--	--	--------------------------------

[0068] In some embodiments, nanoparticles provided herein comprise: sorbitan monostearate (*e.g.*, SPAN® 60), polysorbate 80 (*e.g.*, TWEEN® 80), DOTAP, squalene, and no solid particles. In some embodiments, nanoparticles provided herein comprise: sorbitan monostearate (*e.g.*, SPAN® 60), polysorbate 80 (*e.g.*, TWEEN® 80), DOTAP, squalene, and iron oxide particles. In some embodiments, nanoparticles provided herein comprise an immune stimulant. In some embodiments, the immune stimulant is squalene. In some embodiments, the immune stimulant is Miglyol 810 or Miglyol 812. Miglyol 810 is a triglyceride ester of saturated caprylic and capric fatty acids and glycerol. Miglyol 812 is a triglyceride ester of saturated coconut/palmkernel oil derived caprylic and capric fatty acids and plant derived glycerol. In some embodiments, the immune stimulant can decrease the total amount of protein produced, but can increase the immune response to a composition provided herein (*e.g.*, when delivered as a vaccine). In some embodiments, the immune stimulant can increase the total amount of protein produced, but can decrease the immune response to a composition provided herein.

[0069] Nanoparticles provided herein can be of various average diameters in size. In some embodiments, nanoparticles provided herein have an average diameter (z- average hydrodynamic diameter, measured by dynamic light scattering) ranging from about 20 nanometers (nm) to about 200 nm. In some embodiments, the z-average diameter of the nanoparticle ranges from about 20 nm to about 150 nm, from about 20 nm to about 100 nm, from about 20 nm to about 80 nm, from about 20 nm to about 60 nm. In some embodiments, the z-average diameter of the nanoparticle) ranges from about 40 nm to about 200 nm, from about 40 nm to about 150 nm, from about 40 nm to about 100 nm, from about 40 nm to about 90 nm, from about 40 nm to about 80 nm, or from about 40 nm to about 60 nm. In one embodiment, the z-average diameter of the nanoparticle is from about 40 nm to about 80 nm. In some embodiments, the z-average diameter of the nanoparticle is from about 40 nm to about 60 nm. In some embodiments, the nanoparticle is up to 100 nm in diameter. In some embodiments, the nanoparticle is 50 to 70 nm in diameter. In some embodiments, the nanoparticle is 40 to 80 nm in diameter. In some embodiments, the inorganic particle (*e.g.*, iron oxide) within the hydrophobic core of the nanoparticle can be an average diameter (number weighted average diameter) ranging from about 3 nm to about 50 nm. For instance, the inorganic particle can have an average diameter of about 5 nm, about 10 nm, about 15 nm, about 20 nm, about 25 nm, about

30 nm, about 35 nm, about 40 nm, about 45 nm, or about 50 nm. In some embodiments, the ratio of esters and lipids yield a particle size between 30 nm and 200 nm. In some embodiments, the ratio of esters and lipids yield a particle size between 40 nm and 70 nm.

[0070] Nanoparticles provided herein may be characterized by the polydispersity index (PDI), which is an indication of their quality with respect to size distribution. In some embodiments, average polydispersity index (PDI) of the nanoparticles provided herein ranges from about 0.1 to about 0.5. In some embodiments, the average PDI of the nanoparticles can range from about 0.2 to about 0.5, from about 0.1 to about 0.4, from about 0.2 to about 0.4, from about 0.2 to about 0.3, or from about 0.1 to about 0.3.

[0071] In some embodiments, the nanoparticles provided herein comprise an oil-to-surfactant molar ratio ranging from about 0.1:1 to about 20:1, from about 0.5:1 to about 12:1, from about 0.5:1 to about 9:1, from about 0.5:1 to about 5:1, from about 0.5:1 to about 3:1, or from about 0.5:1 to about 1:1. In some embodiments, the nanoparticles provided herein comprise a hydrophilic surfactant-to-lipid ratio ranging from about 0.1:1 to about 2:1, from about 0.2:1 to about 1.5:1, from about 0.3:1 to about 1:1, from about 0.5:1 to about 1:1, or from about 0.6:1 to about 1:1. In some embodiments, the nanoparticles provided herein comprise a hydrophobic surfactant-to-lipid ratio ranging from about 0.1:1 to about 5:1, from about 0.2:1 to about 3:1, from about 0.3:1 to about 2:1, from about 0.5:1 to about 2:1, or from about 1:1 to about 2:1.

[0072] In some embodiments, the nanoparticles provided herein comprise from about 0.2% to about 40% w/v liquid oil, from about 0.001% to about 10% w/v inorganic solid nanoparticle, from about 0.2% to about 10% w/v lipid, from about 0.25% to about 5% w/v hydrophobic surfactant, and from about 0.5% to about 10% w/v hydrophilic surfactant. In some embodiments, the lipid comprises a cationic lipid, and the oil comprises squalene, and/or the hydrophobic surfactant comprises sorbitan ester.

[0073] In some embodiments, nanoparticles provided herein comprise a ratio of the esters that yields a hydrophilic-lipophilic balance between 8 and 11.

[0074] In some embodiments, nucleic acids provided herein are incorporated, associated with, or complexed a lipid carrier provided herein to form a lipid carrier-nucleic acid complex. The lipid carrier-nucleic acid complex is formed via non-covalent interactions or via reversible covalent interactions.

Nucleic Acids

[0075] Provided herein is a composition comprising a nucleic acid. In some embodiments, the nucleic acid is in complex with the nanoparticle. In some embodiments, the nucleic acid is in complex with the membrane of the nanoparticle. In some embodiments, the nucleic acid is in complex with the hydrophilic surface of the nanoparticle. In some embodiments, the nucleic acid is within the nanoparticle. In some embodiments, the nucleic acid is within the hydrophobic core.

[0076] In some embodiments, the nucleic acid is deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). The nucleic acid may be linear or include a secondary structure (*e.g.*, a hair pin). In some embodiments, the nucleic acid is a polynucleotide comprising modified nucleotides or bases, and/or their analogs. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, modification to the nucleotide structure may be imparted before or after assembly of compositions provided herein. Modified nucleobases which can be incorporated into modified nucleosides and nucleotides and be present in the RNA molecules include: m5C (5-methylcytidine), m5U (5-methyluridine), m6A (N6-methyladenosine), s2U (2-thiouridine), Um (2'-O-methyluridine), m1A (1-methyladenosine); m2A (2-methyladenosine); Am (2-1-O-methyladenosine); ms2m6A (2-methylthio-N6-methyladenosine); i6A (N6-isopentenyladenosine); ms2i6A (2-methylthio-N6isopentenyladenosine); io6A (N6-(cis-hydroxyisopentenyl)adenosine); ms2io6A (2-methylthio-N6-(cis-hydroxyisopentenyl) adenosine); g6A (N6-glycinylicarbamoyladenosine); t6A (N6-threonyl carbamoyladenosine); ms2t6A (2-methylthio-N6-threonyl carbamoyladenosine); m6t6A (N6-methyl-N6-threonylcarbamoyladenosine); hn6A (N6-hydroxynorvalylcarbamoyl adenosine); ms2hn6A (2-methylthio-N6-hydroxynorvalyl carbamoyladenosine); Ar(p) (2'-O-ribosyladenosine (phosphate)); I (inosine); m1I (1-methylinosine); m'Im (1,2'-O-dimethylinosine); m3C (3-methylcytidine); Cm (2T-O-methylcytidine); s2C (2-thiocytidine); ac4C (N4-acetylcytidine); f5C (5-fonnylcytidine); m5Cm (5,2-O-dimethylcytidine); ac4Cm (N4acetyl2TOMethylcytidine); k2C (lysidine); m1G (1-methylguanosine); m2G (N2-methylguanosine); m7G (7-methylguanosine); Gm (2'-O-methylguanosine); m22G (N2,N2-dimethylguanosine); m2Gm (N2,2'-O-dimethylguanosine); m22Gm (N2,N2,2'-O-trimethylguanosine); Gr(p) (2'-O-ribosylguanosine (phosphate)); yW (wybutosine); o2yW (peroxywybutosine); OHyW (hydroxywybutosine); OHyW* (undermodified hydroxywybutosine); imG (wyosine); mimG (methylguanosine); Q (queuosine); oQ (epoxyqueuosine); galQ (galtactosyl-queuosine); manQ (mannosyl-queuosine); preQo (7-cyano-7-deazaguanosine); preQi (7-aminomethyl-7-deazaguanosine); G* (archaeosine); D (dihydrouridine); m5Um (5,2'-O-dimethyluridine); s4U (4-thiouridine); m5s2U (5-methyl-2-

thiouridine); s2Um (2-thio-2'-O-methyluridine); acp3U (3-(3-amino-3-carboxypropyl)uridine); hoSU (5-hydroxyuridine); moSU (5-methoxyuridine); cmo5U (uridine 5-oxyacetic acid); mcmo5U (uridine 5-oxyacetic acid methyl ester); chm5U (5-(carboxyhydroxymethyl)uridine)); mchm5U (5-(carboxyhydroxymethyl)uridine methyl ester); mcm5U (5-methoxycarbonyl methyluridine); mcm5Um (S-methoxycarbonylmethyl-2-O-methyluridine); mcm5s2U (5-methoxycarbonylmethyl-2-thiouridine); nm5s2U (5-aminomethyl-2-thiouridine); mnm5U (5-methylaminomethyluridine); mnm5s2U (5-methylaminomethyl-2-thiouridine); mnm5se2U (5-methylaminomethyl-2-selenouridine); ncm5U (5-carbamoylmethyl uridine); ncm5Um (5-carbamoylmethyl-2'-O-methyluridine); cmnm5U (5-carboxymethylaminomethyluridine); cnmm5Um (5-carboxymethylaminomethyl-2-L-O-methyluridine); cmnm5s2U (5-carboxymethylaminomethyl-2-thiouridine); m62A (N6,N6-dimethyladenosine); Tm (2'-O-methylinosine); m4C (N4-methylcytidine); m4Cm (N4,2-O-dimethylcytidine); hm5C (5-hydroxymethylcytidine); m3U (3-methyluridine); cm5U (5-carboxymethyluridine); m6Am (N6,T-O-dimethyladenosine); rn62Am (N6,N6,O-2-trimethyladenosine); m2'7G (N2,7-dimethylguanosine); m2'2'7G (N2,N2,7-trimethylguanosine); m3Um (3,2T-O-dimethyluridine); m5D (5-methyldihydrouridine); f5Cm (5-formyl-2'-O-methylcytidine); m1Gm (1,2'-O-dimethylguanosine); m'Am (1,2-O-dimethyl adenosine) irinomethyluridine); tm5s2U (S-aurinomethyl-2-thiouridine)); imG-14 (4-demethyl guanosine); imG2 (isoguanosine); ac6A (N6-acetyladenosine), hypoxanthine, inosine, 8-oxo-adenine, 7-substituted derivatives thereof, dihydrouracil, pseudouracil, 2-thiouracil, 4-thiouracil, 5-aminouracil, 5-(C₁-C₆)-alkyluracil, 5-methyluracil, 5-(C₂-C₆)-alkenyluracil, 5-(C₂-C₆)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(C₁-C₆)-alkylcytosine, 5-methylcytosine, 5-(C₂-C₆)-alkenylcytosine, 5-(C₂-C₆)-alkynylcytosine, 5-chlorocytosine, 5-fluorocytosine, 5-bromocytosine, N²-dimethylguanine, 7-deazaguanine, 8-azaguanine, 7-deaza-7-substituted guanine, 7-deaza-7-(C₂-C₆)alkynylguanine, 7-deaza-8-substituted guanine, 8-hydroxyguanine, 6-thioguanine, 8-oxoguanine, 2-aminopurine, 2-amino-6-chloropurine, 2,4-diaminopurine, 2,6-diaminopurine, 8-azapurine, substituted 7-deazapurine, 7-deaza-7-substituted purine, 7-deaza-8-substituted purine, hydrogen (abasic residue), m5C, m5U, m6A, s2U, W, or 2'-O-methyl-U. Any one or any combination of these modified nucleobases may be included in the self-replicating RNA of the invention. Many of these modified nucleobases and their corresponding ribonucleosides are available from commercial suppliers. If desired, the nucleic acid can contain phosphoramidate, phosphorothioate, and/or methylphosphonate linkages. The RNA sequence can be modified with respect to its codon usage, for example, to

increase translation efficacy and half-life of the RNA. A poly A tail (*e.g.*, of about 30 adenosine residues or more) may be attached to the 3' end of the RNA to increase its half-life. The 5' end of the RNA may be capped with a modified ribonucleotide with the structure m7G (5') ppp (5') N (cap 0 structure) or a derivative thereof, which can be incorporated during RNA synthesis or can be enzymatically engineered after RNA transcription (*e.g.*, by using Vaccinia Virus Capping Enzyme (VCE) consisting of mRNA triphosphatase, guanylyl-transferase and guanine-7-methyltransferase, which catalyzes the construction of N7-monomethylated cap 0 structures). Cap structure can provide stability and translational efficacy to the RNA molecule. The 5' cap of the RNA molecule may be further modified by a 2'-O-Methyltransferase which results in the generation of a cap 1 structure (m7Gppp [m2'-O] N), which may further increase translation efficacy. A cap 1 structure may also increase *in vivo* potency.

[0077] In some embodiments, compositions provided herein comprise one or more nucleic acids. In some embodiments, compositions provided herein comprise two or more nucleic acids. In some embodiments, compositions provided herein comprise at least one DNA. In some embodiments, compositions provided herein comprise at least one RNA. In some embodiments, compositions provided herein comprise at least one DNA and at least one RNA. In some embodiments, nucleic acids provided herein are present in an amount of above 5 ng to about 1mg. In some embodiments, nucleic acids provided herein are present in an amount of up to about 25, 50, 75, 100, 150, 175 ng. In some embodiments, nucleic acids provided herein are present in an amount of up to about 1 mg. In some embodiments, nucleic acids provided herein are present in an amount of about 0.05 µg, 0.1 µg, 0.2 µg, 0.5, µg 1 µg, 5 µg, 10 µg, 12.5 µg, 15 µg, 25 µg, 40 µg, 50 µg, 100 µg, 200 µg, 300 µg, 400 µg, 500 µg, 600 µg, 700 µg, 800 µg, 900 µg, 1 mg. In some embodiments, nucleic acids provided herein are present in an amount of 0.05 µg, 0.1 µg, 0.2 µg, 0.5, µg 1 µg, 5 µg, 10 µg, 12.5 µg, 15 µg, 25 µg, 40 µg, 50 µg, 100 µg, 200 µg, 300 µg, 400 µg, 500 µg, 600 µg, 700 µg, 800 µg, 900 µg, 1 mg. In some embodiments, the nucleic acid is at least about 200, 250, 500, 750, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, or 20,000 nucleotides in length. In some embodiments, the nucleic acid is up to about 7000, 8000, 9000, 10,000, 11,000, 12,000, 13,000, 14,000, 15,000, 16,000, 17,000, 18,000, 19,000, or 20,000 nucleotides in length. In some embodiments, the nucleic acid is about 7500, 10,000, 15,000, or 20,000 nucleotides in length.

[0078] In some embodiments, compositions provided herein comprise at least one nucleic acid sequence comprising a sequence which encodes a viral antigen. In some embodiments, the

viral antigen is a surface protein or a transmembrane protein. In some embodiments, the viral antigen is a spike protein, a glycoprotein, or an envelope protein. In some embodiments, the viral antigen is a coronavirus antigen or a fragment thereof. In some embodiments, the antigen is a SARS-CoV antigen, a SARS-CoV-2 antigen, a Middle East Respiratory Syndrome (MERS) coronavirus antigen, a fragment or a variant thereof.

SARS-CoV-2 Spike Protein Antigens

[0079] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a virus that causes the infectious disease called COVID-19 (coronavirus disease 2019). Variants of the SARS-CoV-2 virus include the alpha, beta, delta, mu, and omicron variants. The Alpha (B.1.1.7), Beta (B.1.351, B.1.351.2, B.1.351.3), Delta (B.1.617.2, AY.1, AY.2, AY.3), Omicron (B.1.1.529), and Gamma (P.1, P.1.1, P.1.2) variants circulating in the United States are classified as variants of concern. SARS-CoV-2 structure, its components, along with variants and their various features are described below.

[0080] Coronaviruses are single-stranded RNA-enveloped viruses that have four structural proteins, known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins. The N protein holds the RNA genome, and the S, E, and M proteins together create the viral envelope. In SARS-CoV-2, the spike (S) protein facilitates viral attachment and fusion with the membrane of a host cell via the host cell receptor, angiotensin-converting enzyme 2 (ACE2). The S protein mediates viral cell entry into the host cell. The total length of SARS-CoV-2 spike is generally 1273 amino acids and includes a signal peptide (amino acids 1–13) located at the N-terminus, the S1 subunit (residues 14–685), and the S2 subunit (residues 686–1273); the last two regions are responsible for receptor binding and membrane fusion, respectively. In the S1 subunit, there is an N-terminal domain (14–305 residues) and a receptor-binding domain (RBD, 319–541 residues). The fusion peptide (FP) (788–806 residues), heptapeptide repeat sequence 1 (HR1) (912–984 residues), HR2 (1163–1213 residues), TM domain (1213–1237 residues), and cytoplasm domain (1237–1273 residues) comprise the S2 subunit. Specifically, the HR1 and HR2 are composed of a repetitive heptapeptide: HPPHCPC, where H is a hydrophobic or traditionally bulky residue, P is a polar or hydrophilic residue, and C is another charged residue. HR1 and HR2 form a six-helical bundle (6-HB) referred to as the “stem helix” domain of the S2 protein. When the RBD binds to ACE2 on a host cell membrane, S2 changes conformation by inserting FP into the target cell membrane, exposing the pre-hairpin coiled-coil of the HR1 domain and triggering interaction between the HR2 domain and HR1 trimer to form the stem

helix (6-HB), thus bringing the viral envelope and cell membrane into proximity for viral fusion and entry. The wild-type spike protein amino acid sequence is provided in **SEQ ID NO: 17**. The amino acid sequence corresponding to the stem helix is provided in **SEQ ID NO: 18**.

[0081] Coronaviruses regularly undergo antigenic drift, a type of genetic variation in viruses, arising from the accumulation of mutations in viral genes that encode for virus-surface proteins that host antibodies recognize. Several SARS-CoV-2 variants have been identified by public health agencies and are provided in **Table 2** below.

Table 2. SARS-CoV-2 Variants.

WHO label	Pango lineage*	GISAID clade	Nextstrain clade	Additional spike amino acid changes monitored ^o	Earliest documented samples	Date of designation
Alpha	B.1.1.7	GRY	20I (V1)	N501Y A570D P681H T716I S982A D1118H	United Kingdom, Sep-2020	18-Dec-2020
Beta	B.1.351	GH/501Y.V2	20H (V2)	D80A D215G K417N A701V N501Y E484K	South Africa, May-2020	18-Dec-2020
Delta	B.1.617.2 [§]	G/478K.V1	21A 21I 21J	T19R L452R T478K P681R D950N	India, Oct-2020	VOI: 4-Apr-2021 VOC: 11-May-2021
Epsilon	B.1.427, B.1.429	CAI.20C	21C	I4205V D1183Y S13I W152C	California, USA, May-2020	VOC: March 19, 2021 VOI:

WHO label	Pango lineage*	GISAID clade	Nextstrain clade	Additional spike amino acid changes monitored ^o	Earliest documented samples	Date of designation
				L452R Q677H		February 26, 2021
Eta	B.1.525	G/484K.V3	21D	E484K Q677H F888L	Multiple countries, Dec-2020	17-Mar-2021
Gamma	P.1	GR/501Y.V3	20J (V3)	L18F T20N P26S D138Y R190S K417T E484K N501Y H655Y T1027I	Brazil, Nov-2020	11-Jan-2021
Iota	B.1.526	GH/253G.V1	21F	L5F T95I D253G E484K D614G A701V	United States of America, Nov-2020	24-Mar-2021
Kappa	B.1.617.1	G/452R.V3	21B	S13I Q57H S84L W152C T205I L452R D614G	India, Oct-2020	4-Apr-2021

WHO label	Pango lineage*	GISAID clade	Nextstrain clade	Additional spike amino acid changes monitored ^o	Earliest documented samples	Date of designation
Lambda	C.37	GR/452Q.V1	21G	S:Δ247-253 G75V T76I D614G L452Q F490S T859N	Peru, Dec-2020	14-Jun-2021
Mu	B.1.621	GH	21H	K417N E484K P681H	Colombia, Jan-2021	30-Aug-2021
Omicron	B.1.1.529	GR/484A	21K 21M 21L	A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F	Nov 2021 South Africa, Hong Kong, Belgium, Israel	VOC: 26-Nov-2021

*includes all descendent lineages. The full list of Pango lineages are available on the world wide web at cov-lineages.org/lineage_list.html; for FAQ, visit: pango.network/faqs/

[0082] Provided herein are compositions comprising a coronavirus protein antigen. In some embodiments, coronavirus protein antigens provided herein are derived from a SARS-CoV-2 variant of concern (VOC). A variant of concern is a variant for which there is evidence of an

increase in transmissibility, more severe disease (*e.g.*, increased hospitalizations or deaths), significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures. Possible attributes of a variant of concern include, in addition to the possible attributes of a variant of interest, (i) evidence of impact on diagnostics, treatments, or vaccines, (ii) widespread interference with diagnostic test targets, (iii) evidence of substantially decreased susceptibility to one or more class of therapies, (iv) evidence of significant decreased neutralization by antibodies generated during previous infection or vaccination, (v) evidence of reduced vaccine-induced protection from severe disease, (vi) evidence of increased transmissibility, and (vii) evidence of increased disease severity.

[0083] In some embodiments, coronavirus protein antigens provided herein are derived from a SARS-CoV-2 variant of interest (VOI). A variant of interest is a variant with specific genetic markers that have been associated with changes to receptor binding, reduced neutralization by antibodies generated against previous infection or vaccination, reduced efficacy of treatments, potential diagnostic impact, or predicted increase in transmissibility or disease severity. Possible attributes of a variant of interest include (i) specific genetic markers that are predicted to affect transmission, diagnostics, therapeutics, or immune escape, (ii) evidence that it is the cause of an increased proportion of cases or unique outbreak clusters, and (iii) limited prevalence or expansion in the US or in other countries.

[0084] Provided herein are compositions comprising a nucleic acid encoding for a SARS-CoV-2 spike protein antigen. In some embodiments, the SARS-CoV-2 spike protein antigen is derived from a variant of SARS-CoV-2 listed in **Table 2**. In some embodiments, the SARS-CoV-2 spike protein antigen comprises one or more mutations or an amino acid substitutions listed in **Table 2**. In some embodiments, the SARS-CoV-2 spike protein antigen comprises one or more mutations or amino acid substitutions within the receptor binding domain (RBD). In some embodiments, the SARS-CoV-2 spike protein antigen comprises one or more mutations or amino acid substitutions within the HR1 domain or the HR2 domain. In some embodiments, the SARS-CoV-2 spike protein antigen comprises a glycine residue at position 614 of the surface glycoprotein. In some embodiments, the SARS-CoV-2 spike protein antigen is derived from an alpha variant of SARS-CoV-2. In some embodiments, the SARS-CoV-2 spike protein antigen is derived from a beta variant of SARS-CoV-2. In some embodiments, the SARS-CoV-2 spike protein antigen is derived from a delta variant of SARS-CoV-2. In some embodiments, the SARS-CoV-2 spike protein antigen is derived from a gamma variant of SARS-CoV-2. In some

embodiments, the SARS-CoV-2 spike protein antigen is derived from an iota variant of SARS-CoV-2. In some embodiments, the SARS-CoV-2 spike protein antigen is derived from a kappa variant of SARS-CoV-2. In some embodiments, the SARS-CoV-2 spike protein antigen is derived from a lambda variant of SARS-CoV-2. In some embodiments, the SARS-CoV-2 spike protein antigen is derived from a mu variant of SARS-CoV-2. In some embodiments, the SARS-CoV-2 spike protein antigen is derived from an omicron variant of SARS-CoV-2.

[0085] In some embodiments, nucleic acids provided herein encodes for an antigen listed in **Table 3** or a fragment thereof. In some embodiments, the nucleic acid comprises at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity to a sequence which specifically binds an antigen listed in **Table 3**. In some embodiments, the nucleic acid provided herein comprises at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence similarity to an RNA sequence listed in **Table 3**. In some embodiments, the nucleic acid provided herein comprises a DNA sequence complementary to an RNA sequence listed in **Table 3**. Percent (%) sequence identity for a given sequence relative to a reference sequence is defined as the percentage of identical residues identified after aligning the two sequences and introducing gaps if necessary, to achieve the maximum percent sequence identity. Percent identity can be calculated using alignment methods known in the art, for instance alignment of the sequences can be conducted using publicly available software such as BLAST, Align, ClustalW2. Those skilled in the art can determine the appropriate parameters for alignment, but the default parameters for BLAST are specifically contemplated. Exemplary nucleic acid sequences encoding for exemplary SARS-CoV-2 antigens are listed in **Table 3**.

Table 3. SARS CoV-2 Spike Protein Nucleic Acid and Amino Acid Sequences.

SEQ ID NOS	Name	Variant
SEQ ID NO: 1	Delta V5 RNA Sequence	A.1
SEQ ID NO: 2	K995P-V996P RNA Sequence	A.1-preF
SEQ ID NO: 3	D614G RNA Sequence	B.1
SEQ ID NO: 4	B.1.351-PP-D614G RNA Sequence	Beta-preF
SEQ ID NO: 5	B.1.1.7-PP-D614G RNA Sequence	Alpha -preF
SEQ ID NO: 6	Delta.AY1-S2P-wtFur RNA Sequence	Delta-preF
SEQ ID NO: 7	Delta.AY1-S2P-wtFur-newKozak RNA Sequence	Delta-preF-kozak

SEQ ID NOS	Name	Variant
SEQ ID NO: 8	Omicron- B.1.1.529 RNA Sequence	Omicron
SEQ ID NO: 9	Delta V5 Amino Acid Sequence	A.1
SEQ ID NO: 10	K995P-V996P Amino Acid Sequence	A.1-preF
SEQ ID NO: 11	D614G Amino Acid Sequence	B.1
SEQ ID NO: 12	B.1.351-PP-D614G Amino Acid Sequence	Beta-preF
SEQ ID NO: 13	B.1.1.7-PP-D614G Amino Acid Sequence	Alpha-preF
SEQ ID NO: 14	Delta. AY1-S2P-wtFur Amino Acid Sequence	Delta-preF
SEQ ID NO: 15	Delta. AY1-S2P-wtFur-newKozak Amino Acid Sequence	Delta-preF-kozak
SEQ ID NO: 16	Omicron- B.1.1.529 Amino Acid Sequence	Omicron
SEQ ID NO: 17	Wuhan-Hu-1 -Full-Length Wild-Type Spike Protein Amino Acid Sequence	Wild-type (WT) Spike
SEQ ID NO: 18	Wuhan-Hu-1 -Wild-Type Spike Protein- Stem Helix Amino Acid Sequence [residues 913 to 1213]	Wild-type (WT) Spike
SEQ ID NO: 19	Omicron- B.1.1.529 Amino Acid Sequence of the Stem Helix (HR1 and HR2)	Omicron

*Pre-F is stabilized pre-fusion spike protein

[0086] In some embodiments, compositions provided herein comprise a SARS-CoV-2 spike protein or a fragment thereof, wherein the SARS-CoV-2 spike protein amino acid sequence is encoded by any nucleic acid sequence disclosed herein. In some embodiments, compositions provided herein comprise an RNA sequence set forth in any one of **SEQ ID NOS: 1 to 8**. In some embodiments, the spike protein has an amino acid sequence corresponding to any of the sequences set forth in any one of **SEQ ID NOS: 9 to 19**.

[0087] In some embodiments, compositions provided herein comprise a nucleic acid sequence comprising (i) any vector backbone, and (ii) any of the antigen sequences set forth in **SEQ ID NOS: 24-31**, or any nucleic acid sequence which is at least 80%, or at least 85%, or at least 90%, or at least 93%, or at least 95%, or at least 97% identical to any of the antigen sequences set forth in **SEQ ID NOS: 24-31**.

[0088] In some embodiments, compositions provided herein comprise a nucleic acid sequence comprising (i) a vector backbone as set forth in one of **SEQ ID NOS: 32-38**, and (ii) any sequence encoding for an amino acid sequence defining any SARS-CoV-2 spike protein, or

any sequence encoding an amino acid sequence which is at least 80%, or at least 85%, or at least 90%, or at least 93%, or at least 95%, or at least 97% identical to the sequence defining any SARS-CoV-2 spike protein. In some embodiments, a composition provided herein comprises a DNA sequence complementary to any one of **SEQ ID NOS: 24-38**.

[0089] In some embodiments, compositions provided herein comprise a nucleic acid sequence comprising (i) a vector backbone as set forth in one of **SEQ ID NOS: 32-38**, or any sequence which is at least 80%, or at least 85%, or at least 90%, or at least 93%, or at least 95%, or at least 97% identical to a sequence as set forth in one of **SEQ ID NOS: 32-38**, and (ii) any sequence encoding for an amino acid sequence defining any SARS-CoV-2 spike protein, or any sequence encoding an amino acid sequence which is at least 80%, or at least 85%, or at least 90%, or at least 93%, or at least 95%, or at least 97% identical to the sequence defining any SARS-CoV-2 spike protein.

Self-Replicating Nucleic Acids

[0090] Provided herein are compositions comprising a self-replicating nucleic acid. The SARS-CoV-2 spike antigen provided herein or fragment thereof can be encoded as part of a self-replicating nucleic acid construct. In some embodiments, the self-replicating nucleic acid molecule comprises at least one or more genes selected from the group consisting of viral replicases, viral proteases, viral helicases and other nonstructural viral proteins, and also comprises 5'- and 3'-end cis-active replication sequences, and an antigenic sequence encoding for a SARS-CoV-2 spike protein. A subgenomic promoter that directs expression of the heterologous sequence(s) can be included in the self-replicating nucleotide sequence. If desired, a heterologous sequence may be fused in frame to other coding regions in the self-replicating RNA and/or may be under the control of an internal ribosome entry site (IRES).

[0091] In some embodiments, the self-replicating nucleotide sequence is a self-replicating RNA molecule. Self-replicating RNA molecules are designed so that the self-replicating RNA molecule cannot induce production of infectious viral particles. This can be achieved, for example, by omitting one or more viral genes encoding for structural proteins that are necessary for the production of viral particles in the self-replicating RNA. For example, when the self-replicating RNA molecule is based on an alphavirus, such as Sindbis virus (SIN), Semliki forest virus and Venezuelan equine encephalitis virus (VEE), one or more genes encoding for viral structural proteins, such as capsid and/or envelope glycoproteins, can be omitted. If desired, self-replicating RNA molecules of the invention can be designed to induce production of infectious

viral particles that are attenuated or virulent, or to produce viral particles that are capable of a single round of subsequent infection.

[0092] A self-replicating RNA molecule can, when delivered to an animal cell even without any proteins, lead to the production of multiple daughter RNAs by transcription from itself (or from an antisense copy of itself). The self-replicating RNA can be directly translated after delivery to a cell, and this translation provides an RNA-dependent RNA polymerase which then produces transcripts from the delivered RNA. Thus, the delivered RNA leads to the production of multiple daughter RNAs. These transcripts are antisense relative to the delivered RNA and may be translated themselves to provide *in situ* expression of encoded SARS-CoV-2 spike protein, or may be transcribed to provide further transcripts with the same sense as the delivered RNA which are translated to provide *in situ* expression of the encoded SARS-CoV-2 spike protein (s).

[0093] The self-replicating RNA molecules provided herein can contain one or more modified nucleotides and therefore have improved stability and be resistant to degradation and clearance *in vivo*, and other advantages. In some embodiments, self-replicating RNA molecules that contain modified nucleotides avoid or reduce stimulation of endosomal and cytoplasmic immune receptors when the self-replicating RNA is delivered into a cell. This permits self-replication, amplification and expression of protein to occur. This also reduces safety concerns relative to self-replicating RNA that does not contain modified nucleotides, because the self-replicating RNA that contains modified nucleotides reduce activation of the innate immune system and subsequent undesired consequences (*e.g.*, inflammation at injection site, irritation at injection site, pain, and the like). RNA molecules produced as a result of self-replication are recognized as foreign nucleic acids by the cytoplasmic immune receptors. Thus, self-replicating RNA molecules that contain modified nucleotides provide for efficient amplification of the RNA in a host cell and expression of SARS-CoV-2 spike proteins, as well as adjuvant effects.

[0094] In some embodiments, self-replicating RNA molecules provided herein contain at least one modified nucleotide. Modified nucleotides that are not part of the 5' cap (*e.g.*, in addition to the modification that are part of the 5' cap) can be used. Accordingly, the self-replicating RNA molecule can contain a modified nucleotide at a single position, can contain a particular modified nucleotide (*e.g.*, pseudouridine, N6-methyladenosine, 5-methylcytidine, 5-methyluridine) at two or more positions, or can contain two, three, four, five, six, seven, eight, nine, ten or more modified nucleotides (*e.g.*, each at one or more positions). Preferably, the self-replicating RNA molecules comprise modified nucleotides that contain a modification on or in

the nitrogenous base, but do not contain modified sugar or phosphate moieties. In some examples, between 0.001% and 99% or 100% of the nucleotides in a self-replicating RNA molecule are modified nucleotides. For example, 0.001%-25%, 0.01%-25%, 0.1%-25%, or 1%-25% of the nucleotides in a self-replicating RNA molecule are modified nucleotides. In other examples, between 0.001% and 99% or 100% of a particular unmodified nucleotide in a self-replicating RNA molecule is replaced with a modified nucleotide. For example, about 1% of the nucleotides in the self-replicating RNA molecule that contain uridine can be modified, such as by replacement of uridine with pseudouridine. In other examples, the desired amount (percentage) of two, three, or four particular nucleotides (nucleotides that contain uridine, cytidine, guanosine, or adenine) in a self-replicating RNA molecule are modified nucleotides. For example, 0.001%-25%, 0.01%-25%, 0.1%-25%, or 1%-25% of a particular nucleotide in a self-replicating RNA molecule are modified nucleotides. In other examples, 0.001%-20%, 0.001%-15%, 0.001%-10%, 0.01%-20%, 0.01%-15%, 0.1%-25, 0.01%-10%, 1%-20%, 1%-15%, 1%-10%, or about 5%, about 10%, about 15%, about 20% of a particular nucleotide in a self-replicating RNA molecule are modified nucleotides. It is preferred that less than 100% of the nucleotides in a self-replicating RNA molecule are modified nucleotides. It is also preferred that less than 100% of a particular nucleotide in a self-replicating RNA molecule are modified nucleotides. Thus, preferred self-replicating RNA molecules comprise at least some unmodified nucleotides.

[0095] Self-replicating RNA molecules that comprise at least one modified nucleotide can be prepared using any suitable method. Several suitable methods are known in the art for producing RNA molecules that contain modified nucleotides. For example, a self-replicating RNA molecule that contains modified nucleotides can be prepared by transcribing (*e.g.*, *in vitro* transcription) a DNA that encodes the self-replicating RNA molecule using a suitable DNA-dependent RNA polymerase, such as T7 phage RNA polymerase, SP6 phage RNA polymerase, T3 phage RNA polymerase, and the like, or mutants of these polymerases which allow efficient incorporation of modified nucleotides into RNA molecules. The transcription reaction will contain nucleotides and modified nucleotides, and other components that support the activity of the selected polymerase, such as a suitable buffer, and suitable salts. The incorporation of nucleotide analogs into a self-replicating RNA may be engineered, for example, to alter the stability of such RNA molecules, to increase resistance against RNases, to establish replication after introduction into appropriate host cells (“infectivity” of the RNA), and/or to induce or reduce innate and adaptive immune responses. Suitable synthetic methods can be used alone, or

in combination with one or more other methods (*e.g.*, recombinant DNA or RNA technology), to produce a self-replicating RNA molecule that contain one or more modified nucleotides.

[0096] Nucleic acid synthesis can also be performed using suitable recombinant methods that are well-known and conventional in the art, including cloning, processing, and/or expression of polynucleotides and gene products encoded by such polynucleotides. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic polynucleotides are examples of known techniques that can be used to design and engineer polynucleotide sequences. Site-directed mutagenesis can be used to alter nucleic acids and the encoded proteins, for example, to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations and the like.

[0097] In some embodiments, nucleic acids provided herein encode for an RNA polymerase. In some embodiments, nucleic acids provided herein encode for a viral RNA polymerase. In some embodiments, nucleic acids provided herein encode for: (1) a viral RNA polymerase; and (2) a protein or functional fragment thereof. In some embodiments, compositions provided herein comprise a first nucleic acid encoding for a viral RNA polymerase; and a second nucleic acid encoding for a protein or functional fragment thereof.

[0098] Provided herein are compositions comprising a self-replicating RNA. A self-replicating RNA (also called a replicon) includes any genetic element, for example, a plasmid, cosmid, bacmid, phage or virus that is capable of replication largely under its own control. Self-replication provides a system for self-amplification of the nucleic acids provided herein in mammalian cells. In some embodiments, the self-replicating RNA is single stranded. In some embodiments, the self-replicating RNA is double stranded.

[0099] An RNA polymerase provided herein can include but is not limited to: an alphavirus RNA polymerase, an Eastern equine encephalitis virus (EEEV) RNA polymerase, a Western equine encephalitis virus (WEEV), Venezuelan equine encephalitis virus (VEEV), Also, Chikungunya virus (CHIKV), Semliki Forest virus (SFV), or Sindbis virus (SINV). In some embodiments, the RNA polymerase is a VEEV RNA polymerase. In some embodiments, the nucleic acid encoding for the RNA polymerase comprises at least 85% identity to the nucleic acid sequence of **SEQ ID NO: 20**. In some embodiments, the nucleic acid encoding for the RNA polymerase comprises at least 90% identity to the nucleic acid sequence of **SEQ ID NO: 20**. In some embodiments, the nucleic acid encoding for the RNA polymerase comprises at least 95% identity to the nucleic acid sequence of **SEQ ID NO: 20**. In some embodiments, the nucleic acid encoding for the RNA polymerase comprises at least 99% identity to the nucleic acid

sequence of **SEQ ID NO: 20**. In some embodiments, the nucleic acid encoding for the RNA polymerase is **SEQ ID NO: 20**.

[00100] In some embodiments, the amino acid sequence for VEEV RNA polymerase comprises at least 85% identity to RELPVLDSAAFNVECFKKYACNNEYWETFKENPIRLTEENVVNYITKLKGP (**SEQ ID NO: 21**), TQMRELPLVDSAAFNVECFKKYACNNEYWETFKENPIRLTE (**SEQ ID NO: 22**), or **SEQ ID NO: 23**. In some embodiments, the amino acid sequence for VEEV RNA polymerase comprises at least 90% identity to **SEQ ID NO: 21**, **SEQ ID NO: 22**, or **SEQ ID NO: 23**. In some embodiments, the amino acid sequence for VEEV RNA polymerase comprises at least 95% identity to **SEQ ID NO: 21**, **SEQ ID NO: 22**, or **SEQ ID NO: 23**. In some embodiments, the amino acid sequence for VEEV RNA polymerase comprises at least 99% identity to **SEQ ID NO: 21**, **SEQ ID NO: 22**, or **SEQ ID NO: 23**. In some embodiments, the amino acid sequence for VEEV RNA polymerase is **SEQ ID NO: 21**, **SEQ ID NO: 22**, or **SEQ ID NO: 23**.

[00101] Provided herein are compositions and methods comprising replicon RNA (repRNA) encoding for one or more structural proteins from a non-enveloped virus. In some embodiments, the repRNA encodes a protease. In some embodiments, the repRNA encodes the 3CD protease. In some embodiments, the structural protein and the protease are co-expressed. In further embodiments, the repRNA comprises one or more open reading frames. In some embodiments, the open reading frames are separated by an internal ribosomal entry site (IRES). In some embodiments, the open reading frames are separated by a ribosomal skipping peptide sequence. In some embodiments the ribosomal skipping peptide sequence is from *Thosea asigna* virus (T2A).

Combination Compositions

[00102] Provided herein are compositions comprising a nanoparticle described herein and a nucleic acid encoding for a coronavirus antigen. Further provided herein is a nanoemulsion comprising a plurality of nanoparticles provided herein. In some embodiments, the nucleic acid encodes for a self-replicating RNA polymerase. In some embodiments, the nucleic acid encodes for a self-replicating RNA-dependent RNA polymerase. In some embodiments, the nucleic acid further encodes for an RNA polymerase. In some embodiments the RNA polymerase is a viral RNA polymerase. In some embodiments, the nucleic acid encoding for the RNA polymerase is on the same nucleic acid strand as the nucleic acid sequence encoding for the protein (*e.g.*, *cis*).

In some embodiments, the nucleic acid encoding for the RNA polymerase is on a different nucleic acid strand as the nucleic acid sequence encoding for the protein (*e.g.*, trans). In some embodiments, the nucleic acid encoding for the RNA polymerase is a DNA molecule. In some embodiments, nucleic acid sequences encoding for an antigen provided herein are DNA or RNA molecules. In some embodiments, antigens provided herein are encoded by DNA. Nanoparticles for inclusion include, without limitation, any one of NP-1 to NP-30, or any one of NP-1 to NP-31. In some embodiments, the nanoparticle comprises NP-1. In some embodiments, the nanoparticle comprises NP-2. In some embodiments, the nanoparticle comprises NP-3. In some embodiments, the nanoparticle comprises NP-4. In some embodiments, the nanoparticle comprises NP-5. In some embodiments, the nanoparticle comprises NP-6. In some embodiments, the nanoparticle comprises NP-7. In some embodiments, the nanoparticle comprises NP-8. In some embodiments, the nanoparticle comprises NP-9. In some embodiments, the nanoparticle comprises NP-10. In some embodiments, the nanoparticle comprises NP-11. In some embodiments, the nanoparticle comprises NP-12. In some embodiments, the nanoparticle comprises NP-13. In some embodiments, the nanoparticle comprises NP-14. In some embodiments, the nanoparticle comprises NP-15. In some embodiments, the nanoparticle comprises NP-16. In some embodiments, the nanoparticle comprises NP-17. In some embodiments, the nanoparticle comprises NP-18. In some embodiments, the nanoparticle comprises NP-18. In some embodiments, the nanoparticle comprises NP-19. In some embodiments, the nanoparticle comprises NP-20. In some embodiments, the nanoparticle comprises NP-21. In some embodiments, the nanoparticle comprises NP-22. In some embodiments, the nanoparticle comprises NP-23. In some embodiments, the nanoparticle comprises NP-24. In some embodiments, the nanoparticle comprises NP-25. In some embodiments, the nanoparticle comprises NP-26. In some embodiments, the nanoparticle comprises NP-27. In some embodiments, the nanoparticle comprises NP-28. In some embodiments, the nanoparticle comprises NP-28. In some embodiments, the nanoparticle comprises NP-29. In some embodiments, the nanoparticle comprises NP-30. In some embodiments, the nanoparticle comprises NP-31. In some embodiments, the nanoparticle comprises any of NP-1 to NP-31 and a cryoprotectant. In some embodiments, the cryoprotectant is a sugar described herein. Nucleic acids for inclusion include, without limitation, comprise a region comprising any one of, or a plurality of, **SEQ ID NOS: 1 to 8** and/or **SEQ ID NOS: 24 to 31**. In some instances, the nucleic acids further comprise a region encoding for an RNA polymerase, *e.g.*, a region comprising a sequence of **SEQ ID NO: 20**. In some embodiments, the

nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 1** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 2** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 3** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 4** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 5** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 6** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 7** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 8** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 24** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 25** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 26** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 27** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 28** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 29** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 30** or a functional fragment thereof. In some embodiments, the nucleic acid comprises a sequence that is at least 85% identical to **SEQ ID NO: 31** or a functional fragment thereof. In some embodiments, a nucleic acid described herein comprises a sequence encoded for an infectious disease antigen described here and for an RNA-dependent RNA polymerase. In some embodiments, the RNA-dependent RNA polymerase is a VEEV RNA polymerase. In some embodiments, the two nucleic acid coding elements are present in separate nucleic acids. In some embodiments, the two nucleic acid coding elements are present on the same nucleic acid.

[00103] In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 1** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 2** or a functional

fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 3** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 4** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 5** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 6** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 7** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 8** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid encoding for a SARS-CoV-2 spike protein antigen comprising a glycine at position 614 (G614) of the amino acid sequence. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid encoding for a SARS-CoV-2 spike protein antigen, wherein the SARS-CoV-2 spike protein antigen comprises a mutation or an amino acid substitution relative to **SEQ ID NO: 17**. In some embodiments, compositions provided herein comprise NP-1; and a nucleic acid comprising (i) **SEQ ID NO: 20**; and (ii) a region encoding for a SARS-CoV-2 spike protein antigen, wherein the SARS-CoV-2 spike protein antigen comprises a mutation or an amino acid substitution relative to **SEQ ID NO: 17**. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 24** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 25** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 26** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 27** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 28** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 29** or a functional fragment thereof. In some embodiments,

compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 30** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-1 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 31** or a functional fragment thereof.

[00104] In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 1** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 2** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 3** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 4** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 5** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 6** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 7** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 8** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid encoding for a SARS-CoV-2 spike protein antigen comprising a glycine at position 614 (G614) of the amino acid sequence. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid encoding for a SARS-CoV-2 spike protein antigen, wherein the SARS-CoV-2 spike protein antigen comprises a mutation or an amino acid substitution relative to **SEQ ID NO: 17**. In some embodiments, compositions provided herein comprise NP-2; and a nucleic acid comprising (i) **SEQ ID NO: 20**; and (ii) a region encoding for a SARS-CoV-2 spike protein antigen, wherein the SARS-CoV-2 spike protein comprises a mutation or an amino acid substitution relative to **SEQ ID NO: 17**. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 24** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 25** or a functional fragment thereof. In some embodiments,

compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 26** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 27** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 28** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 29** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 30** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-2 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 31** or a functional fragment thereof.

[00105] In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 1** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 2** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 3** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 4** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 5** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 6** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 7** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 8** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid encoding for a SARS-CoV-2 spike protein antigen comprising a glycine at position 614 (G614) of the amino acid sequence. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid encoding for a SARS-CoV-2 spike protein antigen, wherein the SARS-CoV-2 spike protein antigen comprises a mutation or an amino acid substitution

relative to **SEQ ID NO: 17**. In some embodiments, compositions provided herein comprise NP-30; and a nucleic acid comprising (i) **SEQ ID NO: 20**; and (ii) a region encoding for a SARS-CoV-2 spike protein antigen, wherein the SARS-CoV-2 spike protein antigen comprises a mutation or an amino acid substitution relative to **SEQ ID NO: 17**. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 24** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 25** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 26** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 27** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 28** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 29** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 30** or a functional fragment thereof. In some embodiments, compositions provided herein comprise NP-30 and a nucleic acid comprising a sequence that is at least 85% identical to **SEQ ID NO: 31** or a functional fragment thereof.

[00106] Compositions provided herein can be characterized by an nitrogen:phosphate (N:P) molar ratio. The N:P ratio is determined by the amount of cationic lipid in the nanoparticle which contain nitrogen and the amount of nucleic acid used in the composition which contain negatively charged phosphates. A molar ratio of the lipid carrier to the nucleic acid can be chosen to increase the delivery efficiency of the nucleic acid, increase the ability of the nucleic acid-carrying nanoemulsion composition to elicit an immune response to the antigen, increase the ability of the nucleic acid-carrying nanoemulsion composition to elicit the production of antibody titers to the antigen in a subject. In some embodiments, compositions provided herein have a molar ratio of the lipid carrier to the nucleic acid can be characterized by the nitrogen-to-phosphate molar ratio, which can range from about 0.01:1 to about 1000:1, for instance, from about 0.2:1 to about 500:1, from about 0.5:1 to about 150:1, from about 1:1 to about 150:1, from about 1:1 to about 125:1, from about 1:1 to about 100:1, from about 1:1 to about 50:1, from about 1:1 to about 50:1, from about 5:1 to about 50:1, from about 5:1 to about 25:1, or from

about 10:1 to about 20:1. In certain embodiments, the molar ratio of the lipid carrier to the nucleic acid, characterized by the nitrogen-to-phosphate (N:P) molar ratio, ranges from about 1:1 to about 150:1, from about 5:1 to about 25:1, or from about 10:1 to about 20:1. In one embodiment, the N:P molar ratio of the nanoemulsion composition is about 15:1. In some embodiments, the nanoparticle comprises a nucleic acid provided herein covalently attached to the membrane.

[00107] Compositions provided herein can be characterized by an oil-to-surfactant molar ratio. In some embodiments, the oil-to-surfactant ratio is the molar ratio of squalene: DOTAP, hydrophobic surfactant, and hydrophilic surfactant. In some embodiments, the oil-to-surfactant ratio is the molar ratio of squalene: DOTAP, sorbitan monostearate, and polysorbate 80. In some embodiments, the oil-to surfactant molar ratio ranges from about 0.1:1 to about 20:1, from about 0.5:1 to about 12:1, from about 0.5:1 to about 9:1, from about 0.5:1 to about 5:1, from about 0.5:1 to about 3:1, or from about 0.5:1 to about 1:1. In some embodiments, the oil-to-surfactant molar ratio is at least about 0.1:1, at least about 0.2:1, at least about 0.3:1, at least about 0.4:1, at least about 0.5:1, at least about 0.6:1, at least about 0.7:1. In some embodiments, the oil-to surfactant molar ratio is at least about 0.4:1 up to 1:1.

[00108] Compositions provided herein can be characterized by hydrophilic surfactant-to-lipid (*e.g.*, cationic lipid) ratio. In some embodiments, the hydrophilic surfactant-to-lipid ratio ranges from about 0.1:1 to about 2:1, from about 0.2:1 to about 1.5:1, from about 0.3:1 to about 1:1, from about 0.5:1 to about 1:1, or from about 0.6:1 to about 1:1. Compositions provided herein can be characterized by hydrophobic surfactant-to-lipid (*e.g.*, cationic lipid) ratio ranging. In some embodiments, the hydrophobic surfactant-to-lipid ratio ranges from about 0.1:1 to about 5:1, from about 0.2:1 to about 3:1, from about 0.3:1 to about 2:1, from about 0.5:1 to about 2:1, or from about 1:1 to about 2:1.

[00109] Provided herein is a dried composition comprising a sorbitan fatty acid ester, an ethoxylated sorbitan ester, a cationic lipid, an immune stimulant, and an RNA. Further provided herein are dried compositions, wherein the dried composition comprises sorbitan monostearate (*e.g.*, SPAN® 60), polysorbate 80 (*e.g.*, TWEEN® 80), DOTAP, an immune stimulant, and an RNA.

Thermally Stable, Dried, and Lyophilized SARS-COV-2 RNA Vaccines

[00110] Provided herein are dried or lyophilized compositions and vaccines. Further provided herein are pharmaceutical compositions comprising a dried or lyophilized composition

provided herein that is reconstituted in a suitable diluent and a pharmaceutically acceptable carrier. In some embodiments, the diluent is aqueous. In some embodiments, the diluent is water.

[00111] A lyophilized composition is generated by a low temperature dehydration process involving the freezing of the composition, followed by a lowering of pressure, and removal of ice by sublimation. In certain cases, lyophilisation also involves the removal of bound water molecules through a desorption process. In some embodiments, compositions and vaccine compositions provided herein are spray-dried. Spray drying is a process by which a solution is fed through an atomizer to create a spray, which is thereafter exposed to a heated gas stream to promote rapid evaporation. When sufficient liquid mass has evaporated, the remaining solid material in the droplet forms particles which are then separated from the gas stream (*e.g.*, using a filter or a cyclone). Drying aids in the storage of the compositions and vaccine compositions provided herein at higher temperatures (*e.g.*, greater than 4 degrees C) as compared to the sub-zero temperatures needed for the storage of existing mRNA vaccines. In some embodiments, dried compositions and lyophilized compositions provided herein comprise (a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising: (i) a hydrophobic core; (ii) one or more inorganic nanoparticles; (iii) and one or more lipids; (b) one or more nucleic acids; and (c) at least one cryoprotectant. In some embodiments, the cryoprotectant is selected from the group consisting of: sucrose, maltose, trehalose, mannitol, glucose, and any combinations thereof. Additional examples of cryoprotectants include but are not limited to: dimethyl sulfoxide (DMSO), glycerol, propylene glycol, ethylene glycol, 3-O-methyl-D-glucopyranose (3-OMG), polyethylene glycol (PEG), 1,2-propanediol, acetamide, trehalose, formamide, sugars, proteins, and carbohydrates.

[00112] In some embodiments, compositions and methods provided herein comprise at least one cryoprotectant. Exemplary cryoprotectants for inclusion are, but not limited to, sucrose, maltose, trehalose, mannitol, or glucose, and any combinations thereof. In some embodiments, additional or alternative cryoprotectant for inclusion is sorbitol, ribitol, erythritol, threitol, ethylene glycol, or fructose. In some embodiments, additional or alternative cryoprotectant for inclusion is dimethyl sulfoxide (DMSO), glycerol, propylene glycol, ethylene glycol, 3-O-methyl-D-glucopyranose (3-OMG), polyethylene glycol (PEG), 1,2-propanediol, acetamide, trehalose, formamide, sugars, proteins, and carbohydrates. In some embodiments, the cryoprotectant is present at about 1% w/v to at about 20% w/v, preferably about 10% w/v to at about 20% w/v, and more preferably at about 10% w/v. In certain aspects of the disclosure, the cryoprotectant is sucrose. In some aspects of the disclosure, the cryoprotectant is maltose. In

some aspects of the disclosure, the cryoprotectant is trehalose. In some aspects of the disclosure, the cryoprotectant is mannitol. In some aspects of the disclosure, the cryoprotectant is glucose. In some embodiments, the cryoprotectant is present in an amount of about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 325, 350, 375, 400, 450, 500 or more mg. In some embodiments, the cryoprotectant is present in an amount of about 50 to about 500 mg. In some embodiments, the cryoprotectant is present in an amount of about 200 to about 300 mg. In some embodiments, the cryoprotectant is present in an amount of about 250 mg. In some embodiments, the cryoprotectant is present in amount of a lyophilized composition by weight of at least about 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or more percent. In some embodiments, the cryoprotectant is present in amount of a lyophilized composition by weight of about 95%. In some embodiments, the cryoprotectant is present in amount of a lyophilized composition by weight of 80 to 98%, 85 to 98%, 90 to 98%, or 94 to 96%. In some embodiments, the cryoprotectant is a sugar. In some embodiments, the sugar is sucrose, maltose, trehalose, mannitol, or glucose. In some embodiments, the sugar is sucrose. In some embodiments, the sucrose is present in an amount of about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 325, 350, 375, 400, 450, 500 or more mg. In some embodiments, the sucrose is present in an amount of about 50 to about 500 mg. In some embodiments, the sucrose is present in an amount of about 200 to about 300 mg. In some embodiments, the sucrose is present in an amount of about 250 mg. In some embodiments, the sucrose is present in amount of a lyophilized composition by weight of at least about 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or more percent. In some embodiments, the sucrose is present in amount of a lyophilized composition by weight of about 95%. In some embodiments, the sucrose is present in amount of a lyophilized composition by weight of 80 to 98%, 85 to 98%, 90 to 98%, or 94 to 96%.

[00113] In some embodiments, the cryoprotectant is sucrose. In some embodiments, the cryoprotectant is at a concentration of at least about 0.1% w/v. In some embodiments, the cryoprotectant is at a concentration of about 1% w/v to at about 20% w/v. In some embodiments, the cryoprotectant is at a concentration of about 10% w/v to at about 20% w/v. In some embodiments, the cryoprotectant is at a concentration of about 10% w/v.

[00114] In some embodiments, compositions and vaccine compositions provided herein are thermally stable. A composition is considered thermally stable when the composition resists the action of heat or cold and maintains its properties, such as the ability to protect a nucleic acid

molecule from degradation at given temperature. In some embodiments, compositions and vaccine compositions provided herein are thermally stable at about 25 degrees Celsius (°C) or standard room temperature. In some embodiments, compositions and vaccine compositions provided herein are thermally stable at about 45 °C. In some embodiments, compositions and vaccine compositions provided herein are thermally stable at about - 20 °C. In some embodiments, compositions and vaccine compositions provided herein are thermally stable at about 2 °C to about 8 °C. In some embodiments, compositions and vaccine compositions provided herein are thermally stable at a temperature of at least about -80 °C, at least about -20 °C, at least about 0 °C, at least about 2 °C, at least about 4 °C, at least about 6 °C, at least about 8 °C, at least about 10 °C, at least about 20 °C, at least about 25 °C, at least about 30 °C, at least about 37 °C, up to 45 °C. In some embodiments, compositions and vaccine compositions provided herein are thermally stable for at least about 5 day, at least about 1 week, at least about 2 weeks, at least about 1 month, up to 3 months. In some embodiments, compositions and vaccine compositions provided herein are stored at a temperature of at least about 4° C up to 37 °C for at least about 5 day, at least about 1 week, at least about 2 weeks, at least about 1 month, up to 3 months. In some embodiments, compositions and vaccine compositions provided herein are stored at a temperature of at least about 20 °C up to 25 °C for at least about 5 day, at least about 1 week, at least about 2 weeks, at least about 1 month, up to 3 months.

[00115] Also provided herein are methods for preparing a lyophilized composition comprising obtaining a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids; incorporating one or more nucleic acid into the lipid carrier to form a lipid carrier- nucleic acid complex; adding at least one cryoprotectant to the lipid carrier-nucleic acid complex to form a formulation; and lyophilizing the formulation to form a lyophilized composition.

[00116] Further provided herein are methods for preparing a spray-dried composition comprising obtaining a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids; incorporating one or more nucleic acid into the lipid carrier to form a lipid carrier- nucleic acid complex; adding at least one cryoprotectant to the lipid carrier-nucleic acid complex to form a formulation; and spray drying the formulation to form a spray-dried composition.

[00117] Further provided herein are methods for reconstituting a lyophilized composition comprising: obtaining a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles, and one or more lipids; incorporating

one or more nucleic acid into the said lipid carrier to form a lipid carrier-nucleic acid complex; adding at least one cryoprotectant to the lipid carrier-nucleic acid complex to form a formulation; lyophilizing the formulation to form a lyophilized composition; and reconstituting the lyophilized composition in a suitable diluent.

[00118] Further provided herein are methods for reconstituting a spray-dried composition comprising: obtaining a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles, and one or more lipids, incorporating one or more nucleic acid into the said lipid carrier to form a lipid carrier-nucleic acid complex; adding at least one cryoprotectant to the lipid carrier-nucleic acid complex to form a formulation; spray drying the formulation to form a spray-dried composition; and reconstituting the spray-dried composition in a suitable diluent.

Pharmaceutical Compositions

[00119] Provided herein is a suspension comprising a composition provided herein. In some embodiments, suspensions provided herein comprise a plurality of nanoparticles or compositions provided herein. In some embodiments, compositions provided herein are in a suspension, optionally a homogeneous suspension. In some embodiments, compositions provided herein are in an emulsion form.

[00120] Also provided herein is a pharmaceutical composition comprising a composition provided herein. In some embodiments, compositions provided herein are combined with pharmaceutically acceptable salts, excipients, and/or carriers to form a pharmaceutical composition. Pharmaceutical salts, excipients, and carriers may be chosen based on the route of administration, the location of the target issue, and the time course of delivery of the drug. A pharmaceutically acceptable carrier or excipient may include solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc., compatible with pharmaceutical administration.

[00121] In some embodiments, the pharmaceutical composition is in the form of a solid, semi-solid, liquid or gas (aerosol). Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P., and isotonic sodium chloride solution. In addition, sterile, fixed oils

are employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. The injectable formulations can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[00122] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the encapsulated or unencapsulated conjugate is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, (h) absorbents such as kaolin and bentonite clay, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also comprise buffering agents.

Dosing

[00123] Compositions provided herein may be formulated in dosage unit form for ease of administration and uniformity of dosage. A dosage unit form is a physically discrete unit of a composition provided herein appropriate for a subject to be treated. It will be understood, however, that the total usage of compositions provided herein will be decided by the attending physician within the scope of sound medical judgment. For any composition provided herein the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, such as mice, rabbits, dogs, pigs, or non-human primates. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic efficacy and toxicity of compositions provided herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, ED₅₀ (the dose is therapeutically effective in 50% of the population) and LD₅₀ (the dose is lethal to 50% of the

population). The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD₅₀/ED₅₀. Pharmaceutical compositions which exhibit large therapeutic indices may be useful in some embodiments. The data obtained from cell culture assays and animal studies may be used in formulating a range of dosage for human use.

Administration

[00124] Provided herein are compositions and pharmaceutical compositions for administering to a subject in need thereof. In some embodiments, pharmaceutical compositions provided here are in a form which allows for compositions provided herein to be administered to a subject.

[00125] In some embodiments, the administering is local administration or systemic administration. In some embodiments, a composition described herein is formulated for administration / for use in administration via a subcutaneous, intradermal, intramuscular, inhalation, intravenous, intraperitoneal, intracranial, or intrathecal route. In some embodiments, the administering is every 1, 2, 4, 6, 8, 12, 24, 36, or 48 hours. In some embodiments, the administering is daily, weekly, or monthly. In some embodiments, the administering is repeated at least about every 28 days or 56 days.

[00126] In some embodiments, a single dose of a composition provided herein is administered to a subject. In some embodiments, a composition or pharmaceutical composition provided herein is administered to the subject by two doses. In some embodiments, a second dose of a composition or pharmaceutical composition provided herein is administered about 28 days or 56 days after the first dose. In some embodiments, a first dose is administered, and a second dose is administered about 14 days later, or about 21 days later, or about 28 days later, or about 35 days later, or about 42 days later, or about 49 days later, or about 56 days later, or about 63 days later, or about 70 days later, or about 77 days later, or about 84 days later. In some embodiments, the second dose is administered about 10-90 days following administration of the first dose, or about 15-85 days following administration of the first dose, or about 20-80 days following administration of the first dose, or about 25-75 days following administration of the first dose, or about 30-70 days following administration of the first dose, or about 35-65 days following administration of the first dose, or about 40-60 days following administration of the first dose.

[00127] In some embodiments, a third dose of a composition or pharmaceutical composition provided herein is administered to a subject. In some embodiments, the third dose

is administered about 1 month following administration of the second dose, about 2 months following administration of the second dose, about 3 months following administration of the second dose, about 4 months following administration of the second dose, about 5 months following administration of the second dose, about 6 months following administration of the second dose, about 7 months following administration of the second dose, about 8 months following administration of the second dose, about 9 months following administration of the second dose, about 10 months following administration of the second dose, about 11 months following administration of the second dose, about 12 months following administration of the second dose, about 13 months following administration of the second dose, about 14 months following administration of the second dose, about 15 months following administration of the second dose, about 16 months following administration of the second dose, about 17 months following administration of the second dose, or about 18 months following administration of the second dose.

Therapeutic Applications

[00128] Provided herein are methods of treating or preventing a disease in a subject. In some embodiments, compositions described herein are used for the treatment of an infection. In some embodiments, compositions described herein are used for the treatment of a respiratory infection. In some embodiments, the infection is a viral infection. In some embodiments, the viral infection is from a Coronavirus. In some embodiments, the coronavirus is SARS-CoV-2. In some embodiments, the Coronavirus is MERS or SARS. In some embodiments, the Coronavirus is a SARS-CoV-2 variant.

[00129] Further provided herein are methods for immunoprotecting the subject. In some embodiments, the method reduces the severity of a SARS-CoV-2 infection. In some embodiments, the method prevents a SARS-CoV-2 infection in a subject. In some embodiments, compositions described herein are used for enhancing the immune response of a subject to a viral antigen provided herein or a variant thereof. In some embodiments, compositions described herein are used for immunizing a subject. In some embodiments, compositions described herein are used for the reduction of severity of an infection in a subject. In some embodiments, compositions described herein provide for reduction of severity or duration of symptoms associated with an infection in a subject.

[00130] In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject has or is suspected of having a viral infection. In

some embodiments, the subject has or is suspected of having a coronavirus infection. In some embodiments, the subject has or is suspected of having COVID-19 caused by the SARS-CoV-2 virus or a variant thereof. In some embodiments, the subject has COVID-19 caused by the delta variant of SARS-CoV-2. In some embodiments, the subject has COVID-19 caused by the omicron variant of SARS-CoV-2. In some embodiments, the subject is administered a composition provided herein that comprises a nucleic acid encoding for a stem helix region of the SARS-CoV-2 spike protein. In some embodiments, the subject is immunocompromised. In some embodiments, the subject is immunosuppressed prior to administration (*e.g.*, by an immunosuppressive agent). In some embodiments, the subject has received at least one dose of a SARS-CoV-2 vaccine prior to administration of a composition provided herein. In some embodiments, the subject had previously exhibited at least one symptom of an upper respiratory infection.

Kits

[00131] Provided herein is a kit comprising a composition provided herein, a pharmaceutical composition provided herein; and optionally, a delivery system for administration to a subject. Kits described herein may comprise lyophilized reagents and, optionally, a reagent for hydration. Kits described herein may also comprise non-lyophilized reagents. In some embodiments, the kit comprises two or more separate units comprising the lipid carrier and the nucleic acid, respectively. In some embodiments, the kit comprises a unit that comprises the lipid carrier and the nucleic acid. In some embodiments, the kit further comprises a unit comprising a reagent for hydration of the dried composition. In some embodiments, the reagent for hydration comprises water.

[00132] In some embodiments, the kit further comprises one or more surfactants. In some embodiments, a formulation of a composition described herein is prepared in a single container for administration. In some embodiments, a formulation of a composition described herein is prepared two containers for administration, separating the nucleic acid from the nanoparticle carrier. As used herein, “container” includes vessel, vial, ampule, tube, cup, box, bottle, flask, jar, dish, well of a single-well or multi-well apparatus, reservoir, tank, or the like, or other device in which the herein disclosed compositions may be placed, stored and/or transported, and accessed to remove the contents. Examples of such containers include glass and/or plastic sealed or re-sealable tubes and ampules, including those having a rubber septum or other sealing means

that is compatible with withdrawal of the contents using a needle and syringe. In some implementations, the containers are RNase free.

[00133] In some embodiments, the kit comprises: (a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more lipids, and one or more surfactants; and (b) at least one nucleic acid sequence, which comprises a sequence which encodes a sequence capable of expressing an antigen, wherein the antigen is a SARS-CoV-2 spike protein.

Exemplary Embodiments

[00134] Provided herein are compositions, wherein the compositions comprise: a lipid carrier, wherein the lipid carrier comprises: liquid oil; and surfactants, wherein the surfactants comprise: a cationic lipid; a hydrophilic surfactant; and a hydrophobic surfactant; and at least one nucleic acid, wherein the at least one nucleic acid comprises a sequence at least 85% identical to SEQ ID NOS: 1 to 7, optionally 1 to 8. Further provided herein are compositions, wherein the nucleic acid is at least 85% identical to the sequence SEQ ID NO: 4, optionally at least 85% identical to the sequence SEQ ID NO: 27. Further provided herein are compositions, wherein the nucleic acid comprises a sequence region that is SEQ ID NO: 4. Further provided herein are compositions, wherein the nucleic acid is at least 85% identical to the sequence SEQ ID NO: 8. Further provided herein are compositions, wherein the nucleic acid is identical to SEQ ID NO: 4. Further provided herein are compositions, wherein the nucleic acid is identical to SEQ ID NO: 8. Further provided herein are compositions, wherein the nucleic acid is in complex with the lipid carrier. Further provided herein are compositions, wherein the nucleic acid further encodes for an RNA polymerase. Further provided herein are compositions, wherein the RNA polymerase is a Venezuelan equine encephalitis virus (VEEV) RNA polymerase. Further provided herein are compositions, wherein the nucleic acid encoding for the RNA polymerase comprises the nucleic acid sequence of SEQ ID NO: 20. Further provided herein are compositions, wherein the liquid oil is α -tocopherol, coconut oil, grapeseed oil, lauroyl polyoxylglyceride, mineral oil, monoacylglycerol, palmkernel oil, olive oil, paraffin oil, peanut oil, propolis, squalene, squalane, solanesol, soy lecithin, soybean oil, sunflower oil, a triglyceride, or vitamin E. Further provided herein are compositions, wherein the triglyceride is capric triglyceride, caprylic triglyceride, a caprylic and capric triglyceride, a triglyceride ester, or myristic acid triglycerin. Further provided herein are compositions, wherein the cationic lipid is 1,2-dioleoyloxy-3 (trimethylammonium)propane (DOTAP), 3 β -[N— (N',N'-

dimethylaminoethane) carbamoyl]cholesterol (DC Cholesterol), dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl 3-trimethylammoniumpropane(DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), N-[1-(2,3-dioleoyloxy)propyl]N,N,N-trimethylammonium, chloride (DOTMA), N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), and 1,2-dilinoleoyloxy-3-dimethylaminopropane (DLinDMA), 1,1'-((2-(4-(2-((bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), 306Oi10, tetrakis(8-methylnonyl) 3,3',3'',3'''-(((methylazanediyl) bis(propane-3,1-diyl))bis(azanetriyl))tetrapropionate, 9A1P9, decyl (2-(dioctylammonio)ethyl) phosphate; A2-Iso5-2DC18, ethyl 5,5-di((Z)-heptadec-8-en-1-yl)-1-(3-(pyrrolidin-1-yl)propyl)-2,5-dihydro-1H-imidazole-2-carboxylate; ALC-0315, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); ALC-0159, 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide; β -sitosterol, (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5R)-5-ethyl-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; BAME-O16B, bis(2-(dodecylsulfanyl)ethyl) 3,3'-((3-methyl-9-oxo-10-oxa-13,14-dithia-3,6-diazahexacosyl)azanediyl)dipropionate; BHEM-Cholesterol, 2-((((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)amino)-N,N-bis(2-hydroxyethyl)-N-methylethan-1-aminium bromide; cKK-E12, 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione; DC-Cholesterol, 3 β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol; DLin-MC3-DMA, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino) butanoate; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOSPA, 2,3-dioleoyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; ePC, ethylphosphatidylcholine; FTT5, hexa(octan-3-yl) 9,9',9'',9''',9''''-(((benzene-1,3,5-tricarbonyl)tris(azanediyl)) tris (propane-3,1-diyl)) tris(azanetriyl))hexanonanoate; Lipid H (SM-102), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino) octanoate; OF-Deg-Lin, (((3,6-dioxopiperazine-2,5-diyl)bis(butane-4, 1-diyl))bis(azanetriyl))tetrakis(ethane-2,1-diyl) (9Z,9'Z,9''Z,9'''Z,12Z,12'Z,12''Z,12'''Z)-tetrakis (octadeca-9,12-dienoate); PEG2000-DMG, (R)-

2,3-bis(myristoyloxy)propyl-1-(methoxy poly(ethylene glycol)2000) carbamate; TT3, or N1,N3,N5-tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide.

[00135] Provided herein are compositions, wherein the compositions comprise: a lipid carrier, wherein the lipid carrier comprises: liquid oil; and surfactants, wherein the surfactants comprise: a cationic lipid; a hydrophilic surfactant; and a hydrophobic surfactant; and at least one nucleic acid, wherein the nucleic acid comprises a sequence encoding for a SARS-CoV-2 omicron variant spike protein antigen or functional variant thereof. Further provided herein are compositions, wherein the SARS-CoV-2 omicron variant spike protein antigen or functional variant thereof comprises the stem helix of the SARS-CoV-2 omicron variant spike protein antigen. Further provided herein are compositions, wherein the stem helix of the SARS-CoV-2 omicron variant spike protein antigen comprises an amino acid sequence of SEQ ID NO: 19. Further provided herein are compositions, wherein the nucleic acid encoding for the SARS-CoV-2 omicron variant spike protein antigen comprises a polynucleotide sequence at least 85% identical to the sequence SEQ ID NO: 8, optionally at least 85% identical to the sequence to SEQ ID NO: 31. Further provided herein are compositions, wherein the SARS-CoV-2 omicron variant spike protein comprises the amino acid sequence of SEQ ID NO: 16. Further provided herein are compositions, wherein the nucleic acid is in complex with the lipid carrier. Further provided herein are compositions, wherein the nucleic acid further encodes for an RNA polymerase. Further provided herein are compositions, wherein the RNA polymerase is a Venezuelan equine encephalitis virus (VEEV) RNA polymerase. Further provided herein are compositions, wherein the nucleic acid encoding for the RNA polymerase comprises the nucleic acid sequence of SEQ ID NO: 20. Further provided herein are compositions, wherein the liquid oil is α -tocopherol, coconut oil, grapeseed oil, lauroyl polyoxylglyceride, mineral oil, monoacylglycerol, palmkernel oil, olive oil, paraffin oil, peanut oil, propolis, squalene, squalane, solanesol, soy lecithin, soybean oil, sunflower oil, a triglyceride, or vitamin E. Further provided herein are compositions, wherein the triglyceride is capric triglyceride, caprylic triglyceride, a caprylic and capric triglyceride, a triglyceride ester, or myristic acid triglycerin. Further provided herein are compositions, wherein the cationic lipid is 1,2-dioleoyloxy-3 (trimethylammonium)propane (DOTAP), 3β -[N— (N',N'-dimethylaminoethane) carbamoyl]cholesterol (DC Cholesterol), dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl 3-trimethylammoniumpropane(DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), N-[1-(2,3-dioleoyloxy)propyl]N,N,N-trimethylammonium, chloride (DOTMA), N,N-dioleoyl-N,N-

dimethylammonium chloride (DODAC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), and 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA), 1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), 306Oi10, tetrakis(8-methylnonyl) 3,3',3'',3'''-(((methylazanediyl) bis(propane-3,1-diyl))bis(azanetriyl))tetrapropionate, 9A1P9, decyl (2-(dioctylammonio)ethyl) phosphate; A2-Iso5-2DC18, ethyl 5,5-di((Z)-heptadec-8-en-1-yl)-1-(3-(pyrrolidin-1-yl)propyl)-2,5-dihydro-1H-imidazole-2-carboxylate; ALC-0315, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); ALC-0159, 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide; β -sitosterol, (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5R)-5-ethyl-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; BAME-O16B, bis(2-(dodecylsulfanyl)ethyl) 3,3'-((3-methyl-9-oxo-10-oxa-13,14-dithia-3,6-diazahexacosyl)azanediyl)dipropionate; BHEM-Cholesterol, 2-((((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)amino)-N,N-bis(2-hydroxyethyl)-N-methylethan-1-aminium bromide; cKK-E12, 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione; DC-Cholesterol, 3 β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol; DLin-MC3-DMA, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino) butanoate; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOSPA, 2,3-dioleyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; ePC, ethylphosphatidylcholine; FTT5, hexa(octan-3-yl) 9,9',9'',9''',9''''-(((benzene-1,3,5-tricarbonyl)tris(azanediyl)) tris (propane-3,1-diyl)) tris(azanetriyl))hexanonanoate; Lipid H (SM-102), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino) octanoate; OF-Deg-Lin, (((3,6-dioxopiperazine-2,5-diyl)bis(butane-4, 1-diyl))bis(azanetriyl))tetrakis(ethane-2,1-diyl) (9Z,9'Z,9''Z,9'''Z,12Z,12'Z,12''Z,12'''Z)-tetrakis(octadeca-9,12-dienoate); PEG2000-DMG, (R)-2,3-bis(myristoyloxy)propyl-1-(methoxy poly(ethylene glycol)2000) carbamate; TT3, or N1,N3,N5-tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide.

[00136] Provided herein are compositions, wherein the compositions comprise: a lipid carrier, wherein the lipid carrier comprises: liquid oil; and surfactants, wherein the surfactants comprise: a cationic lipid; a hydrophilic surfactant; and a hydrophobic surfactant; and at least one nucleic acid, wherein the nucleic acid comprises a sequence encoding for a stem helix of

SARS-CoV-2 spike protein antigen or functional variant thereof. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein antigen is derived from an alpha variant of SARS-CoV-2, a beta variant of SARS-CoV-2, a delta variant of SARS-CoV-2, a gamma variant of SARS-CoV-2, a mu variant of SARS-CoV-2, or an omicron variant of SARS-CoV-2. Further provided herein are compositions, wherein the stem helix of the SARS-CoV-2 spike protein antigen comprises an amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 19. Further provided herein are compositions, wherein the nucleic acid is in complex with the lipid carrier. Further provided herein are compositions, wherein the nucleic acid further encodes for an RNA polymerase. Further provided herein are compositions, wherein the RNA polymerase is a Venezuelan equine encephalitis virus (VEEV) RNA polymerase. Further provided herein are compositions, wherein the nucleic acid encoding for the RNA polymerase comprises the nucleic acid sequence of SEQ ID NO: 20. Further provided herein are compositions, wherein the liquid oil is α -tocopherol, coconut oil, grapeseed oil, lauroyl polyoxyglyceride, mineral oil, monoacylglycerol, palmkernel oil, olive oil, paraffin oil, peanut oil, propolis, squalene, squalane, solanesol, soy lecithin, soybean oil, sunflower oil, a triglyceride, or vitamin E. Further provided herein are compositions, wherein the triglyceride is capric triglyceride, caprylic triglyceride, a caprylic and capric triglyceride, a triglyceride ester, or myristic acid triglycerin. Further provided herein are compositions, wherein the cationic lipid is 1,2-dioleoyloxy-3-(trimethylammonium)propane (DOTAP), 3β -[N—(N',N'-dimethylaminoethane) carbamoyl]cholesterol (DC Cholesterol), dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl 3-trimethylammoniumpropane(DMTAP),dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), N-[1-(2,3-dioleoyloxy)propyl]N,N,N-trimethylammonium, chloride (DOTMA), N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), and 1,2- dilinoleyloxy-3-dimethylaminopropane (DLinDMA),1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), 306Oi10, tetrakis(8-methylnonyl) 3,3',3'',3'''-(((methylazanediyl) bis(propane-3,1 diyl))bis (azanetriyl))tetrapropionate, 9A1P9, decyl (2-(dioctylammonio)ethyl) phosphate; A2-Iso5-2DC18, ethyl 5,5-di((Z)-heptadec-8-en-1-yl)-1-(3-(pyrrolidin-1-yl)propyl)-2,5-dihydro-1H-imidazole-2-carboxylate; ALC-0315, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); ALC-0159, 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide; β -sitosterol, (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5R)-5-ethyl-6-methylheptan-2-yl)-10,13-

dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; BAME-O16B, bis(2-(dodecylsulfanyl)ethyl) 3,3'-((3-methyl-9-oxo-10-oxa-13,14-dithia-3,6-diazahexacosyl)azanediyl)dipropionate; BHEM-Cholesterol, 2-((((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)amino)-N,N-bis(2-hydroxyethyl)-N-methylethan-1-aminium bromide; cKK-E12, 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione; DC-Cholesterol, 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol; DLin-MC3-DMA, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino) butanoate; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOSPA, 2,3-dioleyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; ePC, ethylphosphatidylcholine; FTT5, hexa(octan-3-yl) 9,9',9'',9''',9''''-((((benzene-1,3,5-tricarbonyl)tris(azanediyl)) tris (propane-3,1-diyl)) tris(azanetriyl))hexanonanoate; Lipid H (SM-102), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino) octanoate; OF-Deg-Lin, (((3,6-dioxopiperazine-2,5-diyl)bis(butane-4, 1-diyl))bis(azanetriyl))tetrakis(ethane-2,1-diyl) (9Z,9'Z,9''Z,9'''Z,12Z,12'Z,12''Z,12'''Z)-tetrakis (octadeca-9,12-dienoate); PEG2000-DMG, (R)-2,3-bis(myristoyloxy)propyl-1-(methoxy poly(ethylene glycol)2000) carbamate; TT3, or N1,N3,N5-tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide.

[00137] Provided herein are compositions, wherein the compositions comprise: a lipid carrier, wherein the lipid carrier comprises: liquid oil; an inorganic nanoparticle, wherein the inorganic nanoparticle comprises iron oxide present in an amount of about 0.2 milligrams per milliliter (mg/ml) 12 nanometer (nm) iron oxide; and surfactants, wherein the surfactants comprise a cationic lipid; and at least one nucleic acid, wherein the nucleic acid comprises a sequence encoding for a SARS-CoV-2 spike protein antigen sequence or functional variant thereof. Further provided herein are compositions comprising: a nucleic acid present in an amount of up to about 200 micrograms (μg); a cationic lipid present in a concentration of up to about 1.5 mg/ml; iron oxide present in a concentration of up to about 0.01 mg/ml; squalene present in a concentration of up to about 1.88 mg/ml; sorbitan monostearate present in a concentration of up to about 1.86 mg/ml; polysorbate 80 present in a concentration of up to about 1.86 mg/ml; sucrose present in a concentration of up to about 50 mg/ml; and optionally, citric acid monohydrate present in a concentration of up to about 2.1 mg/ml. Further provided herein are compositions, wherein the nucleic acid is RNA or DNA. Further provided herein are

compositions, wherein the nucleic acid is RNA and present in an amount of up to about 50 ug. Further provided herein are compositions, wherein the liquid oil is α -tocopherol, coconut oil, grapeseed oil, lauroyl polyoxylglyceride, mineral oil, monoacylglycerol, palmkernel oil, olive oil, paraffin oil, peanut oil, propolis, squalene, squalane, solanesol, soy lecithin, soybean oil, sunflower oil, a triglyceride, or vitamin E. Further provided herein are compositions, wherein the triglyceride is capric triglyceride, caprylic triglyceride, a caprylic and capric triglyceride, a triglyceride ester, or myristic acid triglycerin. Further provided herein are compositions, wherein the cationic lipid is 1,2-dioleoyloxy-3 (trimethylammonium)propane (DOTAP), 3β -[N— (N',N'-dimethylaminoethane) carbamoyl]cholesterol (DC Cholesterol), dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl 3-trimethylammoniumpropane(DMTAP),dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), N-[1-(2,3-dioleoyloxy)propyl]N,N,N-trimethylammonium, chloride (DOTMA), N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), and 1,2- dilinoleoyloxy-3-dimethylaminopropane (DLinDMA),1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), 306Oi10, tetrakis(8-methylnonyl) 3,3',3'',3'''-(((methylazanediy) bis(propane-3,1 diyl))bis (azanetriyl))tetrapropionate, 9A1P9, decyl (2-(dioctylammonio)ethyl) phosphate; A2-Iso5-2DC18, ethyl 5,5-di((Z)-heptadec-8-en-1-yl)-1-(3-(pyrrolidin-1-yl)propyl)-2,5-dihydro-1H-imidazole-2-carboxylate; ALC-0315, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); ALC-0159, 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide; β -sitosterol, (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5R)-5-ethyl-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; BAME-O16B, bis(2-(dodecylsulfanyl)ethyl) 3,3'-((3-methyl-9-oxo-10-oxa-13,14-dithia-3,6-diazahexacosyl)azanediyl)dipropionate; BHEM-Cholesterol, 2-((((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)amino)-N,N-bis(2-hydroxyethyl)-N-methylethan-1-aminium bromide; cKK-E12, 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione; DC-Cholesterol, 3β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol; DLin-MC3-DMA, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino) butanoate; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOSPA, 2,3-dioleoyloxy-N-[2-(sperminecarboxamido)ethyl]-

N,N-dimethyl-1-propanaminium trifluoroacetate; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; ePC, ethylphosphatidylcholine; FTT5, hexa(octan-3-yl) 9,9',9'',9''',9''''-(((benzene-1,3,5-tricarbonyl)tris(azanediyl)) tris (propane-3,1-diyl)) tris(azanetriyl))hexanonanoate; Lipid H (SM-102), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino) octanoate; OF-Deg-Lin, (((3,6-dioxopiperazine-2,5-diyl)bis(butane-4, 1-diyl))bis(azanetriyl))tetrakis(ethane-2,1-diyl) (9Z,9'Z,9''Z,9'''Z,12Z,12'Z,12''Z,12'''Z)-tetrakis (octadeca-9,12-dienoate); PEG2000-DMG, (R)-2,3-bis(myristoyloxy)propyl-1-(methoxy poly(ethylene glycol)2000) carbamate; TT3, or N1,N3,N5-tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide. Further provided herein are compositions, wherein the nucleic acid is in complex with the lipid carrier. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein antigen is derived from an alpha variant of SARS-CoV-2, a beta variant of SARS-CoV-2, a delta variant of SARS-CoV-2, a gamma variant of SARS-CoV-2, a mu variant of SARS-CoV-2, or an omicron variant of SARS-CoV-2. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein is derived from a variant of SARS-CoV-2 comprising an amino acid substitution of D614G. Further provided herein are compositions, wherein the nucleic acid comprises a sequence as set forth in one of SEQ ID NOS: 1-8. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein antigen sequence or functional variant thereof has an amino acid sequence as set forth in one of SEQ ID NOS: 9-16. Further provided herein are compositions, wherein the nucleic acid is at least 85% identical to the sequence SEQ ID NO: 4, optionally at least 85% identical to the sequence SEQ ID NO: 27. Further provided herein are compositions, wherein the nucleic acid further encodes for an RNA polymerase. Further provided herein are compositions, wherein the RNA polymerase is a Venezuelan equine encephalitis virus (VEEV) RNA polymerase. Further provided herein are compositions, wherein the nucleic acid coding the RNA polymerase comprises the nucleic acid sequence of SEQ ID NO: 20.

[00138] Provided herein are compositions, wherein the compositions comprise: (a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising: about 30 mg/mL DOTAP chloride; about 37.5 mg/mL squalene; about 37 mg/ml sorbitan monostearate; about 37 mg/ml polysorbate 80; about 10 mM sodium citrate; and about 0.2 mg Fe/ml 12 nm oleic acid-coated iron oxide nanoparticles; and (b) at least one nucleic acid, wherein the at least one nucleic acid comprises a sequence encoding for a SARS-CoV-2 spike protein antigen sequence or functional variant thereof. Further provided herein are compositions comprising: a nucleic acid present in

an amount of up to about 200 ug; a cationic lipid present in a concentration of up to about 1.5 mg/ml; iron oxide present in a concentration of up to about 0.01 mg/ml; squalene present in a concentration of up to about 1.88 mg/ml; sorbitan monostearate present in a concentration of up to about 1.86 mg/ml; polysorbate 80 present in a concentration of up to about 1.86 mg/ml; sucrose present in a concentration of up to about 50 mg/ml; and optionally, citric acid monohydrate present in a concentration of up to about 2.1 mg/ml. Further provided herein are compositions, wherein the nucleic acid is RNA or DNA. Further provided herein are compositions, wherein the nucleic acid is RNA and present in an amount of up to about 50 ug. Further provided herein are compositions, wherein the composition further comprises sucrose. Further provided herein are compositions, wherein the sucrose is present in an amount of about 50 mg. Further provided herein are compositions, wherein the nucleic acid is in complex with the lipid carrier. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein antigen is derived from an alpha variant of SARS-CoV-2, a beta variant of SARS-CoV-2, a delta variant of SARS-CoV-2, a gamma variant of SARS-CoV-2, a mu variant of SARS-CoV-2, or an omicron variant of SARS-CoV-2. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein is derived from a variant of SARS-CoV-2 comprising an amino acid substitution of D614G. Further provided herein are compositions, wherein the nucleic acid comprises a sequence as set forth in one of SEQ ID NOS: 1-8. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein antigen sequence or functional variant thereof has an amino acid sequence as set forth in one of SEQ ID NOS: 9-17. Further provided herein are compositions, wherein the nucleic acid further encodes for an RNA polymerase. Further provided herein are compositions, wherein the RNA polymerase is a Venezuelan equine encephalitis virus (VEEV) RNA polymerase. Further provided herein are compositions, wherein the nucleic acid encoding the RNA polymerase comprises the nucleic acid sequence set forth in SEQ ID NO: 20. Further provided herein are compositions, wherein the nucleic acid is at least 85% identical to the sequence SEQ ID NO: 4, optionally at least 85% identical to the sequence SEQ ID NO: 27.

[00139] Provided herein are compositions, wherein the compositions comprise: comprising: (a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising: DOTAP chloride present in an amount of about 0.75 mg; squalene present in an amount of about 0.94 mg; sorbitan monostearate present in an amount of about 0.93 mg; polysorbate 80 present in an amount of about 0.93 mg; citric acid monohydrate present in an amount of about 1.05 mg; and oleic acid-coated iron oxide nanoparticles present in an amount of about 0.005 mg; and (b) at least one

nucleic acid, wherein the at least one nucleic acid comprises a sequence encoding for a SARS-CoV-2 spike protein antigen sequence or functional variant thereof. Further provided herein are compositions, wherein the at least one nucleic acid sequence is present in an amount of up to about 100 micrograms (μg). Further provided herein are compositions, wherein the at least one nucleic acid sequence is present in an amount of up to about 25 μg . Further provided herein are compositions, wherein the composition further comprises sucrose. Further provided herein are compositions, wherein the sucrose is present in an amount of about 50 milligrams (mg). Further provided herein are compositions, wherein the nucleic acid is in complex with the lipid carrier. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein antigen is derived from an alpha variant of SARS-CoV-2, a beta variant of SARS-CoV-2, a delta variant of SARS-CoV-2, a gamma variant of SARS-CoV-2, a mu variant of SARS-CoV-2, or an omicron variant of SARS-CoV-2. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein is derived from a variant of SARS-CoV-2 comprising an amino acid substitution of D614G. Further provided herein are compositions, wherein the nucleic acid comprises a sequence as set forth in one of SEQ ID NOS: 1-8. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein antigen sequence or functional variant thereof has an amino acid sequence as set forth in one of SEQ ID NOS: 9-19. Further provided herein are compositions, wherein the nucleic acid further encodes for an RNA polymerase. Further provided herein are compositions, wherein the RNA polymerase is a Venezuelan equine encephalitis virus (VEEV) RNA polymerase. Further provided herein are compositions, wherein the nucleic acid encoding for the RNA polymerase comprises the nucleic acid sequence of SEQ ID NO: 20. Further provided herein are compositions, wherein the composition is lyophilized. Further provided herein are compositions, wherein the nucleic acid is at least 85% identical to the sequence SEQ ID NO: 4, optionally at least 85% identical to the sequence SEQ ID NO: 27.

[00140] Provided herein is a suspension comprising a composition provided herein. Further provided herein is a pharmaceutical composition comprising a composition provided herein; and a pharmaceutically acceptable excipient.

[00141] Provided herein are compositions, wherein the compositions comprise: a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids; b) at least one nucleic acid sequence, wherein the nucleic acid sequence comprises a sequence capable of expressing an antigen, wherein the antigen is a SARS-CoV-2 spike protein. Further provided herein are compositions, wherein the nucleic acid is RNA. Further provided herein are compositions, wherein the compositions further

comprises a nucleic acid polymerase or a further nucleic acid encoding a sequence capable of expressing a nucleic acid polymerase. Further provided herein are compositions, wherein the compositions further comprise an RNA polymerase or a further nucleic acid encoding a sequence capable of expressing an RNA polymerase. Further provided herein are compositions, wherein the nucleic acid comprises a sequence as set forth in one of SEQ ID NOS: 1-8. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein has an amino acid sequence as set forth in one of SEQ ID NOS: 9-19. Further provided herein are compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 1. Further provided herein are compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 2. Further provided herein are compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 3. Further provided herein are compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 4. Further provided herein are compositions, wherein the nucleic acid is at least 85% identical to the sequence SEQ ID NO: 4, optionally at least 85% identical to the sequence SEQ ID NO: 27. Further provided herein are compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 5. Further provided herein are compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 6. Further provided herein are compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 7. Further provided herein are compositions, wherein the nucleic acid sequence comprises a sequence as set forth in SEQ ID NO: 8. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein is derived from the alpha variant of SARS-CoV-2. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein is derived from the beta variant of SARS-CoV-2. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein is derived from the delta variant of SARS-CoV-2. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein is derived from the gamma variant of SARS-CoV-2. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein is derived from the mu variant of SARS-CoV-2. Further provided herein are compositions, wherein the SARS-CoV-2 spike protein is derived from a variant of SARS-CoV-2 comprising an amino acid substitution of D614G. Further provided herein are compositions, wherein the hydrophobic core comprises an oil. Further provided herein are compositions, wherein the oil comprises at least one of α -tocopherol, lauroyl polyoxylglyceride, monoacylglycerol, propolis, squalene, mineral oil, grapeseed oil, olive oil, paraffin oil, peanut oil, soybean oil, sunflower oil, soy lecithin, triglyceride, and vitamin E, and a medium chain triglyceride. Further provided herein are compositions, wherein the one or more

inorganic nanoparticles is selected from the group consisting of metal salts, metal oxides, metal hydroxides, metal phosphates, metalloids and any combinations thereof. Further provided herein are compositions, wherein the one or more lipids is selected from the group consisting of cationic lipids, anionic lipids, neutral lipids, and any combinations thereof. Further provided herein are compositions, wherein the one or more lipids is a cationic lipid. Further provided herein are compositions, wherein the cationic lipid is selected from the group consisting of 1,2-dioleoyloxy-3-(trimethylammonium)propane (DOTAP); 3β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC Cholesterol); dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl-3-trimethylammoniumpropane (DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP); distearoyltrimethylammonium propane (DSTAP); N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA); N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC); 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); and 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA); 1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), and any combinations thereof. Further provided herein are compositions, wherein the lipid carrier optionally comprises one or more surfactants. Further provided herein are compositions, wherein the one or more surfactants is selected from the group consisting of hydrophobic surfactant, hydrophilic surfactant, and any combinations thereof. Further provided herein are compositions, wherein the hydrophobic surfactant comprises a sorbitan ester selected from the group consisting of sorbitan monostearate, sorbitan monooleate, and sorbitan trioleate; and the hydrophilic surfactant comprises a polysorbate. Further provided herein are compositions, wherein the lipid carrier have a z-average hydrodynamic diameter ranging from about 40 nm to about 150 nm, with an average polydispersity index ranging from about 0.1 to about 0.4. Further provided herein are compositions, wherein the one or more nucleic acids is incorporated or complexed with the lipid carrier to form a lipid carrier-nucleic acid complex. Further provided herein are compositions, wherein the complex is formed via non-covalent interactions or via reversible covalent interactions. Further provided herein are compositions, wherein the molar ratio of the lipid carrier to the one or more nucleic acids, characterized by the nitrogen-to-phosphate (N:P) molar ratio, ranges from about 1:1 to about 150:1. Further provided herein are compositions, wherein the composition is stable at 2 to 8 degrees Celsius.

[00142] Provided herein are vaccine compositions, wherein the vaccine comprises: (a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or

more inorganic nanoparticles and one or more lipids; (b) at least one nucleic acid sequence, wherein the nucleic acid sequence comprises a sequence capable of expressing an antigen, wherein the antigen is a SARS-CoV-2 spike protein. Further provided herein are vaccine compositions, wherein the nucleic acid is RNA. Further provided herein are vaccine compositions, wherein the vaccine compositions further comprise a nucleic acid polymerase or a further nucleic acid encoding a sequence capable of expressing a nucleic acid polymerase. Further provided herein are vaccine compositions, wherein the vaccine compositions further comprise an RNA polymerase or a further nucleic acid sequence encoding a sequence capable of expressing an RNA polymerase. Further provided herein are vaccine compositions, wherein the nucleic acid comprises a sequence as set forth in one of SEQ ID NOS: 1-8. Further provided herein are vaccine compositions, wherein the SARS-CoV-2 spike protein has an amino acid sequence as set forth in one of SEQ ID NOS: 9-17. Further provided herein are compositions, wherein the nucleic acid is at least 85% identical to the sequence SEQ ID NO: 4, optionally at least 85% identical to the sequence SEQ ID NO: 27. Further provided herein are vaccine compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 1. Further provided herein are vaccine compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 2. Further provided herein are vaccine compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 3. Further provided herein are vaccine compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 4. Further provided herein are vaccine compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 5. Further provided herein are vaccine compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 6. Further provided herein are vaccine compositions, wherein the nucleic acid comprises a sequence as set forth in SEQ ID NO: 7. Further provided herein are vaccine compositions, wherein the nucleic acid sequence comprises a sequence as set forth in SEQ ID NO: 8. Further provided herein are vaccine compositions, wherein the SARS-CoV-2 spike protein is the alpha variant of SARS-CoV-2. Further provided herein are vaccine compositions, wherein the SARS-CoV-2 spike protein is the beta variant of SARS-CoV-2. Further provided herein are vaccine compositions, wherein the SARS-CoV-2 spike protein is the delta variant of SARS-CoV-2. Further provided herein are vaccine compositions, wherein the SARS-CoV-2 spike protein is the gamma variant of SARS-CoV-2. Further provided herein are vaccine compositions, wherein the SARS-CoV-2 spike protein is the mu variant of SARS-CoV-2. Further provided herein are vaccine compositions, wherein the SARS-CoV-2 spike protein is the D614G variant of SARS-

CoV-2. Further provided herein are vaccine compositions, wherein the hydrophobic core comprises an oil. Further provided herein are vaccine compositions, wherein the oil comprises at least one of α -tocopherol, lauroyl polyoxylglyceride, monoacylglycerol, propolis, squalene, mineral oil, grapeseed oil, olive oil, paraffin oil, peanut oil, soybean oil, sunflower oil, soy lecithin, triglyceride, vitamin E, a medium chain triglyceride. Further provided herein are vaccine compositions, wherein the one or more inorganic nanoparticles is selected from the group consisting of metal salts, metal oxides, metal hydroxides, metal phosphates, metalloids, and any combinations thereof. Further provided herein are vaccine compositions, wherein the one or more lipids is selected from the group consisting of cationic lipids, anionic lipids, neutral lipids, and any combinations thereof. Further provided herein are vaccine compositions, wherein the one or more lipids is a cationic lipid. Further provided herein are vaccine compositions, wherein the cationic lipid is selected from the group consisting of 1,2-dioleoyloxy-3-(trimethylammonium)propane (DOTAP); 3β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC Cholesterol); dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl-3-trimethylammoniumpropane (DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP); distearoyltrimethylammonium propane (DSTAP); N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA); N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC); 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); and 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA); 1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), and any combinations thereof. Further provided herein are vaccine compositions, wherein the lipid carrier optionally comprises one or more surfactants. Further provided herein are vaccine compositions, wherein the one or more surfactants is selected from the group consisting of hydrophobic surfactant, hydrophilic surfactant, and any combinations thereof. Further provided herein are vaccine compositions, wherein the hydrophobic surfactant comprises a sorbitan ester selected from the group consisting of sorbitan monostearate, sorbitan monooleate, and sorbitan trioleate; and the hydrophilic surfactant comprises a polysorbate. Further provided herein are vaccine compositions, wherein the lipid carrier have a z-average hydrodynamic diameter ranging from about 40 nm to about 150 nm, with an average polydispersity index ranging from about 0.1 to about 0.4. Further provided herein are vaccine compositions, wherein the one or more nucleic acids is incorporated or complexed with the lipid carrier to form a lipid carrier-nucleic acid complex. Further provided herein are vaccine compositions, wherein the complex is formed via

non-covalent interactions or via reversible covalent interactions. Further provided herein are vaccine compositions, wherein the molar ratio of the lipid carrier to the one or more nucleic acids, characterized by the nitrogen-to-phosphate (N:P) molar ratio, ranges from about 1:1 to about 150:1. Further provided herein are vaccine compositions, wherein the vaccine compositions are stable at 2 to 8 degrees Celsius.

[00143] Provided herein are methods of generating an immune response in a subject, wherein the methods comprise administering to said subject a composition comprising: a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids; b) at least one nucleic acid sequence, wherein the nucleic acid sequence comprises a sequence capable of expressing an antigen, wherein the antigen is a SARS-CoV-2 spike protein. Further provided herein are methods, wherein the compositions are administered to the subject by two doses. Further provided herein are methods, wherein the second dose is administered at about 28 days after the first dose. Further provided herein are methods, wherein the methods further comprise administering a third dose of said composition to said subject. Further provided herein are methods, wherein 5 micrograms of said composition is administered to said subject. Further provided herein are methods, wherein 10 micrograms of said composition is administered to said subject. Further provided herein are methods, wherein 25 micrograms of said composition is administered to said subject. Further provided herein are methods, wherein the subject is a mammal. Further provided herein are methods, wherein the mammal is a human. Further provided herein are methods, wherein the composition is administered intramuscularly.

[00144] Provided herein are compositions for immunoprotecting a subject, the compositions comprising: a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids; b) at least one nucleic acid sequence, wherein the nucleic acid sequence comprises a sequence capable of expressing an antigen, wherein the antigen is a SARS-CoV-2 spike protein.

[00145] Provided herein are methods of reducing the severity of a SARS-CoV-2 infection, the methods comprising administering prior to infection a composition comprising: a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids; b) at least one nucleic acid sequence, wherein the nucleic acid sequence comprises a sequence capable of expressing an antigen, wherein the antigen is a SARS-CoV-2 spike protein. Further provided herein are methods, wherein the composition is administered to the subject by two doses. Further provided herein are methods,

wherein the second dose is administered at about 28 days after the first dose. Further provided herein are methods, wherein the methods further comprise administering a third dose of said composition to said subject. Further provided herein are methods, wherein 5 micrograms of said composition is administered to said subject. Further provided herein are methods, wherein 10 micrograms of said composition is administered to said subject. Further provided herein are methods, wherein 25 micrograms of said composition is administered to said subject. Further provided herein are methods, wherein the subject is a mammal. Further provided herein are methods, wherein the mammal is a human. Further provided herein are methods, wherein the composition is administered intramuscularly.

[00146] Provided herein are methods of immunoprotecting a subject, the methods comprising: a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids; b) at least one nucleic acid sequence, wherein the nucleic acid sequence comprises a sequence capable of expressing an antigen, wherein the antigen is a SARS-CoV-2 spike protein. Further provided herein are methods, wherein the composition is administered to the subject by two doses. Further provided herein are methods, wherein the second dose is administered at about 28 days after the first dose. Further provided herein are methods, wherein the methods further comprise administering a third dose of said composition to said subject. Further provided herein are methods, wherein 5 micrograms of said composition is administered to said subject. Further provided herein are methods, wherein 10 micrograms of said composition is administered to said subject. Further provided herein are methods, wherein 25 micrograms of said composition is administered to said subject. Further provided herein are methods, wherein the subject is a mammal. Further provided herein are methods, wherein the mammal is a human. Further provided herein are methods, wherein the composition is administered intramuscularly.

[00147] Provided herein are kits, the kits comprising: (a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids; (b) at least one nucleic acid sequence, wherein the nucleic acid sequence comprises a sequence capable of expressing an antigen, wherein the antigen is a SARS-CoV-2 spike protein. Further provided herein are kits, the kits comprising: (a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more lipids, and one or more surfactants; (b) at least one nucleic acid sequence, which comprises a sequence which encodes a sequence capable of expressing an antigen, wherein the antigen is a SARS-CoV-2 spike protein. Further provided herein are kits, wherein the kit further comprises one or more

surfactants. Further provided herein are kits, wherein the RNA comprises a sequence comprising a vector sequence as set forth in SEQ ID NO: 20. Further provided herein are kits, wherein the RNA comprises a sequence comprising an antigen sequence as set forth in one of SEQ ID NOS: 1-8. Further provided herein are kits, wherein the RNA comprises a sequence comprising a sequence as set forth in one of SEQ ID NOS: 24-31. Further provided herein are kits, wherein the RNA comprises a sequence comprising a vector sequence as set forth in one of SEQ ID NOS: 32-38.

[00148] Provided herein are dried compositions comprising: a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids; b) at least one nucleic acid sequence, which comprises a sequence which encodes a sequence capable of expressing an antigen, wherein the antigen is a SARS-CoV-2 spike protein; and c) at least one cryoprotectant. Further provided herein are dried compositions, wherein the composition is lyophilized. Further provided herein are dried compositions, wherein the dried compositions are spray-dried. Further provided herein are dried compositions, wherein the dried compositions are thermally stable. Further provided herein are dried compositions, wherein the dried compositions are thermally stable at about 25 degrees C. Further provided herein are dried compositions, wherein the dried compositions are thermally stable at about 45 degrees C. Further provided herein are dried compositions, wherein the dried compositions are thermally stable at about -20 degrees C. Further provided herein are dried compositions, wherein the dried compositions are thermally stable at about 2 degrees Celsius to about 8 degrees Celsius. Further provided herein are dried compositions, wherein the dried compositions are thermally stable for at least 1 week, at least 2 weeks, and/or at least 1 month. Further provided herein are dried compositions, wherein the hydrophobic core comprises an oil. Further provided herein are dried compositions, wherein the oil comprises at least one of α -tocopherol, lauroyl polyoxylglyceride, monoacylglycerol, propolis, squalene, mineral oil, grapeseed oil, olive oil, paraffin oil, peanut oil, soybean oil, sunflower oil, soy lecithin, triglyceride, vitamin E, a medium chain triglyceride, dihydroisqualene (DHIS), farnesene and squalane. Further provided herein are dried compositions, wherein the one or more inorganic nanoparticles is selected from the group consisting of metal salts, metal oxides, metal hydroxides, metal phosphates, metalloids, and any combinations thereof. Further provided herein are dried compositions, wherein the one or more lipids is selected from the group consisting of cationic lipids, anionic lipids, neutral lipids, and any combinations thereof. Further provided herein are dried compositions, wherein the one or more lipids is a cationic lipid. Further

provided herein are dried compositions, wherein the cationic lipid is selected from the group consisting of 1,2-dioleoyloxy-3-(trimethylammonium)propane (DOTAP); 3 β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC Cholesterol); dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl-3-trimethylammoniumpropane (DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP); distearoyltrimethylammonium propane (DSTAP); N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA); N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC); 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); and 1,2-dilinoleyloxy-3-dimethylaminopropane (DLin-DMA); 1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl) (2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE); N-decyl-N,N-dimethyldecyl-1-aminium bromide (DDAB); 2,3-dioleoyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA); ethylphosphatidylcholine (ePC); and any combinations thereof. Further provided herein are dried compositions, wherein the lipid carrier optionally comprises at least one surfactant. Further provided herein are dried compositions, wherein the at least one surfactant is selected from the group consisting of a hydrophobic surfactant, a hydrophilic surfactant, and any combinations thereof. Further provided herein are dried compositions, wherein the hydrophobic surfactant comprises a sorbitan ester selected from the group consisting of: SPAN® 20, SPAN® 40, SPAN® 60, SPAN® 65, SPAN® 80 and SPAN® 85; and the hydrophilic surfactant comprises a polysorbate. Further provided herein are dried compositions, wherein the lipid carrier has a z-average hydrodynamic diameter ranging from about 40 nm to about 150 nm, with an average polydispersity index ranging from about 0.1 to about 0.4. Further provided herein are dried compositions, wherein the one or more nucleic acid sequence is an RNA. Further provided herein are dried compositions, wherein the RNA is a self-replicating RNA. Further provided herein are dried compositions, wherein the one or more nucleic acid sequence comprises a sequence which encodes an antigen. Further provided herein are dried compositions, wherein the antigen is derived from a virus. Further provided herein are dried compositions, wherein the virus is selected from the group consisting of: a hepatitis virus, a coronavirus, a mosquito-borne virus, and an HIV virus. Further provided herein are dried compositions, wherein the one or more nucleic acid sequence is incorporated or complexed with the lipid carrier to form a lipid carrier-nucleic acid complex. Further provided herein are dried compositions, wherein the lipid carrier-nucleic acid complex is formed via non-covalent

interactions or via reversible covalent interactions. Further provided herein are dried compositions, wherein the molar ratio of the lipid carrier to the one or more nucleic acids, characterized by the nitrogen-to-phosphate (N:P) molar ratio, ranges from about 1:1 to about 150:1. Further provided herein are dried compositions, wherein the at least one cryoprotectant is selected from the group consisting of sucrose, maltose, trehalose, mannitol, glucose, and any combinations thereof. Further provided herein are dried compositions, wherein the at least one cryoprotectant is sucrose. Further provided herein are dried compositions, wherein the at least one cryoprotectant is at about 1% w/v to at about 20% w/v. Further provided herein are dried compositions, wherein the at least one cryoprotectant is at about 10% w/v to at about 20% w/v. Further provided herein are dried compositions, wherein at least one cryoprotectant is at about 10% w/v.

[00149] Provided herein are pharmaceutical compositions, wherein the pharmaceutical compositions comprise: a composition provided herein reconstituted in a suitable diluent and a pharmaceutically acceptable carrier. Further provided herein are pharmaceutical compositions, wherein the diluent is aqueous. Further provided herein are pharmaceutical compositions, wherein the diluent is water.

[00150] Provided herein are kits comprising a pharmaceutical composition provided herein and a delivery system for administration to a subject.

[00151] Provided herein are vaccine delivery systems comprising a pharmaceutical composition provided herein and optionally, one or more vaccine adjuvants.

[00152] Provided herein are methods for generating an immune response in a subject, the methods comprise: administering to a subject a composition or a pharmaceutical composition provided herein, thereby generating an immune response to an antigen. Further provided herein are methods, wherein the composition is administered to the subject by two doses. Further provided herein are methods, wherein the second dose is administered at about 28 days after the first dose. Further provided herein are methods, wherein the method further comprises administering a third dose of the composition to said subject. Further provided herein are methods, wherein 5 µg of the composition is administered to the subject. Further provided herein are methods, wherein 10 µg of the composition is administered to said subject. Further provided herein are methods, wherein 25 µg of the composition is administered to said subject. Further provided herein are methods, wherein the composition is administered intramuscularly or intranasally. Further provided herein are methods, wherein the subject is a human. Further provided herein are methods, wherein the subject has or is suspected of having a viral infection.

Further provided herein are methods, wherein the viral infection is a coronavirus infection. Further provided herein are methods, wherein the coronavirus infection is caused by a SARS-CoV-2 virus or a variant thereof. Further provided herein are methods, wherein the antigen is a SARS-CoV-2 spike protein or a fragment thereof. Further provided herein are methods, wherein the immune response comprises increasing the amount or titer of neutralizing antibodies to the antigen as compared to a subject that has not been administered the composition. Further provided herein are methods, wherein the immune response comprises increasing the amount of CD4+ and/or CD8+ positive T cells as compared to a subject that has not been administered the composition. Further provided herein are methods, wherein the subject is immunocompromised or immunosuppressed.

[00153] Provided herein are methods of augmenting an immune response in a subject, the method comprising: administering to a subject the composition provided herein, thereby augmenting an immune response to an antigen.

[00154] Provided herein are methods of treating or preventing a disease in a subject, the methods comprise administering a therapeutically effective amount of the pharmaceutical provided herein to the subject.

[00155] Provided herein are methods of imaging and/or tracking delivery of one or more nucleic acids in a subject, the methods comprise administering a therapeutically effective amount of the pharmaceutical composition provided herein to the subject.

[00156] Provided herein are methods for preparing a lyophilized composition comprising: a) obtaining a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids; b) incorporating at least one nucleic acid into the lipid carrier to form a lipid carrier- nucleic acid complex, wherein the nucleic acid comprises a sequence comprising an antigen sequence which is at least 80% identical to a sequence as set forth in one SEQ ID NOS: 1-8, 24-31; c) adding at least one cryoprotectant to the lipid carrier-nucleic acid complex to form a formulation; and d) lyophilizing the formulation to form a lyophilized composition.

[00157] Provided herein are methods for preparing a spray-dried composition comprising: (a) obtaining a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids; (b) incorporating at least one nucleic acid into the lipid carrier to form a lipid carrier- nucleic acid complex, wherein the nucleic acid comprises a sequence comprising an antigen sequence which is at least 80% identical to a sequence as set forth in one of SEQ ID NOS: 1-8, 24-31; (c) adding at least

one cryoprotectant to the lipid carrier-nucleic acid complex to form a formulation; and (d) spray drying the formulation to form a spray-dried composition.

[00158] Provided herein are methods for reconstituting a lyophilized composition comprising: (a) obtaining a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles, and one or more lipids; (b) incorporating at least one nucleic acid into the said lipid carrier to form a lipid carrier-nucleic acid complex, wherein the nucleic acid comprises a sequence comprising an antigen sequence which is at least 80% identical to a sequence as set forth in one of SEQ ID NOS: 1-8, 24-31; (c) adding at least one cryoprotectant to the lipid carrier-nucleic acid complex to form a formulation; (d) lyophilizing the formulation to form a lyophilized composition; and (e) reconstituting the lyophilized composition in a suitable diluent.

[00159] Provided herein are methods for reconstituting a spray-dried composition comprising: (a) obtaining a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles, and one or more lipids; (b) incorporating at least one nucleic acid into the said lipid carrier to form a lipid carrier-nucleic acid complex, wherein the nucleic acid comprises a sequence comprising an antigen sequence which is at least 80% identical to a sequence as set forth in one of SEQ ID NOS: 1-8, 24-31; (c) adding at least one cryoprotectant to the lipid carrier-nucleic acid complex to form a formulation; (d) spray drying the formulation to form a spray-dried composition; and (e) reconstituting the spray-dried composition in a suitable diluent. Further provided herein are methods, wherein the diluent is aqueous. Further provided herein are methods, wherein the diluent is water. Further provided herein are methods, wherein the lyophilized composition is thermally stable. Further provided herein are methods, wherein the lyophilized composition is thermally stable at temperatures up to about 25 °C. Further provided herein are methods, wherein the lyophilized composition is thermally stable at temperatures up to about 45 °C. Further provided herein are methods, wherein the lyophilized composition is thermally stable at temperatures down to about -20 °C. Further provided herein are methods, wherein the lyophilized composition is thermally stable at temperatures ranging from about 2 °C to about 8 °C. Further provided herein are methods, wherein the lyophilized composition is thermally stable for at least 1 week, at least 2 weeks, and/or at least 1 month. Further provided herein are methods, wherein the hydrophobic core comprises an oil. Further provided herein are methods, wherein the oil comprises at least one of α -tocopherol, lauroyl polyoxylglyceride, monoacylglycerol, propolis, squalene, mineral oil, grapeseed oil, olive oil, paraffin oil, peanut oil, soybean oil, sunflower oil, soy lecithin,

triglyceride, vitamin E, medium chain triglyceride, dihydroisqualene (DHIS), farnesene and squalane. Further provided herein are methods, wherein the one or more inorganic nanoparticles is selected from the group consisting of metal salts, metal oxides, metal hydroxides, metal phosphates, metalloids and any combinations thereof. Further provided herein are methods, wherein the one or more lipids is selected from the group consisting of cationic lipids, anionic lipids, neutral lipids, and any combinations thereof. Further provided herein are methods, wherein the one or more lipids is a cationic lipid. Further provided herein are methods, wherein the cationic lipid is selected from the group consisting of 1,2-dioleoyloxy-3-(trimethylammonium)propane (DOTAP); 3β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC Cholesterol); dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl-3-trimethylammoniumpropane (DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP); distearoyltrimethylammonium propane (DSTAP); N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA); N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC); 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); and 1,2-dilinoleyloxy-3-dimethylaminopropane (DLin-DMA); 1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), 1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine (DOPE); *N*-decyl-*N,N*-dimethyldecan-1-aminium bromide (DDAB); 2,3-dioleoyloxy-*N*-[2-(sperminecarboxamido)ethyl]-*N,N*-dimethyl-1-propanaminium trifluoroacetate (DOSPA); ethylphosphatidylcholine (ePC); and any combinations thereof. Further provided herein are methods, wherein the lipid carrier optionally comprises one or more surfactant. Further provided herein are methods, wherein the one or more surfactant is selected from the group consisting of hydrophobic surfactant, hydrophilic surfactant, and any combinations thereof. Further provided herein are methods, wherein the hydrophobic surfactant comprises a sorbitan ester selected from the group consisting of SPAN® 20, SPAN® 40, SPAN® 60, SPAN® 65, SPAN 80®, and SPAN® 85; and the hydrophilic surfactant comprises a polysorbate. Further provided herein are methods, wherein the lipid carrier has a z-average hydrodynamic diameter ranging from about 40 nm to about 150 nm, with an average polydispersity index ranging from about 0.1 to about 0.4. Further provided herein are methods, wherein the one or more nucleic acid is an RNA. Further provided herein are methods, wherein the RNA is a self-replicating RNA. Further provided herein are methods, wherein the one or more nucleic acid encodes an antigen, wherein the antigen is derived from a bacterial infection, a bacterial disease, a viral infection, a viral disease, a protozoan infection, a protozoan

disease, a non-communicable disease, one or more cancers, or an autoimmune disease. Further provided herein are methods, wherein the antigen is derived from a virus. Further provided herein are methods, wherein the virus is selected from the group consisting of a hepatitis virus, a corona virus, a mosquito-borne virus, and a HIV virus. Further provided herein are methods, wherein the one or more nucleic acid is incorporated or complexed with the lipid carrier to form a lipid carrier-nucleic acid complex. Further provided herein are methods, wherein the lipid carrier-nucleic acid complex is formed via non-covalent interactions or via reversible covalent interactions. Further provided herein are methods, wherein the at least one cryoprotectant is selected from the group consisting of sucrose, maltose, trehalose, mannitol, glucose, and any combinations thereof. Further provided herein are methods, wherein the at least one cryoprotectant is sucrose. Further provided herein are methods, wherein the at least one cryoprotectant is at about 1% w/v to at about 20% w/v. Further provided herein are methods, wherein the at least one cryoprotectant is at about 10% w/v to at about 20% w/v. Further provided herein are methods, wherein the at least one cryoprotectant is at about 10% w/v.

[00160] Provided herein are compositions for prophylaxis of SARS-CoV-2, the compositions comprising: a) a sorbitan fatty acid ester; b) an ethoxylated sorbitan ester; c) a cationic lipid; d) an immune stimulant; and e) at least one RNA encoding an antigen sequence or functional fragment thereof. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the sorbitan fatty acid ester is sorbitan monostearate. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the ethoxylated sorbitan ester is TWEEN® 80. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the cationic lipid is DOTAP. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the immune stimulant is squalene. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the RNA encodes a SARS-CoV-2 spike protein. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the ratio of the esters yields a Hydrophilic-Lipophilic Balance between 8 and 11. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the ratio of esters and lipids yields a particle size between 30 and 200 nanometers. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the ratio of esters and lipids yields a particle size between 40 and 70 nanometers. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the immune stimulant decreases the total amount of protein produced, but increases the immune response to the vaccine. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the immune stimulant increases the total amount of

protein, produced, but decreases the immune response to the vaccine. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the immune stimulant is Miglyol 810 or Miglyol 812. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the compositions further comprise sorbitan monostearate, polysorbate 80, DOTAP, and squalene and no solid particles.

[00161] Provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the compositions comprise: (a) sorbitan monostearate; (b) polysorbate 80; (c) DOTAP; (d) an immune stimulant; and (e) at least one RNA encoding an antigen sequence or functional fragment thereof. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the immune stimulant decreases the total amount of protein produced, but increases the immune response to the vaccine. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the immune stimulant increases the total amount of protein, produced, but decreases the immune response to the vaccine. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the immune stimulant is Miglyol 810 or Miglyol 812. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the compositions further comprise squalene and no solid particles. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the ratio of the esters yields a Hydrophilic-Lipophilic Balance between 8 and 11. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the particle size is between 30 and 200 nanometers. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the N to P ratio is between 5 and 35. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the RNA encodes an amino acid sequence as set forth in one of SEQ ID NOS: 9-19. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the RNA comprises a sequence as set forth in one of SEQ ID NOS: 1-8. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the RNA comprises a sequence as set forth in one of SEQ ID NOS: 24-31. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the RNA comprises a sequence comprising a vector sequence as set forth in SEQ ID NO: 20. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the RNA comprises a sequence comprising an sequence as set forth in one of SEQ ID NOS: 1-8, 24-31. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the RNA comprises a sequence comprising a vector sequence as set forth in one of SEQ ID NOS: 32-38. Further provided herein are compositions for prophylaxis of SARS-CoV-2, wherein the compositions comprise a nucleic acid comprising an alphavirus replicon.

[00162] Provided here are dried compositions comprising: a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, and one or more lipids; at least one nucleic acid that comprises a sequence which encodes a sequence capable of expressing an antigen, optionally wherein the antigen is a SARS-CoV-2 spike protein or a functional variant thereof; and at least one sugar present in amount of (i) at least about 50% by weight of the dried composition, or (ii) present in an amount of least 50 mg. Further provided herein are compositions, wherein the composition is lyophilized. Further provided herein are compositions, wherein the composition is thermally stable at about 25 degrees Celsius. Further provided herein are compositions, wherein the composition is thermally stable at about 45 degrees Celsius. Further provided herein are compositions, wherein the composition is thermally stable at about -20 degrees Celsius. Further provided herein are compositions, wherein the composition is thermally stable at about 2 degrees Celsius to about 8 degrees Celsius. Further provided herein are compositions, wherein the composition is thermally stable for at least 1 week, at least 2 weeks, and/or at least 1 month. Further provided herein are compositions, wherein the hydrophobic core comprises an oil. Further provided herein are compositions, wherein the oil comprises at least one of α -tocopherol, lauroyl polyoxyglyceride, monoacylglycerol, propolis, squalene, mineral oil, grapeseed oil, olive oil, paraffin oil, peanut oil, soybean oil, sunflower oil, soy lecithin, triglyceride, vitamin E, a caprylic/capric triglyceride, a triglyceride ester of saturated coconut/palmkernel oil derived caprylic and capric fatty acids and plant derived glycerol, dihydroisosqualene (DHIS), farnesene and squalane. Further provided herein are compositions, wherein the one or more lipids is selected from the group consisting of cationic lipids, anionic lipids, neutral lipids, and any combinations thereof. Further provided herein are compositions, wherein the one or more lipids comprises a cationic lipid. Further provided herein are compositions, wherein the cationic lipid is selected from the group consisting of 1,2-dioleoyloxy-3-(trimethylammonium)propane (DOTAP); 3β -[N-(N',N'-dimethylaminoethane)-carbonyl]cholesterol (DC Cholesterol); dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl-3-trimethylammoniumpropane (DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP); distearoyltrimethylammonium propane (DSTAP); N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA); N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC); 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); and 1,2-dilinoleoyloxy-3-dimethylaminopropane (DLin-DMA); 1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200),

1,2- dioleoyl-*sn*-glycero-3-phosphoethanolamine (DOPE); *N*-decyl-*N,N*-dimethyldecyl-1-aminium bromide (DDAB); 2,3-dioleyloxy-*N*-[2-(sperminecarboxamido)ethyl]-*N,N*-dimethyl-1-propanaminium trifluoroacetate (DOSPA); ethylphosphatidylcholine (ePC); and any combinations thereof. Further provided herein are compositions, wherein the lipid carrier comprises at least one surfactant. Further provided herein are compositions, wherein the at least one surfactant is selected from the group consisting of a hydrophobic surfactant, a hydrophilic surfactant, and any combinations thereof. Further provided herein are compositions, wherein the hydrophobic surfactant comprises a sorbitan ester selected from the group consisting of sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, and sorbitan trioleate; and the hydrophilic surfactant comprises a polysorbate. Further provided herein are compositions, wherein the lipid carrier has a z-average hydrodynamic diameter ranging from about 40 nm to about 150 nm, with an average polydispersity index ranging from about 0.1 to about 0.4. Further provided herein are compositions, wherein the one or more nucleic acid is a DNA. Further provided herein are compositions, wherein the one or more nucleic acid is a RNA. Further provided herein are compositions, wherein the RNA is a self-replicating RNA. Further provided herein are compositions, wherein the hydrophobic core comprises one or more inorganic nanoparticles. Further provided herein are compositions, wherein the one or more inorganic nanoparticles is selected from the group consisting of a metal salt, metal oxide, metal hydroxide, metal phosphate, and any combinations thereof. Further provided herein are compositions, wherein the one or more nucleic acid is incorporated or complexed with the lipid carrier to form a lipid carrier-nucleic acid complex. Further provided herein are compositions, wherein the lipid carrier-nucleic acid complex is formed via non-covalent interactions or via reversible covalent interactions. Further provided herein are compositions, wherein a molar ratio of the lipid carrier to the one or more nucleic acids, characterized by the nitrogen-to-phosphate (N:P) molar ratio, ranges from about 1:1 to about 150:1. Further provided herein are compositions, wherein the at least one sugar is selected from the group consisting of sucrose, maltose, trehalose, mannitol, glucose, and any combinations thereof. Further provided herein are compositions, wherein the at least one sugar is present in an amount of at least about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 or more mg. Further provided herein are compositions, wherein the at least one sugar is present in an amount of 50 mg to 250 mg. Further provided herein are compositions, wherein the at least one sugar is present in an amount of at least about 250 mg. Further provided herein are compositions, wherein

the sugar is present in amount of the composition by weight of at least about 50, 55, 60, 65, 70, 75, 80, 85, 90, 95% or more. Further provided herein are compositions, wherein the sugar is present in amount of the composition by weight of 80 to 98%, optionally 94 to 96%. Further provided herein are compositions, wherein the sugar is present in amount of the composition by weight of about 95%. Further provided herein are compositions, wherein the at least one sugar comprises sucrose. Further provided herein are pharmaceutical compositions, comprising a dried composition disclosed herein reconstituted in a suitable diluent and a pharmaceutically acceptable carrier. Further provided herein are pharmaceutical compositions wherein the diluent is aqueous. Further provided herein are pharmaceutical compositions wherein the diluent is water. Further provided herein are kits comprising a pharmaceutical composition described herein and a delivery system for administration to a subject. Further provided are methods for generating an immune response in a subject, comprising administering a therapeutically effective amount of the pharmaceutical composition described herein. Further provided are methods of treating or preventing a disease in a subject, comprising administering a therapeutically effective amount of the pharmaceutical composition described herein. Further provided herein are methods of imaging and/or tracking delivery of one or more nucleic acids in a subject, comprising administering a therapeutically effective amount of the pharmaceutical composition described herein. Provided here are compositions, wherein the compositions comprise: a first nucleic acid comprising sequence encoding for an RNA-dependent RNA polymerase; and a second nucleic acid sequence encoding for a SARS-CoV-2 omicron antigen sequence. Further provided here are compositions, wherein the first nucleic acid comprising sequence and second nucleic acid sequence are present on a shared nucleic acid. Further provided here are compositions, wherein the first nucleic acid comprising sequence and second nucleic acid sequence are present on separate nucleic acids. Further provided here are compositions, wherein the RNA-dependent RNA polymerase comprises a VEEV RNA polymerase. Further provided here are compositions, further comprising a nanoparticle carrier system. Further provided here are compositions, wherein the nanoparticle carrier system comprises a cationic lipid and a hydrophobic core. Further provided here are compositions, wherein the hydrophobic core comprises an inorganic nanoparticle. Further provided here are compositions, wherein the first nucleic acid and/or second nucleic acid comprises RNA. Further provided here are compositions, wherein the second nucleic acid sequence comprises a sequence at least 85% identical to SEQ ID NO: 8. Further provided here are compositions, wherein the compositions comprise: a first nucleic acid comprising sequence encoding for an RNA-dependent RNA polymerase; and a

second nucleic acid sequence encoding for a SARS-CoV-2 spike S2 sequence region, optionally a stem helix region. Further provided here are compositions, wherein the first nucleic acid and second nucleic acid are present on a shared nucleic acid. Further provided here are compositions, wherein the first nucleic acid and the second nucleic acid sequence are present on separate nucleic acids. Further provided here are compositions, wherein the RNA-dependent RNA polymerase comprises a VEEV RNA polymerase. Further provided here are compositions, further comprising a nanoparticle carrier system. Further provided here are compositions, wherein the nanoparticle carrier system comprises a cationic lipid and a hydrophobic core. Further provided here are compositions, wherein the hydrophobic core comprises an inorganic nanoparticle. Further provided here are compositions, wherein the first nucleic acid and/or second nucleic acid comprises RNA. Further provided here are compositions, wherein the second nucleic sequence acid comprises a sequence at least 85% identical to SEQ ID NO: 18. Further provided here are compositions, wherein the second nucleic sequence acid comprises a sequence at least 85% identical to SEQ ID NO: 19. Provided herein are methods of treating or preventing a disease in a subject, the methods comprise administering a therapeutically effective amount of the pharmaceutical composition provided herein to the subject.

[00163] The following examples are set forth to illustrate more clearly the principle and practice of embodiments disclosed herein to those skilled in the art and are not to be construed as limiting the scope of any claimed embodiments. Unless otherwise stated, all parts and percentages are on a weight basis.

EXAMPLES

Example 1: Immune response in macrophages.

[00164] Various formulations comprising lipid carrier and repRNA were prepared and analyzed to assess innate immune response of the lipid carrier in macrophages. Protein expression and stimulation of tumor necrosis factor alpha (*e.g.*, TNF- α) production in THP-1 macrophages were assayed.

[00165] Initially, the THP-1 monocytes were differentiated into macrophages using phorbol 12-myristate 13-acetate (PMA). The cells were then transfected with various formulations with Nano luciferase (NanoLuc) encoding replicon RNA. The cell culture media was then assessed for NanoLuc and TNF α expression.

[00166] The formulations and their characteristics such as particle size and PDI that were used in this assay are described in Table 4. The concentration of repRNA encoding NanoLuc was 909 nanograms per microliter (ng/μl) and maintained at -80 degrees Celsius. Miglyol 812 N (caprylic/capric triglyceride) was used in this example.

Table 4. Formulations.

Formulation	Particle size [diameter, nm]	PDI	Iron [mg Fe/ml]	Aluminum [mg Al/ml]	DOTAP [mg/ml]	Squalene [mg/ml]	Miglyol [mg/ml]	Solanesol [mg/ml]
NP-1: Fe-lipid carrier	59.3	0.23	0.19	n/a	27.9	39.4	n/a	n/a
NP-2: High Fe-lipid carrier	57.5	0.24	0.85	n/a	29.1	40.5	n/a	n/a
NP-3: Fe-lipid carrier miglyol	48.7	0.2	0.18	n/a	28.3	n/a	not measured	n/a
NP-4: High Fe-lipid carrier miglyol	62.6	0.28	0.94	n/a	27.7	n/a	not measured	n/a
NP-5: Alum-lipid carrier	64.5	0.25	n/a	0.88	27.4	41.2	n/a	n/a
NP-6: Fe-lipid carrier solanesol (SLN)	86.1	0.26	0.16	n/a	26.2	n/a	n/a	36
NP-7: NLC	50	0.26	n/a	n/a	26.7	34.1	n/a	n/a
NP-8: CNE	105.4	0.06	n/a	n/a	4.4	47.4	n/a	n/a
NP-30: lipid carrier (w/o IO)	54.2	0.22	n/a	n/a	19.3	32.6	n/a	n/a

[00167] **Fe-lipid carrier formulation- NP-1 (prepared at 100 ml scale):** Fe-lipid carrier formulation comprises 37.5 mg/ml squalene (SEPPIC), 37 mg/ml SPAN® 60 (Millipore Sigma), 37 mg/ml TWEEN® 80 (Fisher Chemical), 30 mg/ml DOTAP chloride (LIPOID), 0.2 mg Fe/ml 12 nm oleic acid-coated iron oxide nanoparticles (Imagion Biosystems, San Diego, CA, USA) and 10 mM sodium citrate dihydrate (Fisher Chemical). 1 ml of 20 mg Fe/ml 12 nm diameter oleic acid-coated iron oxide nanoparticles in chloroform (Imagion Biosystems, lot# 95-127) were washed three times by magnetically separating in a 4:1 acetone:chloroform (v/v) solvent mixture. After the third wash, the volatile solvents (acetone and chloroform) were allowed to completely evaporate in a fume hood leaving behind a coating of dried oleic acid iron oxide nanoparticles. To this iron oxide coating, 3.75 grams squalene, 3.7 grams SPAN® 60, and 3 grams DOTAP

were added to produce the oil phase. The oil phase was sonicated for 45 minutes in a 65 degree C water bath. Separately, the aqueous phase was prepared by dissolving 19.5 grams TWEEN® 80 in 500 ml of 10 mM sodium citrate buffer prepared in nuclease free water. 92 ml of the aqueous phase was transferred to a separate glass bottle and heated to 65 degrees Celsius for 30 minutes. The oil phase was mixed with the 92 ml of aqueous phase by adding the warm oil phase to the warm aqueous phase. The mixture was emulsified using a VWR® 200 homogenizer (VWR International, Radnor, PA, USA) and the resulting crude emulsion was processed by passing through a M110P microfluidizer (Microfluidics, Westwood, MA, USA) at 30,000 psi equipped with a F12Y 75 µm diamond interaction chamber and an auxiliary H30Z-200 µm ceramic interaction chamber until the z-average hydrodynamic diameter – measured by dynamic light scattering (Malvern Zetasizer Nano S) – reached 40-80 nm with a 0.1-0.25 polydispersity index (PDI). The microfluidized NP-1 formulation was terminally filtered with a 200 nm pore-size polyethersulfone (PES) filter and stored at 2 to 8 degrees C. Iron concentration was determined by inductively coupled plasma-optical emission spectrometry (ICP-OES). DOTAP and squalene concentration were measured by reverse phase high-performance liquid chromatography (RP-HPLC).

[00168] High Fe-lipid carrier formulation NP-2 (prepared at 100 ml scale): High Fe-lipid carrier formulation comprises 37.5 mg/ml squalene (SEPPIC), 37 mg/ml SPAN® 60 (Millipore Sigma), 37 mg/ml TWEEN® 80 (Fisher Chemical), 30 mg/ml DOTAP chloride (LIPOID), 1 mg Fe/ml 15 nm oleic acid-coated iron oxide nanoparticles (Imagion Biosystems) and 10 mM sodium citrate dihydrate (Fisher Chemical). 5 ml of 20 mg Fe/ml 15 nm diameter oleic acid-coated iron oxide nanoparticles in chloroform (Imagion Biosystems, Lot# 95-133) were washed three times by magnetically separating in a 4:1 acetone:chloroform (v/v) solvent mixture. After the third wash, the volatile solvents (acetone and chloroform) were allowed to completely evaporate in a fume hood leaving behind a coating of dried oleic acid iron oxide nanoparticles. To this iron oxide coating, 3.75 grams squalene, 3.7 grams SPAN® 60, and 3 grams DOTAP were added to produce the oil phase. The oil phase was sonicated for 45 minutes in a 65 degree Celsius water bath. Separately, the aqueous phase was prepared by dissolving 19.5 grams TWEEN® 80 in 500 ml of 10 mM sodium citrate buffer prepared in nuclease free water. 92 ml of the aqueous phase was transferred to a separate glass bottle and heated to 65 degrees Celsius for 30 minutes. The oil phase was mixed with the 92 ml of aqueous phase by adding the warm oil phase to the warm aqueous phase. The mixture was emulsified using a VWR® 200 homogenizer (VWR International) and the resulting crude emulsion was processed by passing through a M110P

microfluidizer (Microfluidics) at 30,000 psi equipped with a F12Y 75 μm diamond interaction chamber and an auxiliary H30Z-200 μm ceramic interaction chamber until the z-average hydrodynamic diameter – measured by dynamic light scattering (Malvern Zetasizer Nano S) – reached 40-80 nm with a 0.1-0.3 polydispersity index (PDI). The microfluidized formulation was terminally filtered with a 200 nm pore-size polyethersulfone (PES) filter and stored at 2 to 8 degrees C. Iron concentration was determined by ICP-OES. DOTAP and Squalene concentration were measured by RP-HPLC.

Example 2: Fe-lipid carrier miglyol formulation NP-3 (prepared at 100 ml scale)

[00169] The Fe-lipid carrier miglyol formulation comprises 37.5 mg/ml Miglyol 812 N (IOI Oleo GmbH), 37 mg/ml SPAN® 60 (Millipore Sigma), 37 mg/ml TWEEN® 80 (Fisher Chemical), 30 mg/ml DOTAP chloride (LIPOID), 0.2 mg Fe/ml 15 nm oleic acid-coated iron oxide nanoparticles (Imagion Biosystems) and 10 mM sodium citrate dihydrate (Fisher Chemical). 1 ml of 20 mg Fe/ml 15 nm diameter oleic acid-coated iron oxide nanoparticles in chloroform (Imagion Biosystems, Lot# 95-127) were washed three times by magnetically separating in a 4:1 acetone:chloroform (v/v) solvent mixture. After the third wash, the volatile solvents (acetone and chloroform) were allowed to completely evaporate in a fume hood leaving behind a coating of dried oleic acid iron oxide nanoparticles. To this iron oxide coating, 3.75 grams squalene, 3.7 grams SPAN® 60, and 3 grams DOTAP were added to produce the oil phase. The oil phase was sonicated for 45 minutes in a 65 degree C water bath. Separately, the aqueous phase was prepared by dissolving 19.5 grams TWEEN® 80 in 500 ml of 10 mM sodium citrate buffer prepared in nuclease free water. 92 ml of the aqueous phase was transferred to a separate glass bottle and heated to 65 degree C for 30 minutes. The oil phase was mixed with the 92 ml of aqueous phase by adding the warm oil phase to the warm aqueous phase. The mixture was emulsified using a VWR® 200 homogenizer (VWR International) and the resulting crude emulsion was processed by passing through a M110P microfluidizer (Microfluidics) at 30,000 psi equipped with a F12Y 75 μm diamond interaction chamber and an auxiliary H30Z-200 μm ceramic interaction chamber until the z-average hydrodynamic diameter – measured by dynamic light scattering (Malvern Zetasizer Nano S) – reached 40-80 nm with a 0.1-0.3 polydispersity index (PDI). The microfluidized formulation was terminally filtered with a 200 nm pore-size polyethersulfone (PES) filter and stored at 2 to 8 degrees C. Iron concentration was determined by ICP-OES. DOTAP concentration was measured by RP-HPLC.

Example 3: High Fe-lipid carrier Miglyol formulation NP-4 (prepared at 100 ml scale)

[00170] High Fe-lipid carrier Miglyol formulation comprises 37.5 mg/ml Miglyol 812 N (IOI Oleo GmbH), 37 mg/ml SPAN® 60 (Millipore Sigma), 37 mg/ml TWEEN® 80 (Fisher Chemical), 30 mg/ml DOTAP chloride (LIPOID), 1 mg/ml 15 nm oleic acid-coated iron oxide nanoparticles (ImagionBio) and 10 mM sodium citrate dihydrate (Fisher Chemical). 5 ml of 20 mg Fe/ml 15 nm diameter oleic acid-coated iron oxide nanoparticles in chloroform (ImagionBio, Lot# 95-127) were washed three times by magnetically separating in a 4:1 acetone:chloroform (v/v) solvent mixture. After the third wash, the volatile solvents (acetone and chloroform) were allowed to completely evaporate in a fume hood leaving behind a coating of dried oleic acid iron oxide nanoparticles. To this iron oxide coating, 3.75 grams squalene, 3.7 grams SPAN® 60, and 3 grams DOTAP were added to produce the oil phase. The oil phase was sonicated for 45 minutes in a 65 degree C water bath. Separately, the aqueous phase was prepared by dissolving 19.5 grams TWEEN® 80 in 500 ml of 10 mM sodium citrate buffer prepared in nuclease free water. 92 ml of the aqueous phase was transferred to a separate glass bottle and heated to 65 degrees Celsius for 30 minutes. The oil phase was mixed with the 92 ml of aqueous phase by adding the warm oil phase to the warm aqueous phase. The mixture was emulsified using a VWR® 200 homogenizer (VWR International) and the resulting crude emulsion was processed by passing through a M110P microfluidizer (Microfluidics) at 30,000 psi equipped with a F12Y 75 µm diamond interaction chamber and an auxiliary H30Z-200 µm ceramic interaction chamber until the z-average hydrodynamic diameter – measured by dynamic light scattering (Malvern Zetasizer Nano S) – reached 40-80 nm with a 0.1-0.3 polydispersity index (PDI). The microfluidized formulation was terminally filtered with a 200 nm pore-size polyethersulfone (PES) filter and stored at 2 to 8 degrees C. Iron concentration was determined by ICP-OES. DOTAP concentration was measured by RP-HPLC.

Example 4: Alum-lipid carrier formulation NP-5 (prepared at 100 ml scale)

[00171] Alum-lipid carrier formulation comprises 37.5 mg/ml squalene (SEPPIC), 37 mg/ml SPAN® 60 (Millipore Sigma), 37 mg/ml TWEEN® 80 (Fisher Chemical), 30 mg/ml DOTAP chloride (LIPOID), 1 mg Al/ml TOPO-coated Alhydrogel® (aluminum oxyhydroxide) particles (Croda) and 10 mM sodium citrate. 10 ml of Alhydrogel was washed three times in methanol by centrifuging at 1000 rpm for 20 minutes. After the third wash, Alhydrogel was dispersed in 10 ml methanol and to this dispersion was added 1 ml of 250 mg/ml trioctylphosphine oxide (TOPO) and incubated overnight in a 37 °C orbital shaker. Excess TOPO was removed by additional

methanol washes and then dispersed in 11 ml methanol. Methanol was allowed to evaporate overnight in the fume hood leaving behind a dry layer of TOPO-Alhydrogel. To this dry TOPO-Alhydrogel layer, 3.75 grams squalene, 3.7 grams SPAN® 60, and 3 grams DOTAP were added to produce the oil phase. The oil phase was sonicated for 45 minutes in a 65 degree C water bath. Separately, the aqueous phase was prepared by dissolving 19.5 grams TWEEN® 80 in 500 ml of 10 mM sodium citrate buffer prepared in nuclease free water. 92 ml of the aqueous phase was transferred to a separate glass bottle and heated to 65 degrees Celsius for 30 minutes. The oil phase was mixed with the 92 ml of aqueous phase by adding the warm oil phase to the warm aqueous phase. The mixture was emulsified using a VWR® 200 homogenizer (VWR International) and the resulting crude emulsion was processed by passing through a M110P microfluidizer (Microfluidics) at 30,000 psi equipped with a F12Y 75 µm diamond interaction chamber and an auxiliary H30Z-200 µm ceramic interaction chamber until the z-average hydrodynamic diameter – measured by dynamic light scattering (Malvern Zetasizer Nano S) – reached 40-80 nm with a 0.1-0.3 polydispersity index (PDI). The microfluidized formulation was terminally filtered with a 200 nm pore-size polyethersulfone (PES) filter and stored at 2 to 8 degrees C. Aluminum concentration was determined by ICP-OES. DOTAP and Squalene concentration were measured by RP-HPLC.

Example 5: Fe-lipid carrier solanesol formulation NP-6 (prepared at 100 ml scale)

[00172] Fe-lipid carrier solanesol formulation (NP-6) comprises 37.5 mg/ml Solanesol (Cayman chemicals), 37 mg/ml SPAN® 60 (Millipore Sigma), 37 mg/ml TWEEN® 80 (Fisher Chemical), 30 mg/ml DOTAP chloride (LIPOID), 0.2 mg Fe/ml oleic acid-coated iron oxide nanoparticles (ImagionBio) and 10 mM sodium citrate. 1 ml of 20 mg Fe/ml 15 nm diameter oleic acid-coated iron oxide nanoparticles in chloroform (ImagionBio, Lot# 95-133) were washed three times by magnetically separating in a 4:1 acetone:chloroform (v/v) solvent mixture. After the third wash, the volatile solvents (acetone and chloroform) were allowed to completely evaporate in a fume hood leaving behind a coating of dried oleic acid iron oxide nanoparticles. To this iron oxide coating, 3.75 grams solanesol, 3.7 grams SPAN® 60, and 3 grams DOTAP were added to produce the oil phase. The oil phase was sonicated for 45 minutes in a 65 degree C water bath. Separately, the aqueous phase was prepared by dissolving 19.5 grams TWEEN® 80 in 500 ml of 10 mM sodium citrate buffer prepared in nuclease free water. 92 ml of the aqueous phase was transferred to a separate glass bottle and heated to 65 degrees Celsius for 30 minutes. The oil phase was mixed with the 92 ml of aqueous phase by adding the warm oil phase to the warm aqueous phase. The

mixture was emulsified using a VWR® 200 homogenizer (VWR International) and the resulting crude emulsion was processed by passaging through a M110P microfluidizer (Microfluidics) at 30,000 psi equipped with a F12Y 75 µm diamond interaction chamber and an auxiliary H30Z-200 µm ceramic interaction chamber. The microfluidized formulation was terminally filtered with a 200 nm pore-size polyethersulfone (PES) filter and stored at 2 to 8 degrees C. Iron concentration was determined by ICP-OES. DOTAP and solanesol concentration were measured by RP-HPLC.

Example 6: NP-7 formulation (prepared at 100 ml scale)

[00173] NP-7 formulation comprises 37.5 mg/ml squalene (SEPPIC), 37 mg/ml SPAN® 60 (Millipore Sigma), 37 mg/ml TWEEN® 80 (Fisher Chemical), 30 mg/ml DOTAP chloride (LIPOID), 2.4 mg/ml Dynasan 114 (IOI Oleo GmbH) and 10 mM sodium citrate. To a 200 ml beaker 3.75 grams squalene, 3.7 grams SPAN® 60, 0.24 grams Dynasan 114 and 3 grams DOTAP were added to produce the oil phase. The oil phase was sonicated for 45 minutes in a 65 degree C water bath. Separately, the aqueous phase was prepared by dissolving 19.5 grams TWEEN® 80 in 500 ml of 10 mM sodium citrate buffer prepared in nuclease free water. 92 ml of the aqueous phase was transferred to a separate glass bottle and heated to 65 degrees Celsius for 30 minutes. The oil phase was mixed with the 92 ml of aqueous phase by adding the warm oil phase to the warm aqueous phase. The mixture was emulsified using a VWR® 200 homogenizer (VWR International) and the resulting crude emulsion was processed by passaging through a M110P microfluidizer (Microfluidics) at 30,000 psi equipped with a F12Y 75 µm diamond interaction chamber and an auxiliary H30Z-200 µm ceramic interaction chamber until the z-average hydrodynamic diameter – measured by dynamic light scattering (Malvern Zetasizer Nano S) – reached 40-80 nm with a 0.1-0.3 polydispersity index (PDI). The microfluidized formulation was terminally filtered with a 200 nm pore-size polyethersulfone (PES) filter and stored at 2 to 8 degrees C. DOTAP and Squalene concentration were measured by RP-HPLC.

Example 7: NP-8 formulation (prepared at 100 ml scale)

[00174] The NP-8 formulation comprises 43 mg/ml squalene (SEPPIC), 5 mg/ml SPAN® 85 (Millipore Sigma), 5 mg/ml TWEEN® 80 (Fisher Chemical), 4 mg/ml DOTAP chloride (LIPOID) and 10 mM sodium citrate. To a 200 ml beaker 4.3 grams squalene, 0.5 grams SPAN® 85, and 0.4 grams DOTAP were added to produce the oil phase. The oil phase was sonicated for 45 minutes in a 65 degree C water bath. Separately, the aqueous phase was prepared by dissolving 2.6 grams TWEEN® 80 in 500 ml of 10 mM sodium citrate buffer prepared in nuclease free water.

95 ml of the aqueous phase was transferred to a separate glass bottle and heated to 65 degrees Celsius for 30 minutes. The oil phase was mixed with the 95 ml of aqueous phase by adding the warm oil phase to the warm aqueous phase. The mixture was emulsified using a VWR® 200 homogenizer (VWR International) and the resulting crude emulsion was processed by passing through a M110P microfluidizer (Microfluidics) at 30,000 psi equipped with a F12Y 75 µm diamond interaction chamber and an auxiliary H30Z-200 µm ceramic interaction chamber until the z-average hydrodynamic diameter – measured by dynamic light scattering (Malvern Zetasizer Nano S) – reached 100±10 nm with a 0.05-0.1 polydispersity index (PDI). The microfluidized formulation was terminally filtered with a 200 nm pore-size polyethersulfone (PES) filter and stored at 2 to 8 degrees C. DOTAP and Squalene concentration were measured by RP-HPLC.

[00175] The treatment groups were prepared. Eight of those groups were NanoLuc repRNA groups, with 600 ng dose per well was prepared using the Fe-lipid carrier, High Fe-lipid carrier, Fe-lipid carrier miglyol, High Fe-lipid carrier miglyol, Alum-lipid carrier, Fe-lipid carrier solanesol (SLN), NLC, and CNE formulations. The untreated group did not have NanoLuc.

[00176] The various formulations were prepared by diluting NanoLuc repRNA to 8 ng/µL in 2.2 mL of RNase-free water. The lipid carrier formulations and RNA master mix was complexed by adding 250 µL of each diluted formulation with 250 µL of diluted RNA, and mixed by pipetting up and down.

[00177] Cell transfections were carried out by seeding 7×10^5 THP-1s per well in a 24-well plate. 80 micromolar (µM) PMA added to each well and incubated at 37 degrees Celsius. The next day, the PMA-containing media was removed and replaced with complete RPMI (cRPMI) medium for one hour before transfection. The samples were then serially diluted in Opti-MEM™ (Thermo Fisher Scientific, Waltham, MA USA) to make a 10-point 1.5-fold dilution series starting at 0.45 ng/µL. The culture media was then removed from the plates by pipetting. 450 µL of Opti-MEM™ and 150 µL of the complexed formulation were added to the plate in duplicate. The empty wells were given 450 µL of Opti-MEM™ only. After four hours, the samples were removed from the plate by pipetting and replaced with 500 µL of growth media. The plate was then incubated overnight at 37 degrees Celsius. The growth media was harvested the next day and stored at -80 degrees Celsius. Downstream assays were conducted and described below.

[00178] The luciferase assay was performed by first diluting the Nano-Glo® luciferase assay reagent 1:50 in buffer. 25 µL of supernatant was removed and mixed with 25 µL of Nano-Glo® reagent in a 96-well plate. This was incubated at room temperature for 3 minutes. The

luminescence was read using a luminometer.

[00179] Next, an ELISA assay was performed to evaluate the TNF- α (α) protein levels in cell culture media using the human TNF- α DUOSET™ ELISA (R&D Systems) according to the manufacturer's protocol. The 96-well microplate was coated with anti-TNF α capture antibody. The plate was blocked and then media samples were added directly without dilution. After addition of the biotinylated detection antibody, SA-HRP, and substrate, the absorbance was read at 450 nm on a SPECTRAMAX® i3 (Molecular Devices) plate reader.

[00180] All studies in this example were done in duplicates. Results from the duplicates are presented as first experiment and second experiment respectively. The formulation comprising a lipid carrier and miglyol induced higher protein production off the replicon, as shown in the first experiment in **FIG. 4A** and in the second experiment in **FIG. 4B**. A reduced innate immune response was detected, as measured by TNF- α secretion (**FIG. 5A-5B**).

[00181] The correlation between enhanced protein production and low TNF- α stimulation was observed with the miglyol lipid carrier formulation, as shown in the first experiment in **FIG. 6A** and in the second experiment in **FIG. 6B**. The solanesol lipid carrier formulation induced slightly lower protein production, but a higher TNF α production (**FIGS. 6A-6B**). Correlation data from the first assay is shown in **FIG. 6A** are derived from the data represented in **FIG. 4A** and **FIG. 5A**. Correlation data from second assay is shown in **FIG. 6B**, which is derived from the data represented in **FIG. 4B** and **FIG. 5B**.

Example 8: Techniques and materials for the production of lipid carriers

[00139] The following materials were used in the manufacturing of lipid-inorganic nanoparticles (i.e., lipid carriers). The compositions, kits and methods described herein are not limited to the techniques or materials described herein.

[00140] Iron oxide nanoparticles at 25 mg Fe/ml in chloroform and of various average diameters (5, 10, 15, 20, 25 and 30 nm) were purchased from Ocean Nanotech (San Diego, CA, USA). Squalene and SPAN® 60 (sorbitan monostearate) were purchased from Millipore Sigma. TWEEN® 80 (polyethylene glycol sorbitan monooleate) and sodium citrate dihydrate were purchased from Fisher Chemical. The chloride salt of the cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP chloride) was purchased from Corden Pharma. Ultrapure water (18.2 mega ohm-centimeter (MOhm-cm) resistivity) was obtained from a Milli-Q water purification system (Millipore Sigma).

[00141] The lipid carrier comprises squalene, sorbitan monostearate (*e.g.*, SPAN® 60),

polysorbate 80 (*e.g.*, TWEEN® 80), DOTAP chloride, iron oxide nanoparticles and sodium citrate dihydrate. In general, to iron oxide nanoparticles with a number-weighted average diameter of 5 nm, chloroform was added. Chloroform was allowed to evaporate in a fume hood leaving behind a dry coating of iron oxide nanoparticles. To the iron oxide nanoparticles, SPAN® 60, squalene, and DOTAP chloride were added to prepare the “oil” phase.

[00142] The oil phase was sonicated 30 minutes in a water bath pre-heated to 60° C. Separately, in a 1 liter glass bottle, the “aqueous” phase was prepared by adding TWEEN® 80 to sodium citrate dihydrate solution prepared with Milli-Q water.

[00143] The aqueous phase was stirred for 30 minutes to allow complete dissolution of TWEEN® 80. After complete dissolution of TWEEN® 80, the aqueous phase was transferred to a beaker and incubated in a water bath pre-heated to 60° C. To the heated oil phase, the pre-heated aqueous phase was added.

[00144] The mixture was immediately emulsified using a VWR® 200 homogenizer (VWR International) until a homogenous colloid with a milk-like appearance was produced. The colloid was subsequently processed by passing the fluid through a Y-type interaction chamber of a LM10 microfluidizer at 20,000 psi.

[00145] The fluid was passaged until the z-average hydrodynamic diameter, measured by dynamic light scattering (Malvern Zetasizer Nano S), was 59 nm with a 0.2 polydispersity index.

[00146] The microfluidized lipid carrier sample was terminally filtered with a 200 nm pore-size polyethersulfone (PES) syringe filter.

Example 9: Exemplary techniques and materials for producing lipid carriers

[00147] The following materials were used in the manufacturing of lipid-inorganic nanoparticles (*i.e.*, lipid carriers). The compositions, kits and methods described herein are not limited to the techniques or materials describe herein.

[00148] Iron oxide nanoparticles at 25 mg Fe/ml in chloroform and of various average diameters (5, 10, 15, 20, 25 and 30 nm) were purchased from Ocean Nanotech (San Diego, CA). Squalene and SPAN® 60 (sorbitan monostearate) were purchased from Millipore Sigma. TWEEN® 80 (polyethylene glycol sorbitan monooleate) and sodium citrate dihydrate were purchased from Fisher Chemical. The chloride salt of the cationic lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP chloride) was purchased from Corden Pharma. Ultrapure water (18.2 MOhm-cm resistivity) was obtained from a Milli-Q water purification system (Millipore Sigma).

[00149] Lipid carriers were prepared which comprised 37.5 mg/ml squalene, 37 mg/ml

SPAN® 60, 37 mg/ml TWEEN® 80, 30 mg/ml DOTAP chloride, 0.1 mg/ml 10 nm iron oxide nanoparticles and 10 mM sodium citrate dihydrate.

[00150] The lipid carriers were manufactured using the following procedures. In a 200 ml beaker, 0.4 ml of iron oxide nanoparticles at 25 mg Fe/ml in chloroform, with a number-weighted average diameter of 10 nm, were added.

[00151] Chloroform was allowed to evaporate in a fume hood leaving behind a dry coating of iron oxide nanoparticles. To the iron oxide nanoparticles, 3.7 grams of SPAN® 60, 3.75 grams of squalene, and 3 grams of DOTAP chloride were added to prepare the “oil” phase.

[00152] The oil phase was sonicated 30 minutes in a water bath pre-heated to 60° C. Separately, in a 1 liter glass bottle, the “aqueous” phase was prepared by adding 39 grams of TWEEN® 80 to 1,000 ml 10 mM sodium citrate dihydrate solution prepared with Milli-Q water.

[00153] The aqueous phase was stirred for 30 minutes to allow complete dissolution of TWEEN® 80. After complete dissolution of TWEEN® 80, 96 ml of the aqueous phase was transferred to a 200 ml beaker and incubated in a water bath pre-heated to 60° C. To the heated oil phase, 96 ml of the pre- heated aqueous phase was added. The mixture was immediately emulsified using a VWR® 200 homogenizer (VWR International) until a homogenous colloid with a milk-like appearance was produced. The colloid was subsequently processed by passing the fluid through a Y-type interaction chamber of a LM10 microfluidizer at 20,000 psi. The fluid was passaged until the z-average hydrodynamic diameter, measured by dynamic light scattering (Malvern Zetasizer Nano S), was 54 nm with a 0.2 polydispersity index. The microfluidized lipid carrier sample was terminally filtered with a 200 nm pore-size polyethersulfone (PES) syringe filter.

Example 10: Exemplary techniques and materials for producing nanoparticles described herein

[00154] Lipid carriers were prepared which comprised 37.5 mg/ml squalene, 37 mg/ml SPAN® 60, 37 mg/ml TWEEN® 80, 30 mg/ml DOTAP chloride, 0.2 mg/ml 15 nm iron oxide nanoparticles, and 10 M sodium citrate dihydrate. The lipid carriers of Example 9 were manufactured using the following procedures.

[00155] In a 200 ml beaker, 0.8 ml of iron oxide nanoparticles at 25 mg Fe/ml in chloroform, with a number-weighted average diameter of 15 nm, was added. Chloroform was allowed to evaporate in a fume hood leaving behind a dry coating of iron oxide nanoparticles. To the iron oxide nanoparticles, 3.7 grams of SPAN® 60, 3.75 grams of squalene, and 3 grams of DOTAP

chloride were added to prepare the “oil” phase.

[00156] The oil phase was sonicated 30 minutes in a water bath pre-heated to 60° C. Separately, in a 1 liter glass bottle, the “aqueous” phase was prepared by adding 39 grams of TWEEN® 80 to 1,000 ml of 10 mM sodium citrate dihydrate solution prepared with Milli-Q water. The aqueous phase was stirred for 30 minutes to allow complete dissolution of TWEEN® 80.

[00157] After complete dissolution of TWEEN® 80, 96 ml of the aqueous phase was transferred to a 200 ml beaker and incubated in a water bath pre-heated to 60° C. To the heated oil phase, 96 ml of the pre-heated aqueous phase was added. The mixture was immediately emulsified using a VWR® 200 homogenizer (VWR International) until a homogenous colloid with a milk-like appearance was produced. The colloid was subsequently processed by passing the fluid through a Y-type interaction chamber of a LM10 microfluidizer at 20,000 psi.

[00158] The fluid was passaged until the z-average hydrodynamic diameter, measured by dynamic light scattering (Malvern Zetasizer Nano S), was 52 nm with a 0.2 polydispersity index. The microfluidized lipid carrier sample was terminally filtered with a 200 nm pore-size polyethersulfone (PES) syringe filter.

Example 11: Lipid Carrier without inorganic core formulation (Prepared at 100 mL Scale)

[00159] Described herein is a lipid carrier formulation without inorganic core particles comprising: 37.5 mg/ml squalene (SEPPIC), 37 mg/ml SPAN® 60 (Millipore Sigma), 37 mg/ml TWEEN® 80 (Fisher Chemical), 30 mg/ml DOTAP chloride (LIPOID) and 10 mM sodium citrate.

[00160] This composition was prepared as follows: In a 200 ml beaker, 3.75 grams squalene, 3.7 grams SPAN 60®, and 3.0 grams DOTAP were added to produce the oil phase. The oil phase was sonicated for 45 minutes in a 65 degree C water bath. Separately, the aqueous phase was prepared by dissolving 19.5 grams TWEEN® 80 in 500 ml of 10 mM sodium citrate buffer prepared in nuclease free water. 96 ml of the aqueous phase was transferred to a separate glass bottle and heated to 65 degrees Celsius for 30 minutes. The oil phase was mixed with the 96 ml of aqueous phase by adding the warm oil phase to the warm aqueous phase.

[00161] The mixture was then emulsified using a VWR® 200 homogenizer (VWR International) and the resulting crude emulsion was processed by passing through a M110P microfluidizer (Microfluidics) at 30,000 psi equipped with a F12Y 75 µm diamond interaction chamber and an auxiliary H30Z-200 µm ceramic interaction chamber until the z-average

hydrodynamic diameter – measured by dynamic light scattering (Malvern Zetasizer Nano S) – reached 40-80 nm with a 0.1 to 0.3 polydispersity index (PDI). The microfluidized lipid carrier composition (without inorganic core) formulation was then terminally filtered with a 200 nm pore-size polyethersulfone (PES) filter and stored at 2 to 8 degrees Celsius (°C). DOTAP and squalene concentration were then measured by RP-HPLC.

Example 12: Exemplary techniques and materials for producing nanoparticles described herein

[00162] In a murine assay, C57BL/6 mice were inoculated as described in Table 6 below, after which secreted embryonic alkaline phosphatase (SEAP) levels were measured in serum. A summary of the materials used in the example is provided in Table 5.

Table 5. Materials.

Description	Concentration	Temperature/Location
DNA encoding SEAP (DNA sequence as set forth in SEQ ID NO: 39)	5 mg/mL	-20°C
repRNA encoding SEAP	2217 µg/mL	-80°C
Lipid carrier formulation	30 mg DOTAP/mL	4°C

Table 6. Treatment Groups.

Group	n	Formulation	DNA/RNA- SEAP	RNA dose [µg]	DNA dose [µg]	N:P	Injection Volume [µL]
1	5	Naked	DNA-SEAP		20	n/a	50
2	5	Lipid carrier	DNA-SEAP		10	15	50
3	5	Lipid carrier	DNA-SEAP		10	7.5	
4	5	Lipid carrier	DNA-SEAP		20	15	
5	5	Lipid carrier	DNA-SEAP		20	7.5	
6	5	Lipid carrier	RNA-SEAP	1		15	50
7	5	Miglyol + lipid carrier	RNA-SEAP	1		15	50

[00163] Seven different formulations were prepared and administered intramuscularly across the seven treatment groups (Groups 1-7). DNA-SEAP or RNA-SEAP was diluted according to the volumes set forth in Table 7 to prepare the formulations for Groups 1-7.

Table 7. Formulation Preparation; Dilution of RNA/DNA

Group	DNA- or RNA-SEAP	DNA or RNA [μL]	40% sucrose [μL]	water [μL]	Total [μL]
1	DNA-SEAP	40.0	125.0	85.0	250.0
2	DNA-SEAP	20.0	0.0	230.0	250.0
3	DNA-SEAP	20.0	0.0	230.0	250.0
4	DNA-SEAP	40.0	125.0	85.0	250.0
5	DNA-SEAP	40.0	0.0	210.0	250.0
6	RNA-SEAP	4.5	0.0	245.5	250.0
7	RNA-SEAP	4.5	0.0	245.5	250.0

[00164] The concentrations of diluted DNA or RNA prior to complexing with the lipid carrier was as follows (measured by NanoDrop spec): Groups 1, 4 and 5 contains about 820 μg/ml DNA; Groups 2 and 3 contained about 480 μg/ml DNA; and Groups 6 and 7 contained about 43 μg/ml RNA.

[00165] Formulations for Groups 1-7 were diluted with 100 mM citrate as set forth in Table 8 below.

Table 8. Dilution of lipid carrier formulations.

Group	Formulation	Lipid Carrier [μl]	40% sucrose [μl]	100 mM citrate [μl]	Water [μl]	Total [μl]
1	Naked	0	0	30	270	300
2	Lipid carrier	120	150	30	0	300
3	Lipid carrier	60	150	30	60	300
4	Lipid carrier	240	0	30	30	300
5	Lipid carrier	120	150	30	0	300
6	Lipid carrier	12	150	30	108	300
7	Miglyol +	12	150	30	108	300

Group	Formulation	Lipid Carrier [μl]	40% sucrose [μl]	100 mM citrate [μl]	Water [μl]	Total [μl]
	lipid carrier					

[00166] The above formulations were complexed by adding 250 μl diluted lipid carrier to 250 μl diluted DNA or RNA. The resulting complexed formulations were incubated on ice for at least 30 minutes. Table 9 sets forth the experiment schedule for the assay.

Table 9. Experiment schedule.

Day	Procedure	Notes on Mice
0	All inoculations	None
4	Bleed	Group 4 had ruffled fur, one mouse emaciated (died during collection). Hydropaque placed in cage.
6	Bleed	None
8	Bleed	None
11	Bleed	None
14	Bleed	None

[00167] Mice were bled at regular intervals and serum was prepared immediately and stored at -80 degrees Celsius until analyses for SEAP activity.

[00168] To evaluate SEAP levels in serum, all serum samples were thawed at the same time and SEAP detection was conducted. **FIGS. 7A-7F** illustrate the SEAP levels in BALB/c mice injected intramuscularly with varying iterations of lipid carrier-formulated DNA SEAP. Mice were bled at regular intervals, serum prepared and stored until analysis by SEAP assay. Data are displayed as mean and SE (n = 5 per group).

[00169] As can be seen from **FIGS. 7A-7F**, lipid carrier formulations aid target protein production over delivery of DNA alone, particularly after day 6 following injection. Additionally, the data shows that inclusion of miglyol enhances protein production from an RNA replicon over lipid carrier formulations lacking miglyol.

Example 13: Additional nanoparticle formulations

[00170] Additional nanoparticle formulations are produced according to the following tables (Table 10 and Table 11). In a first example, the mRNA comprises a sequence encoding the SARS-CoV-2 omicron variant spike protein B.1.1.529 with a VEEV replicon mRNA backbone (**SEQ ID NO: 31**). In a second example, the mRNA comprises a sequence encoding the SARS-CoV-2 spike B.1.351-PP-D614G RNA Sequence with a VEEV replicon mRNA backbone (**SEQ ID NO: 27**).

Table 10. mRNA Vaccine Formulation.

Dosage form:	Solution for Injection for IM route of administration		
Composition:	Each 0.5 ml Vial Contains:	Quantity	Concentration (mg/ml)
	mRNA	25 mcg	0.05
	DOTAP	0.75 mg	1.5
	Iron Oxide Nanoparticles	0.005 mg	0.01
	Squalene	0.94 mg	1.88
	Sorbitan Monostearate	0.93 mg	1.86
	Polysorbate 80	0.93 mg	1.86
	Sucrose IP	50 mg	100
	Citric Acid Monohydrate	1.05 mg	2.1
	Water for Injection	q.s. to 0.5 ml	

Table 11. Lyophilized mRNA Vaccine Formulation.

Dosage form:	Lyophilized powder			
Composition:	Each 5 dose vial contains:	Quantity	Concentration (mg/ml)	Approximate dry weight %
	mRNA	50 mcg	0.02	0.02
	DOTAP	1.5 mg	0.6	0.57
	Squalene	1.88 mg	0.752	0.72
	Sorbitan Monostearate	1.86 mg	0.744	0.71
	Polysorbate 80	1.86 mg	0.744	0.71
	Sucrose IP	250 mg	100	95.3
	Citric Acid Monohydrate	5.25 mg	2.1	2

Dosage form:	Lyophilized powder		
	Water for Injection (for reconstitution)	2.5 ml	

Example 14: Self-replicating mRNA construct

[00171] A plasmid encoding a T7 promoter followed by the 5' and 3' UTRs and nonstructural genes of Venezuelan equine encephalitis virus (VEEV) strain TC-83 was generated using standard DNA synthesis and cloning methods. The VEEV replicon mRNA backbone is set forth in **SEQ ID NO: 20**.

Example 15: An alphavirus-derived replicon RNA vaccine for SARS-CoV-2 neutralizing antibody and T cell responses in nonhuman primates

[00172] The immunogenicity and safety of NP-1 to NP-31 in combination with repRNA-CoV2 S protein vaccines are assessed in pigtail macaques. To protect the RNA replicons from degradation, NP-1 which consists of inorganic superparamagnetic iron oxide (SPIO) nanoparticles within a hydrophobic squalene core is used to enhance formulation stability. Replicon RNA (**SEQ ID NOS: 1 to 8**) are complexed with NP formulations. Pigtail macaques are used to test the response to the vaccines. Blood is collected at baseline (week -2 or -1), and at days 10, 14, 28, and 42 post-prime vaccination. Blood is also collected 10 days post-boost (38 days post-prime) in 50 µg vaccinated animals. Serum and plasma are collected and PBMCs are isolated from whole blood. Animals are sedated with an intramuscular injection (10 mg/kg) of ketamine (Ketaset®; Henry Schein) prior to blood collection or vaccination. The 50 µg vaccine is delivered intramuscularly into the quadriceps muscle with one 250 µl injection on weeks 0 and 4. To maintain consistency in the vaccine formulation and concentration, the 250 µg vaccine is delivered intramuscularly by inoculating 250 µl injections into 5 intramuscular injections sites, 2 in the right quadriceps, 1 in the left quadricep, and 1 each in the left and right deltoids on week 0. All injection sites are monitored post-injection for any signs of local reactogenicity. Serum chemistries and complete blood counts are assessed along with antigen-specific antibody responses.

[00173] Blood is collected from venipuncture of anesthetized macaques. Antigen-specific IgG, IgG1, IgG2a, and IgG2c responses are detected by enzyme linked immuno- sorbent assay (ELISA) using recombinant SARS-CoV-2 S as the capture antigen. SARS-CoV-2 neutralization assays are also performed to determine whether vaccine compositions can induce antibody

responses to SARS-CoV-2 infection. Immune responses in macaques are monitored by IFN- γ ELISpot assay and intracellular cytokine staining. Multiparameter flow cytometry is used to determine T- cell immune responses using peptide stimulated PBMCs. S-specific CD4⁺ or CD8⁺ T cells are screened before and after immunization.

Example 16: Evaluation of lyophilized COVID vaccines in mice

[00174] The following was performed to assay activity of lyophilized NP-1 with replicon RNA encoded SARS-CoV-2 spike antigen sequence, physicochemical properties of reconstituted vaccines, potency, and immunogenicity. Briefly, materials in Table 12 were used.

Table 12. Materials.

Name	Stock concentration
NP-1	30 mg/ml (measuring DOTAP conc.)
NP-7	30 mg/ml (measuring DOTAP conc.)
repRNA-CoV2-spike (wild type) VEE-S-v5 Delta (“WT-S”)	1687 μ g/ml
repRNA-CoV2-spike (delta) VEE-nCoV19-S-Delta.AY1-S2P-wtFur (“Delta-S”)	783 μ g/ml
Sucrose (EMD, Millipore)	----
Na-citrate (Teknova)	1M

[00175] *Preparation of formulation complexes.* Compositions of lipid nanoparticle / RNA complexes were prepared in this assay as shown below in Table 13. NP-1 or NP-7 and repRNAs were complexed at a N-to-P ratio of 15 and complexed to obtain a final repRNA concentration of 50 mg/ml or 100 mg/ml (“2X” material), and 10% or 20% w/v sucrose content, respectively. Complexed material with 10% sucrose (50 mg/ml repRNA) contained 5 mM sodium citrate while that with 20% sucrose (100 mg/ml repRNA) contained 10 mM citrate. Complexes were filled in 2 ml sterile, depyrogenated and baked vials. Complexes with 10% sucrose were filled at 0.7 ml per vial and 20% sucrose at 0.35 ml per vial. Vials were then either lyophilized and stored or stored as is in liquid form. Storage temperature was 25 degrees Celsius or 42 degrees Celsius for 1 week. Quantity of lyophilized and liquid vials per composition is summarized in Table 13.

Table 13. Formulations and characteristics.

Description	N:P	DOTAP [μg/ml]	RNA [μg/ml]	Volume per vial [ml]	Lyo vials	Liquid vials
NP-1 + WT-S in 10% sucrose	15	1500	50	0.7	8	6
NP-1 + Delta-S in 10% sucrose	15	1500	50	0.7	2	0
NP-1 + WT-S in 20% sucrose	15	3000	100	0.35	8	0
NP-1 + Delta-S in 20% sucrose	15	3000	100	0.35	2	0
NP-7 + WT-S in 10% sucrose	15	1500	50	0.7	8	6

[00176] *Lyophilization cycle.* An SP VirTis Advantage Pro tray and batch lyophilizer with inert gas fill and stoppering capability was used. Summary of the lyophilization cycle is shown in Table 14 below. After end of cycle, vials were backfilled with nitrogen at 48 torr and stoppered, before equilibrating to room pressure.

Table 14. Conditions.

Time [hours]	Temp [° C]	Pressure [mT]	Notes
0	5	760	Shelf pre-cooled to 5 degrees C
0.5	5	760	Freezing
2	-50	760	
2.5	-50	50	Evacuation
3	-30	50	Primary drying
20.5	-30	50	
22.5	25	50	Secondary drying
24	25	50	

[00177] *Condition groups.* A summary of 14 groups analyzed in this assay is provided in Table 15 below. Groups 1 and 4, as indicated in the storage column, were prepared fresh to serve as positive controls for comparison with standard protocol for vaccine preparation.

Table 15. Conditions.

Group	Formulation	RNA	Sucrose [% w/v]	Form	Storage [temp/time]
-------	-------------	-----	--------------------	------	------------------------

1	NP-1	WT-S	10	Liquid	Fresh
2	NP-1	WT-S	10	Liquid	25C/1wk
3	NP-1	WT-S	10	Liquid	42C/1wk
4	NP-7	WT-S	10	Liquid	Fresh
5	NP-7	WT-S	10	Liquid	25C/1wk
6	NP-7	WT-S	10	Liquid	42C/1wk
7	NP-1	WT-S	10	Lyo	25C/1wk
8	NP-1	WT-S	10	Lyo	42C/1wk
9	NP-1	WT-S	20	Lyo	25C/1wk
10	NP-1	WT-S	20	Lyo	42C/1wk
11	NP-7	WT-S	10	Lyo	25C/1wk
12	NP-7	WT-S	10	Lyo	42C/1wk
13	NP-1	Delta-S	10	Lyo	25C/1wk
14	NP-1	Delta-S	20	Lyo	25C/1wk

[00178] *Immunogenicity assay.* Induction of anti-spike IgG responses were evaluated in 6 to 8 weeks old female C57Bl/6 mice. A group size of 5 mice was used. The schedule is shown in Table 16.

Table 16. Immunogenicity schedule.

Date	Day	Procedure
8/23/21	-7	Lyophilization
9/01/21	0	Immunization by IM route
9/15/21	14	Bleed
9/29/21	28	Bleed
10/8/21	37	Mice sacrificed

[00179] After 1 week of storage in 25 degrees Celsius or 42 degrees Celsius stability chamber, lyophilized nanoparticle/RNA complexes were reconstituted in 0.7 ml sterile milliQ water and gently swirled until no particles were visible to the naked eye. Particle size (z-average) and size distribution (PDI) of the complexes was measured and is summarized in **FIG. 8**, with group designations shown in Table 15. Particle size and PDI of freshly prepared NP-1/WT-S complex (group 1) was 76.8 nm and 0.223, respectively. After reconstitution, lyophilized samples (groups 7-14) grew by an average of 45% (+/-11%). Summary of % change in z-average relative to group 1 is included in Table 17.

Table 17. Percent % change in z-average.

Group #	2	3	4	5	6	7	8	9	10	11	12	13	14
% change z-average vs. group 1	2 %	0%	15 %	-4%	-1%	30 %	42 %	59 %	53 %	48 %	33 %	41 %	55 %

[00180] *Agarose gel electrophoresis of phenol-chloroform extracted repRNA.* Liquid formulations of NP-1/repRNA and NP-7 + repRNA in 10% sucrose or 20% sucrose, stored for 1 week at NP-1/repRNA and NP-7 + repRNA, resulted in partial or full degradation of repRNA product, respectively. (Data not shown.) Lyophilization of NP-1/repRNA and NP-7 + repRNA in 10% sucrose or 20% sucrose preserved repRNA integrity after 1 week storage at NP-1/repRNA and NP-7 + repRNA. (Data not shown.)

[00181] *Potency Assay.* Lyophilized NP-1/WT-S in 10% sucrose stored for 1 week at 25 degrees Celsius produced a dose-dependent expression of spike protein in transfected BHK cells. The expression profile was similar to freshly complexed NP-1/WT-S. 1 week storage at 42 degrees Celsius of lyophilized NP-1/WT-S in 10% sucrose significantly reduced *in vitro* protein expression. Liquid NP-1/WT-S in 10% sucrose stored for 1 week at 25 degrees Celsius or 42 degrees Celsius did not produce spike protein in BHK cells. (Data not shown.)

[00182] *Anti-D614G spike IgG responses by ELISA.* Serum anti-D614G spike IgG levels was assessed on days 14 and 28 post-prime shown below in **FIGS. 9A** and **9B**, respectively. Mouse sera were assayed in an anti-D614G spike ELISA at 1:40 (day 14) or 1:200 (day 28) dilution. Serum IgG level in µg/ml was interpolated from a 4 parameter logistic (4PL) standard curve generated by a known concentration of mouse IgG standard.

[00183] *Day 28 post-prime anti-D614G IgG response.* After 1 week at 25 degrees C, liquid NP-1/WT-S in 10% sucrose resulted in a statistically significant reduction in anti-spike IgG compared to the freshly prepared NP-1/WT-S positive control. There was no significant difference in mean IgG levels between freshly prepared NP-1/WT-S and lyophilized NP-1/WT-S in 10% sucrose stored for 1 week at 25 degrees C.

[00184] After 1 week at 42 degrees C, lyophilized NP-1/WT-S in 10% sucrose induced 100% seroconversion but mean IgG level was significantly reduced compared to freshly prepared NP-1/WT-S. Summary mean +/- standard deviation IgG concentration data from day 28 post-immunization, including p-values determined by ordinary one-way ANOVA comparing against the freshly prepared NP-1/WT-S positive control, shown in Table 18. $P < 0.05$ are considered statistically significant differences.

Table 18. Mean IgG at 1:200 serum dilution.

Group	Formulation	RNA	Sucrose [% w/v]	State	Storage temp. and time	D28 mean IgG at 1:200 serum dilution [$\mu\text{g/ml}$]	SD [$\mu\text{g/ml}$]	P-value vs. group 1
1	NP-1	WT-S	10	Liquid	Fresh	30.38	12.29	n/a
2	NP-1	WT-S	10	Liquid	25C/1wk	0.17	0.23	0.0014
3	NP-1	WT-S	10	Liquid	42C/1wk	0.02	0.02	0.0013
4	NP-7	WT-S	10	Liquid	Fresh	25.69	16.45	0.9990
5	NP-7	WT-S	10	Liquid	25C/1wk	8.47	15.99	0.0385
6	NP-7	WT-S	10	Liquid	42C/1wk	0.00	0.00	0.0013
7	NP-1	WT-S	10	Lyo	25C/1wk	27.44	14.68	0.9994
8	NP-1	WT-S	10	Lyo	42C/1wk	7.34	10.63	0.0257
9	NP-1	WT-S	20	Lyo	25C/1wk	9.07	6.41	0.0474
10	NP-1	WT-S	20	Lyo	42C/1wk	10.56	11.25	0.0777
11	NP-7	WT-S	10	Lyo	25C/1wk	27.53	24.96	0.9994
12	NP-7	WT-S	10	Lyo	42C/1wk	5.33	2.68	0.0121
13	NP-1	Delta-S	10	Lyo	25C/1wk	25.83	6.66	0.9990
14	NP-1	Delta-S	20	Lyo	25C/1wk	28.25	5.60	0.9996

[00185] *Comparison of fresh versus lyophilized formulations.* Day 28 post-prime anti-D614G spike IgG concentration in serum is shown in **FIG. 10**. Statistical differences between mean IgG values were determined by ordinary one-way ANOVA with Dunnett's multiple comparisons test. All groups compared to freshly prepared NP-1/RNA in 10% sucrose. No significant difference was shown between freshly prepared NP-1/RNA and lyophilized NP-1/RNA in 10% sucrose stored for 7 days at 25 degrees Celsius. At 42 degrees C, lyophilized NP-1/RNA in 10% or 20% sucrose induced significantly lower anti-spike IgG compared to freshly prepared NP-1/RNA. Lyophilized NP-1/RNA in 20% sucrose, and stored at 25 degrees Celsius or 42 degrees C, induced significantly lower IgG than freshly prepared NP-1/WT-S. Lyophilized NP-1/Delta-S in 10% or 20% sucrose, and stored at 25 degrees C, induced similar mean IgG (statistically not significant) than freshly prepared NP-1/WT-S.

SEQUENCES

[00186] The following sequences (**SEQ ID NOS: 24-31**) are formatted to signify vector backbone and antigen open reading frames as follows: lower case letter signify the VEEV

replicon backbone sequence; UPPER CASE letters signify spike open reading frame; **bold** signifies start codons; and underlined signifies mutated codons relative to the parental Wuhan spike sequence.

SEQ ID NO: 24- Full-length VEEV+ Delta V5 Antigen Encoding RNA Sequence

auaggcggcgcaugagagaagccagaccaauuaccuacccaaauggagaaaguucacguugacaucgaggaagac
agcccauuccucagagcuuugcagcggagcuucccgaguuugagguagaagccaagcaggucacugauaagacca
ugcuaauggccagagcguuuucgcaucuggcuucaaacugaucgaaacggagguggacccauccgacacgauccuug
acaauuggaagugcgcccgcccgagaauguaauucuaagcacaaguaucuuuguaucuguccgaugagauugcgga
gauccggacagauuguaaaguaugcaacuaagcugaagaaaaacuguaaggaaauaacuguaaggaauuggacaa
gaaaaugaaggagcuggccgcccgucaugagcgaccucgaccuggaaaacugagacuaugugccuccacgacgacgagu
cgugucgcuacgaagggcaagucgcuguuuaccaggauguaucgcggguagcggaccgacaagucucuaacccaa
gccaaauaggaguuagagucgcccacuggaugagccuugacaccacccuuuuuaguuuaagaacuuuggcuggagc
auauccaucauacucuaaccaacugggcccgcagaaaccguguaacggcucguaaacauaggccuauugcagcucugacg
uuauaggagcggucacguagagggauguccauucuuagaaagaaguuuagaaaccauccaacaauugucuaucucuc
guuggcucgaccaucuaaccagagaagaggacuuacugaggagcuggcaccugccgucuguaauuacacuuacgugg
caagcaaaaauacacaugucggugugagacuaauaguuaguugcgacggguacgucguuaaaagaauagcuauacaguc
caggccuguauggggaagccuucaggcuaugcugcuacgaugcaccgcgagggauucuuugucugcaaaugacagac
acaauugaacggggagagggucucuuuuuccgugugcacguaugugccagcuacaauugugugacaaaugacuggcau
acuggcaacagaugucagugcggacgacgcgcaaaaacugcugguugggcucaaccagcguauagucgucaacgguc
gcacccagagaaaacaccaauaccaugaaaaauuaccuuuugcccguaguggcccaggcauuugcuaggugggcaaa
gaauuaaaggaagaucagaagaagaugaaaggccacuaggacuaacgagauagacaguuagucaguggguguuuugggc
uuuuagaaggcacaagauaacaucuaauuuuaagcgcccgauacccaaaccaucauaaagugaacagcgauuucc
acucauucgugcugcccaggauaggcaguaacacauuggagaucgggcugagaacaagaucaggaaaauguuagag
gagcacaaggagccgucaccucuaauaccgcccaggagcguacaagaagcuaagugcgacccgaugaggcuaggga
ggugcgugaagccgaggaguugcgcgacgucuaaccacuuuggcagcugauguugaggagccacucuggaggcgag
acgucgacuugauguuacaagaggcuggggccggcucaguggagacaccucguggcuugauaaagguuaccagcuac
gauggcgaggacaagaucggcucuaacgcugugcuuucuccgcaggcuguaacuaagagugaaaaauuacuuugcau
ccacccucucgcugaacaagucuauguguaacacacucuggccgaaaaggcguaugccguggaaccuauaccaug
guaaaguaguggugccagagggaugcaauaccguccaggacuuucaagcucugagugaaagugccaccauuugug
uacaacgaacgugaguucguaaacagguuaccugcaccuauuugccacacauaggaggagcgcuagaacacugaugaa
auuuuacaaaacugucaagcccagcgagcacgacggcgaaucuguaacgaucgacaggaaaacagucgcuaga
aagaacuagucacugggcuagggcucacaggcgagcuggggaucuccccuuccauggaaauucgcuacgagagucug
agaacacgaccagccgcuccuuaaccaaguaccaaccuagggguguauggcgugccaggauagaggcaagucuggcau
cauuuuuaggcgagucacccaaaaagaucauguggugagcgccaagaaagaaaaacugugcagaaauuaaagggacg
ucaagaaaaugaaagggcuggacgucaaugccagaacuguggacucagugcucuugaauuggaugcaaacaccccgua
gagaccuguaauugacgaagcuuuugcuugucagguacucucagagcgcucauagccauuaaagaccuaa
aaaggcgagugcucugcggggaucacccaaacagugcgguuuuuuaacaugaugugccugaaagugcauuuuuacccag
agauuugcacacaagucuuaccacaaaagcaucucucgcccguugcacuaaaucugugacuucggucgucuaaccuug

uuuuacgacaaaaaaugagaacgacgaauccgaaagagacuaagauugauugacacuaccggcaguaccaaacc
uaagcaggacgaucucacuuucacuuuuucagagggguggaagcaguugcaaaauagauuacaaaggcaacgaaa
uaaugacggcagcugccucucaagggcugacccguaaagguguguaugccguucgguaacaaggugaauaaaauccu
cuguacgcacccaccucagaacaugugaaacguccuacugacccgcacggaggaaccgcaucguguggaaaaacacuagc
cggcgacccauggauaaaaacacugacugccaaguacccugggaaauuacugccacgauagaggaguggcaagcag
agcaugaugccaucaugaggcacaucuuggagagaccggacccuaccgacgucuccagaauaaggcaaacgugugu
ugggccaaggcuuugugccggugcugaagaccguggcgauagacauagaccacugaacaauuggaacacuguggauua
uuuugaaacggacaaagcucacucagcagagauagauugaaccaacuaugcgugagguuccuuggacucgaucugg
acuccggucuauuucugcaccacuguccguuauccauaggaauaauacacugggaaacuccccgucgccaac
auguacgggucugaauaaagaagugguccgucagcucucucgcagguacccaacaucggccucgggcaguugccaucgg
aagagucuaugacaugaacacugguacacugcgcaauuauagauccgcgcauaaaaccuaguaccuguaaacagaagac
ugccuacugcuuuguccuccaccauaaagaacacccacagagugacuuuuuucauucgucagcaaaauugaagggc
agaacuguccuggugugcgggaaaaguuguccguccaggcaaaaugguugacugguugucagaccggccugaggc
uaccuucagagcucggcuggauuuaggcaucccaggugaugugcccaaaauagacauaaauuuuguaauugugagga
ccccauaauaaauaccaucacuaucagcagugugaagaccgaugccauuaagcuuagcauguugaccaagaaagcuugu
cugcaucugaaucccgcggaaccugugucagcauagguuauugguuacgucgacagggccagcgaaagcaucauugg
ugcuauagcgcgccaguucaaguuuuccggguaugcaaacggaaauccucauugaagagacgggauguucguuuug
uauucauuggguacgaucgcaaggcccguaacgacaaauccuuaacaagcuuucacuaaccuugaccaacauuuuauaca
gguuccagacuccacgaagccggauugcaccucacuaucagugggugcgaggggaaauugccacggccaccgaagg
agugauuauaaugcugcuaacagcaaaggacaaaccuggcgaggggugugcgagcguguaaagaaaaucccg
aaagcuucgauuuacagccgaucgaaggaaggaagcgcgacuggucaaaggugcagcuaaaacauaucuucagucc
guaggaccaaacuuaacaaaguuucggagguugaaggugacaaacaguuggcagaggcuuauaguccaucgcuaa
gauugucaacgaaacaaauuacaagucaguagcgauuccacuguuuccaccggcaucuuuuccgggaacaaagauc
gacuaaccccauauugaaccauugcugacagcuuugacaccacugaugcagauguagccauauacugcagggac
aagaaugggaaaugacucucaaggaagcaguggcuaggagagaagcaguggaggagauaugcauuccgacgcacuc
uucagugacagaaccugaugcagagcugggugagggugcauccgaagaguuccuuggcuggaagggaagggcuacagca
caagcgauuggcaaaacuucacauuuuuggaagggaccaaguucaccaggcgcccaaggauauagcagaaaauau
gcaugugggccguugcaacggaggccaauagcagguauugcauguaauucccgagaaagcaugagcaguauuag
gucgaaaugccccgucgaagagucggaagccuccacaccaccuagcacgcugccuugcuugugcauccaugccauga
cuccagaaagaguacagcgccuaaaagccuacguccagaacaaauuacugugugcucauccuuuccauugccgaag
uauagaauacacuggugugcagaagaucacauugcucccagccuauauuguuucacaccgaaagugccugcguaauuca
uccaagggaaguaucucguggaacaccaccgguaagcagagacuccggagccaucggcagagaaccaauccacagagg
ggacaccugaacaaccaccacuuauaacggaggauagagaccaggacuagaaacggcugagccgaucacauucgaagag
gaagaagaggauagcauaaguuugcugucagauggcccgacccaccaggugcugcaagucgaggcagacauucaagg
gccgcccucuguaucuaugcuaucuccgguccauuccuacugcauccgacuuugauguggacaguuuauccauacuug
acaccugggaggggagcugcugacagcggggcaacgucagccgagacuaacucuuacuuucgcaagagauuggag
uuucuggcgcgaccggugccugcgccucgaacagauuucaggaaccuccacaucccgucuccgcgacaagaacacc
gucacuugcaccacagcagggccugcucgagaaccagccuaguuuccaccccgccaggcgugaauagggugaucacua
gagaggagcucgagggcguaaccccgucacgcacuccuagcaggucggucugagaaccagccuggucuccaaaccg
ccaggcguaauagggugauuacaagagaggaguuugaggcgucguagcaacaacaauagacgguuugaugcggg

ugcauacauuuuccuccgacacccggucaagggcauuuacaacaaaaucaguaaggcaaacggugcuauccgaag
ugguguuggagaggaccgaauuggagauuucguaugccccgcgccucgaccaagaaaaagaagaauuacuacgcaag
aaauuacaguuaaaucccacaccugcuaacagaagcagauaccaguccaggaagguggagaacaugaaagccauaac
agcuagacguauucugcaaggccuagggcauuauugaaggcagaaggaaaagguggagugcuaccgaaccugcgauc
cuguuccuuuguaaucaucuagugugaaccgugccuuuucagccccaggucgcaguggaaggccuguaacgccaug
uugaaagagaacuuuccgacuguggcuuuacuguaauauuccagaguacgaugccuauuuggacaugguugacgg
agcuucaugcugcuuagacacugccaguuuuugcccugcgaagcugcgcagcuuuccaaagaaacacuccuauuugg
aaccacaaauacgaucggcagugccuucagcgauccagaacacgcuccagaacguccuggcagcugccacaaaaaga
aaugcaaugucacgcaauagagagaauugcccguauuggauucggcggccuuuauguggaauugcuucaagaaaua
ugcguguaauaangaauuugggaaacguuuuaagaaaaacccaucaggcuuacugaagaaaacgugguaauuaca
uuaccaaauuaaaaggacccaaaagcugcugcucuuuuugcgaagacacauaauuugaauauguugcaggacauacca
auggacagguuuguaauggacuuaaagagagacgugaaagugacuccaggaacaaaacauacugaagaacggcccaa
gguaacaggugauccaggcugccgauccgcuaagcaacagcguaucugugcggaauccaccgagagcugguuaggagau
uaaauugcgguccugcuuccgaacauucauacacuguuugauaugucggcugaagacuuugacgcuauuauagccgag
cacuuccagccuggggauuguguucuggaaacugacaucgcgucguuugauaaaagugaggacgacgccauggcucu
gaccgcguuaaугауucuggaagacuuaagguguggacgcagagcuguuugacgcugauugaggcggcuuucggcgaaa
uuucaucaauacauuugcccacuaaaacuaauuuuaauucggagccaugaugaaaucuggaauuguccucacacug
uuugugaacacagucauuaacauuguaaucgcaagcagaguguugagagaacggcuaaccggaucccaugugcagc
auucauugggagaugacaauaucgugaaaггagucaaaucggacaaaуааuggcagacaggugcggcaccugguuga
auauggaagucaagauuauagaugcuguggguggcgagaaagcgccuuuuucuguggaggguuuauuuugugugac
uccgugacccggcacagcггugccггugggcagacccccuaaaaaggcuguuuааgcuugggcaaacccucuggcagcaga
cgauгаacаугаугагacaggagaaggгcauugcaugaagагucaacacггuggaaccггagugguauuucuuacг
agcugugcaaggcagugaгаaucaagguaugaaaccггaggaacuuuccaucauguauggccaugacucucuaгcu
agcaguguaaaуcauucagcuaccugagagggggcccuauaacucucuaacggcuaaccugaauggacuacгacaua
gucuагuccгccaag**AUGUUUCUGUCACAAACCAACGCACUAUGUUUGUUUCCUCGUGCUGCUCUUUUUGGUAAG**
UUCUCAGUGUGUAACCUGACAACACGAACCCAGUUGCCUCCAGCUUAUACCAACUCAUUUACUCGCGGAGUAUAUU
AUCCCGAUAAGGUCUUUAGAAGUAGCGUGUUGCACUCUACACAGGAUCUGUUCUUGCCCUUCUUUAGUAACGUUACC
UGGUUUCAUGCAAUACAUGUGAGCGGAACAAAUGGAACAAAAGAUUUGACAAUCCAGUGCUUCCAUAUUAUGAUGG
GGUUUACUUUGCCAGUACCGAAAAGUCAAACAUAUCCGGGGUGGAUCUUUGGAACCACUUUGGACUCUAAGACAC
AGUCUCUCCUCAUAGUAAACAACGCCACCAUGUUGUCAUAAAAGUAUGCGAAUUUCAGUUUUGCAACGAUCCCUUU
CUCGGGGUGUAUUACCAUAAGAAUAUAAAUCCUGGAUGGAGUCUGAGUUCGGGUUUUAUGUAGUGCUAAUAAUUG
CACUUUCGAAUACGUGUCCCAACCAUUCUCU AUGGACCUUGAGGGCAACAGGGGAUUUUAAAACUUGCGCGAAU
UUGUCUUUAAGAAUAUCGACGGAUACUUUAAGAUUAUAGUAAACACACUCCUAUCAACCUCGUUCGGGAUCUUCCC
CAAGGCUUUUCUGCUCUCGAACCCUCGUAGACUUGCCAAUUGGGAUAAAUUACUCUCGUUUCAAACUUUGCUUGC
CCUCCACAGGAGCUACCUGACACCCGGCGACUCUUUCUUGGUUGGACCGCCGGCGCCGUGCCUAUUAUGUUGGUU
ACCUUCAGCCACGAACAUUCUUGCUCAAGUAUAACGAGAAUGGCACCAUUAACGACGCCGUGCAUUGUGCAUUGGAU
CCCUUGUCUGAAACAAAUGUACCUUGAAGUCCUUUACCGUAGAGAAAGGCAUAUACCAGACUCCAACUUCGAGU
UCAGCCUACAGAAUCCAUUGUGAGAUUUCCTAACAUACAAACCUCUGCCCUUUCGGUGAAGUAUUUAAUGCUACAC
GCUUCGCUUCAGUCUAUGCCUGGAUAGGAAGCGCAUAUCAAUUGCGUGGCCGAUUAUUCAGUCCUCUAUAAUAGC
GCAUCCUUCAGUACUUUCAAGUGCUACGGCGUUUCCCCACCAAACUCAAUGAUUUUGCUUCACCAACGUCUAUGC

[illegible]

SEQ ID NO: 25- Full-length VEEV+ K995P-V996P RNA Sequence Antigen Encoding RNA Sequence

auaggcggcgcaugagagaagcccagaccaaauaccuacccaaauggagaaaguucacguugacaucgaggaagac
agccc auuccucagagcuuugcagcggagcuucccgaguuugagguagaagccaagcaggucacugauaagacca
ugcuaauggccagagcguuuucgcaucuggcucaaaacugaucgaaacggagguggacccauccgacacgauccuug
acaauuggaagugcgccccgcccgcagaauguaauucuaagcacaaaguaucuuuguaucuguccgaugagaugugcgga
gauccggacagauuguaaaguaugcaacuaagcugaagaaaaacuguaaggaaauaacuguaaggaaauuggacaa
gaaaaugaaggagcuggccgcccgcuaugagcgaccucugacccggaaaauagagacuaugugccuccacgacgaggu
cgugucgcuacgaagggcaagucgcuuuuaccaggauguaucgcgguugacggaccgacaagucucuaacccaa
gccaaauaggaguuagagucgccuacuggauaggcuuugacaccacccuuuuauuuuagaacuuuggcuggagc
auauccaucauacucuaaccaucugggcccgcagaaacgguguaacggcucguaacauaggccuauugcagcucugacg
uuauaggagcggucacguagagggauguccauucuuagaaagaaguuuagaaaccauccaacaauugucuaucucu
guuggcucgaccaucuaaccagagaaagggacuuacugaggagcuggcaccugccgucuguaauuacacuuacgugg
caagcaaaaauacacaugucggugugagacuauguuaguugcgacggguacgucguuaaaagaauagcuauacaguc
caggccuguauggggaagccuucaggcuauugcugcuacgaugcacccgagggauucuuugugcugcaagugacagac
acaauugaacggggagaggguucuuuuuccgugugcacguaugugccagcuacaauugugugaccaaauagacuggcau
acugggcaacagaugucagugcggacgacgcgcaaaaacugcugguugggcucaaccagcguauagucgucaaccgguc
gcaaccagagaaacaccaauaccaugaaaaauaccuuuugcccguaguggcccaggcauuugcuaggugggcaaaag
gaauuaaagggaagaucaagaagaugaaaggccacuaggacuaagagauagacaguuagucaguggguguuuuggggc
uuuuagaaggcacaagauaacaucuaauuuuaagcgcccgauacccaaccuaucaaaagugaacagcgauuuucc
acucauucgugcugcccaggauaggcaguaacacauuggagauccgggcugagaacaagaucaggaaaauguuagag
gagcacaaggagccgucaccucuaauaccgcccagggacguacaagaagcuagugcgagccgaugaggcuaggga
ggugcgugaagccgaggaguugcgcgacgucuaaccacuuuggcagcugauguugaggagccacucuggaggcgag
acgucgacuugauguuacaagaggcugggggccggcucaguggagacaccucguggcuugauaaagguuaccagcuac
gauggcgaggacaagaucggcucuuacgcugugcuuuucuccgagggcuuacucaagagugaaaaauuacuuugcau
ccaccucucgcugaacaagucuaugugauaacaacacucuggccgaaaaggggcuuaugccguggaaccuauaccag
guaaaugauguggugccagagggaugcaauaccguccaggacuuuacaagcucugagugaaagugccaccauuugug
uacaacgaacgugaguucguaaacagguaccugcaccauauugccacacauaggaggagcgcuagaacacugaugaga
auuuuacaaaacugucaagcccagcgagcacgacggcgaaauaccguuacgacauogacaggaaaacagugcguaaga
aagaacuagucacugggcuagggcucacaggcgagcuggggaucuccuccuuccauagaauucgcuacgagagucug
agaacacgaccagccgcuccuuaaccaaguaccaaccuagggguguauggcgugccaggauagggaagucuggcau
cauuuuuaggcgagucacccaaaaagaucauguggugagcgccaagaaagaaaaacugugcagaaauuaaagggaagc
ucaagaaaaugaaaggcguggagcucaaugccagaacuguggacucagugcucuugaauuggaugcaaacaccccgua
gagaccucguauauugacgaagcuuuugcuugucaugcagguacucucagagcgcucauagccauuaaagaccuaa
aaaggcagugcucugcggggaucacaaaacagugcgguuuuuuuaacaugaugugccugaaagugcauuuuuaccacg
agauuugcacacaagucuuaccacaaaagcaucucucgcccguugcacuaaaucugugacuucggucgucuaaccuug
uuuuuacgacaaaaaaugagaacgacgaauccgaaagagacuaagauugugauugacacuaccggcaguuacaaaac
uaagcaggacgaucucauucucacuuguuucagaggggugggugaagcaguugcaaaugauuacaaaggcaacgaaa
uaaugacggcagcugccucuaagggcugacccguaaagguguguaugccguucgguaacaaggugaauagaaaauccu
cuguaacgacccaccucagaacaugugaacguccuacugacccgcacggaggaccgcaucguguggaaaaacacuagc
cggcgacccauggauaaaaacacugacugccaaguacccugggaauuucacugccacgaugaggaguggcaagcag

agcaugaugccaucaugaggcacauuuggagagaccggacccuaccgacgucuccagaauaaggcaaacgugugu
ugggccaaaggcuuugugccggugcugaagaccguggcagauagaccacugaacaauaggaaacuguggauua
uuuugaaacggacaaagcucacucagcagagauaguauugaaccaacuaugcgugagguuccuuggacucgaucugg
acuccggucuauuuucugcacccacuguccguuauccauuaggaaauaacacuggggaauaacuccccgucgccaac
auguacgggucgaauaaagaagugguccgucagcucucucgcagguaccca caacugccucgggcaguuugccacugg
aagagucuaugacaugaacacugguacacugcgcauuuauaugauccgcgcauaaaaccuaguaccuguaaacagaagac
ugccucaugcuuuguccuccaccauaaagaacacccacagagugacuuuucuucauucgucagcaauuugaagggc
agaacuguccuggugugcgggaaaaguuguccgucccaggcaaaaugguugacugguugucagaccggccugaggc
uaccuucagagcucggcuggauuuaggcaucccaggugaugugcccaauaugacauaauuuuguaauugugagga
ccccauuaaaauaccaucacuaucagcagugugaagaccaugccauuaagcuuagcauguugaccaagaaagcuugu
cugcaucugaauuccggcggaaccugugucagcauagguuauugguuacgcugacagggccagcgaaagcaucauugg
ugcuauagcgcgccgaguucaaguuuuccggguaugcaaacggaaauccucauugaagagacgggauguucguuuug
uauucauuggguacgaucgcaaggcccguaacgcacaauccuacaagcuuucacaaccuugaccaacauuuuaca
gguuuccagacuccacgaagccggauugcaccuccauaucauguggugcgagggggaauuugccacggccaccgaagg
agugauuaauaaugcugcuaacagcaaaaggacaaccuggcgaggggugugcgagcguguaaagaaaauuccgg
aaagcuucgauuuacagccgaucgaaguaggaaaagcgcgacuggucaaaaggugcagcuaaaacauaucuucguc
guaggacaaaacuucaacaaaguuuccggagguugaaggugacaaacaguuggcagaggcuuauugaguccaucgcuaa
gauugucaacgaaacaauuacaagucaguagcgauuccacuguuuccaccggcaucuuuuccgggaacaaagauc
gacuaaccccauacauugaaccauuugcugacagcuuugacaccacugaugcagauguagccauauacugcagggac
aagaaugggaaaugacucucaaggaagcaguggcuaggagagaagcaguggaggagauaugcauuccgacgcacuc
uucagugacagaaccugaugcagagcugggugagggugcauccgaagaguuccuuggcuggaagggaagggcuacagca
caagcgauuggcaaaaacuuucucauauuuuggaagggaccaaguuccaccaggcgcccaaggauauagcagaaaauau
gccauugggcccguugcaacggagggccaauagcagguaugcauguauuuccucggagaaagcaugagcaguauuag
gucgaaaugccccgucgaagagucgggaagccuccacaccaccuagcaccgucgcuugcugcauccaugccauga
cuccagaaagaguacagcgccuaaaagccucacgucaccagaacaaauuacugugugcucauccuuuccauugccgaag
uauagaauacacuggugugcagaagaauccauugcuccagccuauauuuguuucaaccgaaagugccugcguaauuca
uccaaggaaguauucguggaaacaccaccgguagacgagacuccggagccaucggcagagaaccaauccacagagg
ggacaccugaacaaccaccacuuuaaaccgaggaugagaccaggacuagaaacggcugagccgaucacucgaagag
gaagaagaggauagcauauuugcugucagauaggcccgaccaccaggugcugcaagucgaggcagacaauucaggg
gccgcccucuguaucuaucuccugguccaauuccucaugcauccgacuuugauguggacaguuuuuccauacuug
acaccugggaggaggcuagcgugaccagcggggcaacgucagccgagacuaacucuuacuucgcaagagauuggag
uuucuggcgcgaccggugccugcgccucgaacaguuuacaggaacccuccacaucccgccucgcacagaacacc
gucacuugcaccaccagcagggccugcucgagaaccagccuaguuuccaccccgccaggcgugaauaggguuacacua
gagaggagcucgaggcgcuuaccccgucacgcacuccuagcagguccgucgagaaccagccugguccaaaccgg
ccaggcguaauuaggguuauuacaagagaggaguuugaggcgucguagca caacaacaugacgguuugaugcggg
ugcauacaucuuuuccuccgacaccggucaaggggcauuuacaacaaaaucaguaaggcaaacggugcuauccgaag
ugguguuggagaggaccgaauuggagauuucguauugccccgcgccucgaccaagaaaaagaagaauuacucgcaag
aaaauacaguuaaaauccacaccugcuaacagaagcagauaccaguccaggaagguggagaacaugaaagccauaac
agcuagacguauucugcaaggccuagggcauuauuugaaggcagaaggaaaugggagugcuaccgaaccucgcauc
cuguuuccuuuguaaucaucuauguguaaccgugccuuuuaagccccaggucgcaguggaaggccuguaacgccaug

uugaaagagaacuuuccgacuguggcuuuacuguaauauuccagaguacgaugccuauuuggacaugguugacgg
agcuucaugcugcuuagacacugccaguuuuugcccugcaaagcugcgcagcuuuccaaagaaacacuccuauuugg
aaccacaaauacgaucggcagugccuucagcgauccagaacacgcuccagaacguccuggcagcugccacaaaaga
aaugcgaugucacgcaaauagagagaaauugcccguauuggauucggcgccuuuauguggaauugcuucaagaaaua
ugcguguaaauaauagaauuugggaaacguuuuaagaaaaccccaucaggcuuacugaagaaaacgugguaauuaca
uuaccaaauuaaaaggaccaaagcugcugcucuuuuugcgaagacacauaauuugaauauguugcaggacauacca
auggaaggguuuguaauuggacuuaaagagagacgugaaagugacuccaggaaacaaaacauacugaagaacggcccaa
gguaacaggugauccaggcugccgaucggcuagcaacagcguaucugugcggaauccaccgagagcugguuaggagau
uaaauugcgguccugcuuccgaacauucauacacuguuugauaugucggcugaagacuugacgcuaauuauagccgag
cacuuccagccuggggaauuguguucuggaaacugacaucgcgucguuuugauaaaagugaggacgacgccauggcucu
gaccgcguuaauagaauucuggaagacuagguguggacgcagagcuguugacgcugauugaggcgccuuucggcgaaa
uuucaucaauacauuugcccacuaaaacuaauuuuaauucgggagccaugaugaaucuggaauuguccucacacug
uuugugaacacagucauuaacauuguaaucgcaagcagaguguugagagaaacggcuacccggaucccaugugcagc
auucauuggagauagacaauaucgugaaaggagucaaaucggacaaaauaauuggcagacaggugcgccaccugguuga
auauggaagucaagauuauagauugcugugggggcgagaaagcgccuauuuucuguggagggguuauuuugugugac
uccgugacccggcacagcugcgugccguguggcagacccccuaaaaaggcuguuuuagcuuggcaaaccucuggcagcaga
cgaugaacaugaugaugacaggagaagggaucguagaagagucacacgcuggaaccgaguggguaucuuucag
agcugugcaaggcagugaaaucaagguaugaaaccguaggaaacuuccaucauguuauuggccaugacuacucugacu
agcaguguuuuaucauucagcuaccugagagggggcccuauaacucucuaacggcuaccugaauggacuacgacaua
gucuaugccgccaag**AUGUUUCUGCUCACAACCAAACGCACUAUGUUUGUUUUCCUCGUGCUGCUCUUUUUGGUAAG**
UUCUCAGUGUGUAAACUGACAACACGAACCCAGUUGCCUCCAGCUUAUACCAACUCAUUUACUCGCGGAGUAUAUU
AUCCCGAUAAGGUCUUUAGAAGUAGCGUGUUGCACUCUACACAGGAUCUGUUCUUGCCCUUCUUUAGUAACGUUACC
UGGUUUCAUGCAAUACAUGUGAGCGGAACAAAUGGAACAAAAGAUUUACAAUCCAGUGCUUCCAUUUAAUGAUGG
GGUUUACUUUGCCAGUACCGAAAAGUCAAAACAUAAUCCGGGGUGGAUCUUUGGAACCACUUUGGACUCUAAGACAC
AGUCUCUCCUCAUAGUAAACAACGCCACCAUGUUGUCAUAAAAGUAUGCGAAUUUCAGUUUUGCAACGAUCCCUUU
CUCGGGGUGUAUUACCAUAAGAAUAAUAAUCCUGGAUGGAGUCUGAGUUCGGGUUUUAUGUAGUGCUAAUAAUUG
CACUUUCGAUACGUGUCCCAACCAUUCUUCUUGGACCUUGAGGGCAAACAGGGGAUUUUAAAACUUGCGCGAAU
UUGUCUUUAAGAAUACGACGGAUACUUUAAGAUCAUAGUAAACACACUCCUAUCAACCUCGUUCGGGAUCUUCCC
CAAGGCUUUUCUGCUCUCGAACCCUCGUAGACUUGCCAAUUGGGAUAAAUACACUCGCUUUCAAACUUUGCUUGC
CCUCCACAGGAGCUACCUGACACCCGGCGACUCUUCUUCUGGUUGGACCGCCGGCGCCGUGCCUAUUUAUGUUGGUU
ACCUUCAGCCACGAACAUUCUUGCUCAAGUAUAACGAGAAUGGCACCAUUAACGACGCCGUGCAUUGUGCAUUGGAU
CCCUUGUCUGAAACAAAUGUACCUUGAAGUCCUUUACCGUAGAGAAAGGCAUAUACCAGACUCCAACUUCGAGU
UCAGCCUACAGAAUCCAUGUGAGAUUUCCCAACAUACAAACCUCUGCCCUUUCGGUGAAGUAUUAAUGCUACAC
GCUUCGCUUCAGUCUUGCCUGGAAUAGGAAGCGCAUAUCAAUUGCGUGGCCGAUUAUUCAGUCCUCUAUAAUAGC
GCAUCCUUCAGUACUUUCAAGUGCUACGGCGUUUCCCCACCAAACUCAAUGAUUUUGCUUCACCAACGUCUUAUC
UGACAGUUUUGUCAUACGAGGCGACGAAGUACGCCAGAUUGCCCCCGGGCAGACAGGUAAAAUUGCUAUUAUAAUU
AUAAACUCCCAGAUGACUUUACUGGAUGCGUCAUAGCCUGGAAUCCAACAAUCUUGAUUCCAAGGUUGGUGGGAAU
UAUAAUUAACUUUAUCGACUGUUCAGAAAGAGUAAACUUUGAAACCAUUGAGAGAGACAUUCCACCGAGAUUUACCA
GGCAGGCAGUACUCCUUGUAACGGCGUUGAGGGAAUUUAAUCGCUAUUUUCCUUUGCAAUCCUAUGGCUUUCAACCAA
CAAACGGGGUUGGCUAUCAACCCUAUCGAGUGGUUGUCCUGAGCUUUGAACUUUUGCACGCUCGCCACAGUCUCG

SEQ ID NO: 26- Full-length VEEV+ D614G Antigen Encoding RNA Sequence

aaagggcggcgcaugagagaagcccagaccauuaccuacccaaaugggagaaaguuacacguugacaucgaggaagac
agcccauuccucagagcuuugcagcgagcuucccgaguuugagguagaagccaagcaggucacugauaaugacca
ugcuaaugccagagcguuuuucgcaucuggcucaaaaacugaucgaaacgggagguggacccauccgacacgauccuug
acauuggaagugcgcccgcccgagaauguauucuaagcacaagaucauuguaucuguccgaugagauugcgga

gauccggacagauuguaaaguaugcaacuaagcugaagaaaaacuguaaggaaauaacugauaaggaauggacaa
gaaaaugaaggagcuggccgcucaugagcgaccugaccuggaaacugagacuaugugccuccacgacgacgagu
cgugucgcuacgaagggcaagucgcuguuuaccaggauguaucgcggguagacggaccgacaagucucuaucaccaa
gccaaauaaggaguuagagucgccuacuggauaggcuuugacaccacccuuuuauuguuuuagaacuuuggcuggagc
auauccaucauacucuaaccaacuggggccgacgaaaaccguguaaacggcucguaaacauaggccuauagcagcucugacg
uuauaggagcggucacguagagggauguccauucuuagaaagaaguauuugaaaccauccaacauguucuaucucuc
guuggcucgaccaucuaaccagagaagaggacuuacugaggagcuggcaccugccgucuguaauuucacuuacgugg
caagcaaaaauacacaugucggugugagacuauaguauagugcgacggguacgucguuaaaagaauagcuauaguc
caggccuguaugggaagccuucaggcuauagcugcuacgaugcaccgagggauucuuugugcugcaagugacagac
acauugaacggggagagggucucuuuucccgugugcacguauugccagcuacauugugugaccaaagacuggcau
acuggcaacagaugucagugcgacgacgacgcaaaaaacugcugguugggcucaaccagcguaugucgucaacgguc
gcaccagagaaaaacccaauaccaugaaaaauuacuuuugcccguaugggccagggcauuugcuaggugggcaaaag
gaauuaagggaagaucaagaagaugaaaggccacuaggacuacgagauagacaguuaugcauggggguguuuugggc
uuuuagaaggcacaagauaacaucuaauuuuaaaggcgcccgauacccaaaccaucauaaagugaacagcgauuuucc
acucauucgugcugcccaggauaggcaguaacacauuggagauccgggcugagaacaagaauaggaaaauguuagag
gagcacaaggagccgucaccucucauuaccgcccaggagcguacaagaagcuaagugcgacggcgaugaggcuaggga
ggugcgugaagccgaggaguugcgcgagcucuaaccacuuuggcagcugauguugaggagccacucuggaggcag
acgucgacuugauguuacaagaggcuggggccggcucaguggagacaccucguggcuugauaaagguuaccagcuac
gauggcgaggacaagaucggcucuuacgugugcuuucuccgagggcuguaucuagagugaaaaauuacuuugcau
ccaccucucgcugaacaagucuaugugauaacacacucuggccgaaaaggcguaugccguggaaccauaccaug
guaaaugaugugggcccagagggaugcauaacccguccaggacuucuaagcucugagugaaagugccaccauugug
uacaacgaacgugaguucguaaacagguaccugcaccuauuugccacacauaggaggagcgcuagaacacugaugaaga
auuuuacaaaacugucaagcccagcgagcacgacggcgaauaccguuacgacaucgacaggaaaacagugcguaaga
aagaacuaugucacugggcuagggcucacaggcgagcuggggaucuccuccuuccaugaaauccgcuacgagagucug
agaacacgacaccagccgcuccuuaaccaaguaccaacccauagggguguauggcgugccaggauacaggcaagucuggcau
cauuuuuaggcgagucacccaaaaaagaucuaugggugagcgccaagaagaaaaacugugcagaaauuaaggggacg
ucaagaaaaugaaagggcuggacgucauugccagaacuguggacucagugcucuugaauuggaugcaaacaccccgua
gagacccuguaauuugacgaagcuuugcuugucaugcagguacucucagagcgcucauagccauuaaagaccuaa
aaaggcgagugcucugcggggaucacaaaacagugcgguuuuuuuuacauaugugccugaaagugcauuuuuacacg
agauuugcacacaagucuuaccacaaaagcaucucucgcccguugcacuaaaucugugacuucggucgucucaaccuug
uuuuacgacaaaaaaaugagaacgacgaauccgaaagagacuaagauuugauugacacuaccggcaguaccaaaacc
uaagcaggacgaucucauuucacuuuuuagaggggugggugagcaguugcaauagauuacaaaggcaacgaaa
uaaugacggcgagcugccucuaaggggcugacccguaaagguguguaugccguuacgguacaaggugaauaaaauccu
cuguaacgacccaccucagaacaugugaaacguccuacugacccgcacggaggaccgcaucguguggaaaaacacuaagc
cggcgacccauggauaaaaacacugacugccaaguacccugggaauuuacugccaagauagaggaguggcaagcag
agcaugaugccaucaugaggcacauucuuaggagagacccgacccuaccgacgucuuaccagaauaaggcaaacgugugu
ugggccaaggcuuagugccggugcugaagaccgcuggcauagacauagaccacugaacaauggaacacuguggauua
uuuugaaacggacaaagcucacucagcagagauaguauugaaccaacuaugcgugaggguucuuuggacucgauucgg
acuccggucuauuuucugcaccacucguuuccguuaucacauuaggaauaauacugggauaacuccccgucgcuuac
auguacgggcugaauaaagaagugguccgucagcucucucgcagguacccaacaacugccucgggcaguugccacugg

aagagucuaugacaugaacacugguacacugcgcauuuugauuccgcgcauaaaccuaguaccuguaaacagaagac
ugccucaugcuuuaguccuccaccauaaugaacacccacagagugacuuuucuucauucgucagcaaaauugaagggc
agaacuguccugggugugcggggaaaaguuguccguccagggcaaaaugguugacugguugucagaccggccugagggc
uaccuucagagcucggcuggauuuaggcaucccaggugaugugcccaaaauagacauaaauuuuguuaauugugagga
ccccauuaaaaauaccaucacuaucagcagugugaagaccaugccauuaagcuuagcauguugaccaagaagcuugu
cugcaucugaaucccggcggaaccugugucagcauaggguuauugguuacgcugacagggccagcgaaagcaucauugg
ugcuauagcgcggcaguucaaguuuucccgguaugcaaacggaaauccucauugaagagacgggauguucguuuug
uauucauuggguacgaucgcaaggcccguaucgcacaaucuuacaagcuuucaucaaccuugaccaacauuuauaca
gguuccagacuccacgaagccggauugucacccucauaucauguggugcgaggggauauugccacggccaccgaagg
agugauuuauaaugcugcuaacagcaaaggacaaccuggcgaggggugugcgagcguguaaagaaaaucccgg
aaagcuucgauuuacagccgaucgaaguaggaaaagcgcgacuggucaaaggugcagcuaaacauaucuauugcc
guaggaccaaacuuaacaaaguuuucggaggguugaaggugacaaacaguuggcagaggcuuauaguccaucgcuaa
gauugucaacgaaacaauuacaagucaguagcgauuccacuguuuguccaccggcaucuuuuccgggaacaaagauc
gacuaacccaaucauugaaccauuugcugacagcuuuagacaccacugaugcagauguagccauauacugcagggac
aagaaugggaaaugacucucaaggaagcaguggcuaggagagaagcaguggaggagauaugcauauccgacgcacuc
uucagugacagaaccugaugcagagcugggugagggugcauccgaagaguucuuuggcuggaagggaaggggcuacagca
caagcgauuggcaaaaacuucucauauuuuggaagggaccaaguucaccaggcgggccaaggauauagcagaaaauau
ggcauguggcccguugcaacggaggccaauagcagguaugcauguauauccucggagaaagcaugagcaguauuag
gucgaaaugcccgcugcaagagucggaagccuccacaccaccuagcacgcugccuugcuugugcauccaugccauga
cuccagaaagaguacagcgccuaaaagccucacguccagaacaaaauacugugugcuaucuuuccauugccgaag
uauagaauacacuggugugcagaagaucacauugcucccagccuauauuguucucacccgaaagugccugcguaauuca
uccaagggaaguauucuguggaaacaccaccgguaagcagagacuccggagccaucggcagagaaccaauccacagagg
ggcacaccugaacaaccaccacuuuaaaccgagggaugagaccaggacuagaaacggccugagccgaucacuaucgaagag
gaagaagaggauagcauaaguuugcugucagauggcccgaaccaccaggugcugcaagucgaggcagacaauucaagg
gccgcccucuguaucuaugcuaucuccgguccaauccucaugcauuccgacuuugauguggacaguuuauccauacuug
acaccucggaggaggcuagcgugaccagcggggcaacgucagccgagacuaacucuuacuucgcaaaagaguauaggag
uuucuggcgcgaccggugccugcgccucgaacaguauucaggaaccuccacaucuccgcuccgcgcacaagaacacc
gucacuugcaccacagcagggccugcucgagaaccagccuaguuuuccaccccggcaggcgugaauaggggugaucacua
gagaggagcucgagggcgcuaccccguacgcacuccuagcagguccgucucgagaaccagccugucuccaaaccg
ccaggcguaauaggggugauuacaagagaggaguugaggcgucguagcaacaacaauagcgguuugaugcgggg
ugcauacaucuuuuccuccgacaccggucaaggggcauuuacaacaaaaucaguaaggcaaacggugcuauccgaag
ugguguuaggagaggaccgaauuggagauuucguauugcccgcgcccugacccaagaaaaagaagaauuacuacgcaag
aaaauacaguuaaaauccacaccugcuaacagaagcagauaccaguccaggaagguggagaaacauagaagccauaac
agcuagacguauucugcaaggccuaggggcauuauugaaggcagaaggaaaugggagugcuaccgaaccucgcauc
cuguuuccuuuguaucuaucuguguaaccgugccuuuuaagccccaggucgcaguggaaggccuguaacgccaug
uugaagagagaacuuuccgacuguggcuucuuacuguaauuauuccagaguacgaugccuauuuggacaugguuagcgg
agcuucaugcugcuuagacacugccaguuuuugcccugcaaaagcugcgagcuuuccaaagaaacacuccuauuugg
aaccacacaaucgaucggcagugccuucagcgauccagaacacgcuccagaacguccuggcagcugccacaaaaaga
aaauugcaaugucacgcaauagagagaauugcccguauuggauucggcgccuuuaauuguggaauugcuucaagaaaua
ugcguguaauaauagaauuugggaacguuuuaagaaaaccccaucaggcuuacugaagaaaacgugguaauuaca

uuaccaaauaaaaggaccaaaagcugcugcucuuuuugcgaagacacauaaauugaauauguugcaggacauacca
 auggcagguuuguaauggacuaaaagagagacgugaaagugacuccaggaaacaaacauacugaagaacggcccaa
 gguacaggugauccaggcugccgauccgcuagcaacagcguaucugugcggaauccaccgagagcugguuaggagau
 uaaaugcggguccugcuuccgaacauuacacuguuugauaugucggcugaagacuugacgcuaauuagccgag
 cacuuccagccuggggauuguguucuggaaacugacaucgcgucguuuugauaaaagugaggacgacgccauggcucu
 gaccgcguuaaugauucuggaagacuagguugggacgcagagcuguugacgcugauugaggcggcuuucggcgaaa
 uuucaucaauacauuugcccacuaaaacuaauuuuuuuuucggagccaugaugaaaucuggaauuuccucacacug
 uuugugaacacagucuaaaucauuguaaucgcaagcagaguguugagagaaacggcuaaccggaucccaugugcagc
 auucauuggagauagacaauaucgugaaaggagucaaaucggacaaaauauggcagacaggugcgccaccugguuga
 auauggaagucaagauuauagaugcugugggggcgagaaagcgccuuuuucuguggagggguuuuuuugugugac
 uccgugacccggcacagcgugccgugugggcagacccccuaaaaaggcuguuuuagcuuggcaaaccucuggcagcaga
 cgaugaaaugaugaugacaggagaagggaucugaagaagaucaacacgcuggaaccgaguggguaucuuuucag
 agcugugcaaggcagugagaaucaagguaugaaaccguaggaaacuuccaucauguuauggccaugacuacucuaagcu
 agcaguguuuuuacauucagcuaccugagagggggcccuauaacucucuaacggcuaaccugaauaggacuaagcaua
 gucuaguccgcgaag**AUGUUUUCUGUCACAAACCAACGCACUAUGUUUUUUUCCUCGUGCUGCUCUUUUUGGUAAG**
UUUCUCAGUGUGUAACCUGACAACACGAACCCAGUUGCCUCCAGCUUAUACCAACUCAUUUACUCGCGGAGUAUAUU
AUCCCGAUAAGGUCUUUAGAAGUAGCGUGUUGCACUCUACACAGGAUCUGUUCUUGCCCUUCUUUAGUAACGUUACC
UGGUUUCAUGCAAUACAUGUGAGCGGAACAAAUGGAACAAAAGAUUUGACAAUCCAGUGCUUCCAUUUAAUGAUGG
GGUUUACUUUGCCAGUACCGAAAAGUCAAAACUAUAAUCCGGGGUGGAUCUUUGGAACCACUUUGGACUCUAAGACAC
AGUCUCUCCUCAUAGUAAACAACGCCACCAUGUUGUCAUAAAAGUAUGCGAAUUUCAGUUUUGCAACGAUCCCUUU
CUCGGGGUGUAUUACCAUAGAUAUAAUAAUAAUCCUGGAUGGAGUCUGAGUUCCGGGUUUAUAGUAGUCUAUAAUUG
CACUUUCGAAUACGUGUCCCAACCAUUCUCAUGGACCUUGAGGGCAAACAGGGGAUUUUAAAACUUUGCGCGAAU
UUGUCUUUAAGAAUACGACGGAUACUUUAAGAUUAUAGUAAACACACUCCUAUCAACCUCGUUCGGGAUCUUCCC
CAAGGCUUUUCUGCUCUCGAACCCCUUGAGACUUGCCAAUUGGGAUAAAUAUCACUCGCUUCAAACUUUGCUUGC
CCUCCACAGGAGCUACCUGACACCCGGCGACUCUUUCUUGGUUGGACCGCCGGCGCCGUGCCUAUUUAUGUUGGUU
ACCUUCAGCCACGAACAUUCUUGCUCAAGUAUAACGAGAAUGGCACCAUUAACGACGCCGUGCAUUGUGCAUUGGAU
CCCUUGUCUGAAACAAAUGUACCUUGAAGUCCUUUACCGUAGAGAAAGGCAUAUACCAGACUCCAACUUCGAGU
UCAGCCUACAGAAUCCAUGUGAGAUUUCCCAACUACAAACCUCUGCCCUUUCGGUGAAGUAUUUAAUGCUACAC
GCUUCGCUUCAGUCUAUGCCUGGAUAGGAAGCGCAUAUCAAUUGCGUGGCCGAUUAUUCAGUCCUCUAUAAUAGC
GCAUCCUUCAGUACUUUCAAGUGCUACGGCGUUUCCCCACCAAACUCAUUAUUCUUGCUUCACCAACGUCUAUGC
UGACAGUUUUGUCAUACGAGGCGACGAAGUACGCCAGAUUGCCCCGGGCGACAGGUAAAAUUGCUGAUUUAUAAUU
AUAAACUCCAGAUACUUUACUGGAUGCGUCAUAGCCUGGAAUCCAACAAUCUUGAUUCCAAGGUUGGUGGGAAU
UAUAAUUACCUUUUACGACUGUUCAGAAAGAGUAACUUGAAACCAUUUGAGAGAGACAUUCCACCGAGAUUUACCA
GGCAGGCAGUACUCCUUGUAACGGCGUUGAGGGAUUUUACUGCUAUUUUCCUUUGCAAUCCUUGGCUUUCAACCAA
CAAACGGGGUUGGCUAUCAACCCUAUCGAGUGGUUGUCCUGAGCUUUUGAACUUUUGCACGCUCGCCCCACAGUCUGC
GGACCAAAAAAGAGUACAAUUCUUGUCAAGAAUAAGUGCGUAAAUUUCAAUUGGCCUUACAGGAACAGGCGU
GCUGACUGAGUCAACAAGAAGUUCUGCCAUUUCAGCAGUUUGGGCGGGAUUAAGCAGACACAACUGACGCUGUAC
GCGAUCCUCAGACUUUGGAGAUUUGGACAUACUCCCUUGUUCUUUCGGAGGGGUUUCUGUCAUACCCCCGGAACU
AAUACAUCAAUACAGGUCGCUUGUUGUACCAAGAUGUCAACUGCACAGAAGUCCCCGUUGCUAUACACGCAGGCCA
GCUCACCCCCACAUGGCGGGUGUACUCAACUGGCUCAACGUAUUCAGACCAGAGCUGGGUGCUUGAUCGGUGCUG

[illegible]

SEQ ID NO: 27- Full-length VEEV+ B.1.351-PP-D614G Antigen Encoding RNA Sequence

[illegible]

uuauaggagcggucacguagagggauuccauucuuagaaagaaguauuuugaaaccauccaacaauuguucuaucucuc
guuaggcucgaccaucuaaccacgagaagaggacuuacugaggagcuggcaccugccgucuguaauuucacuuacgugg
caagcaaaaauacacaugucggugugagacuauaguauugcgacggguacgucguuaaaagaauagcuaucaguc
cagggccuguauggggaagccuucaggcuaugcugcuaacgaugcaccgcgagggauucuuugugcugcaagugacagac
acauugaaacggggagaggggucucuuuucccgugugcacguaugugccagcuaacauugugugacaaaugacuggcua
acuggcaacagaugucagugcgagcgcgcgcaaaaacugcugguugggcucaaccagcguauagucgucaacgguc
gcacccagagaaaacaccauaccaugaaaaauaccuuuugcccguaguggcccaggcauuugcuaggugggcaag
gaauuaaaggaagaucaagaagaugaaaggccacuaggacuacgagauagacaguuaugcaugggguguuuguggg
uuuuagaaggcacaagauaacaucuaauuaaaggcgccggauacccaaaccuacuaaagugaacagcgauuucc
acucauucgugcugcccaggauaggcaguaacacauuggagaucgggcugagaacaagaucaggaaaauguuagag
gagcacaaggagccgucaccucucauuaccgcgaggacguacaagaagcuaagugcgagccgaugaggcuuagga
ggugcgugaagccgaggaguugcgcgagcucuaaccacuuuggcagcugauguaggaggccacucuggaggcgag
acgucgacuugauguuacaagaggcugggggccggcucaguggagacaccucguggcuugauaaagguuaccagcuac
gauggcgaggacaagaucggcucuuacgugugcuuucuccgcaggcuguaacuaagagugaaaaauuacuuugcau
ccaccucucgcugaacaagucuaugugauaacacacucuggccgaaaaggcguaaugccguggaaccuauaccag
guaaaaguaguggugccagagggaucgaaucacccguccaggacuuucaagcucugagugaaagugccaccuauug
uacaacgaacgugaguuucguaaacagguaaccugcaccuauuugccacacauaggaggagcgugaaacugaugaa
auuuuacaaaacugucaagcccagcgagcacgacggcgaaucacuguaacgaucgacaggaaaacagugcguaaga
aagaacuaugucacugggcuagggcucacaggcgagcuggggaucuccuccuuccauggaaucgcuacgagagucug
agaacacgacccagccgcuccuuaccaaguaccaaccuagggguguauggcgugccaggauccaggcaagucuggcau
cauuuuuaggcgagucacccaaaaagaucuaguggugagcgccaagaaagaaaaacugugcagaaauuaaagggacg
ucaagaaaaugaaaggcguggacgucaauggccagaacuguggacucagugcucuugaauggaugcaaacaccccgua
gagaccucguauauugacgaagcuuuugcuugucaugcagguacucucagagcgcucauagccauuaaagaccuaa
aaaggcgagugcucugcggggaucacaaaacagugcgguuuuuuuaacauaugugccugaaagugcauuuuuacccag
agauuugcacacaagucuuaccacaaaagcaucucucgcgcguugcacuaaaucugugacuucggucgucucaaccuug
uuuuacgacaaaaaaugagaacgacgaauccgaaagagacuaagaauugugauugacacuaccggcaguaccaccc
uaagcaggacgaucucauucucacuuuuucagaggggugggugaagcaguugcaaaauagaauacaaaggcaacgaaa
uaaugacggcgagcugccucuaagggcugacccguaaagguguguaugccguucgguaacaaggugaauaaaauccu
cuguaacgacccaccucagaacaugugaaacguccuacugacccgcacggaggaccgcaucguguggaaaaacacugc
cggcgacccauggauaaaaacacugacugccaaguacccugggaauuucacugccaagauagaggaguggcaagcag
agcaugaugccaucaugaggcacauucgagagacccgacccuaccgacgucuuaccagaauaaggcaaacgugugu
ugggccaaggcuuugugccggugcugaagaccguggcuaagacauagaccacugaacaauggaacaacuguggauua
uuuugaaaacggacaaaagcucacucagcagagauaguauugaaccaacuaugcgugagguucuuuggacucgaucugg
acuccggucuaauuucugcacccacuguuuccguuaucacauuaggaaauaacacugggauaacucccgucgcuaac
auguacggggcugaauaaagaagugguccgucagcucucucgcagguaccacaacugccucgggcaguuugccacugg
aagagucuaugacaugaacacugguacacugcgcaauuauugauccgcgcauaaaaccuaguaccuguaaacagaagac
ugccucaugcuuuguccuccacauaauagaacacccacagagugacuuuucuuacuuucgucagcaauuugaagggc
agaacuguccuggugugcggggaaaaguuguccguccaggcaaaaugguugacugguugucagaccggccugaggc
uaccuucagagcucggcuggaauuaggcauccaggugaugugcccaauuauagacauaauuuuguaauugugagga
cccauauaaaauaccuacuaucagcagugugaagaccaugccauuagcuuagcauguugaccaagaaagcuugu

cugcaucugaaucccgcggaaccugugucagcauagguaugguuacgcugacagggccagcgaaagcaucauugg
ugcuauagcgcggcaguucaaguuuuccggguaugcaaaccgaaauccucauugaagagacggaaguucuguuug
uauucauuggguacgaucgcaaggcccguaacgcacaauccuacaagcuuucacaaaccuugaccaacauuuauaca
gguuccagacuccacgaagccggaugugcaccucacauaucauguggugcgagggggaauuugccacggccaccggaagg
agugauuuauaaugcugcuacagcaaaggacaaccuggcgaggggugugcgagcguguaaagaaaauuccggg
aaagcuucgauuuacagccgaucgaaguaggaaaagcgcgacuggucaaaggugcagcuaaaacaucauucaugcc
guaggacaaaacuucaacaaaguuucggagguugaaggugacaaacaguuggcagaggcuuauagauccaucgucaa
gauugucaacgaaacaaauacaagucaguagcgauuccacuguguccaccggcaucuuuuccgggaacaaagauc
gacuaaccacaaucauugaaccauuugcugacagcuuagacaccacugaugcagauguagccauauacugcagggac
aagaauggggaaaugacucucaagggaagcaguggcuaggagagaagcaguggaggagauaugcauauccgacgcacuc
uucagugacagaaaccugaugcagagcugggugagggugcauccgaagaguucuuuggcuggaagggaaggggcuacagca
caagcgauuggcaaaaacuuucacauuuuuggaagggaccaaguuccaccaggcgggccaagggaauagcagaaaauau
ggcauguggcccgugcaacggagggccaugagcagguaugcauguaauuccucggagaaagcaugagcaguauuag
gucgaaaugcccgugcgaagagucggaagccuccacaccaccuagcagcugccuugcugugcauccaugccauga
cuccagaaagaguacagcgccuaaaagccucacguccagaacaaaauacugugugcucauccuuuccauugccgaag
uauagaauacacuggugugcagaagaucacaaugcucccagccuauauuugucacacgaaagugccugcguaauuca
uccaagggaaguauucuguggaaacaccaaccgguaagcagagacuccggagccaucggcagagaaccaauccacagagg
ggacaccugaacaaccaccacuuauaacggaggauagagaccaggacuagaaacggcugagccgaucacaucaagagag
gaagaagaggauagcauauuugcugucagauggcccgacccaccaggugcugcaagucgaggcagacaauucaagg
gccgcccucuguaucuaagcucacuccugguccauuccucaugcauccgacuuugauguggacaguuuauccauacuug
acaccucggaggaggagcuagcugagaccagcggggcaacgucagccgagacuaacucuuacuucgcaaagaguauaggag
uuucuggcgcgacccggugccugcgccucgaacaguuuucaggaaccuccucauucccgucuccgcgcaagaacacc
gucacuugcaccacagcagggccugcucgagaaccagccuaguuuuccaccccgccaggcgugaauaggggugauacua
gagaggagcucgagggcgcuaccccgucacgcacuccuagcaggugcgucugagaaccagccuggucuccaaacccg
ccaggcguaaaauaggggugauuacaagagaggaguuugaggcgcuucguagcaacaacaacaaugacgguuugaugcggg
ugcauacacuuuuuccuccgacaccggcucaagggaauuacaacaaaaucaguaaggcaaacggugcuauccgaag
ugguguuaggagaggaccgaauuggagauuucguaugcccgcgccucgaccaagaaaaagaagaauuacuacgcaag
aaaauacaguuaaaauccacaccugcuacacagaagcagauaccaguccaggaagguggagaacaugaaagccauaac
agcuagacguauucugcaaggccuagggcauuauugaaggcagaaggaaaaugggagugcuaccgaaccucgcauc
cuguuuccuuuguaucacuauguguaaccgugccuuuuaagccccaaaggucgcaguggaaggccuguaacgccaug
uugaaagagaaacuuuccgacuguggcuuuuaucuguaauuauuccagaguacgaugccuauuuggacaugguugacgg
agcuucaugcugcuuagacacugccaguuuuugcccgcaagcugcgagcuuuccaaagaaacacuccuauuuug
aaccacacaaucgaucggcagugccuucagcgauccagaacacgcuccagaacguccuggcagcugccacaaaaaga
aaauugcaaugucacgcaaaugagagaauugcccguaauuggauucggcgccuuuauguggaauugcuucaagaaaua
ugcguguaauaaugaaauuugggaaacguuuuaagaaaaccccaucaggcuuacugaagaaaacgugguaauuaca
uuaccaaauuaaaaggacacaaaagcugcugcucuuuuugcgaaagacacauaaauugaauugcaggacauacca
auggacaggguuuguaauggacuuaaagagagacgugaaagugacuccaggaacaaaacauacugaagaacggcccaa
gguaacaggugauccaggcugccgauccgcuagcaacagcguauucugcggaauccaccgagagcugguuaggagau
uaaauugcgguccugcuuccgaacauuacacuguuugauaugucggcugaagacuuugacgcuaauuauagccgag
cacuuccagccuggggauuguguucuggaaacugacauccgucguuugauaaaagugaggacgacgccauggcucu

gaccgcguuaaugauucuggaagacuuagguguggacgcagagcuguugacgcugauugaggcgguucggcgaaa
uuucaucaauacauuugcccacuaaaacuaaaauuaauucggagccaugaugaaucuggaauuccucacacug
uuugugaacacagucauaaacaauuguaaucgcaagcagaguguugagagaaacggcuaaccggaucccaugugcagc
auucauuggagagaugacaauaucgugaaaggagucaaaucggacaaauaauggcagacaggugcgccaccugguuga
auauggaagucaagauuauagaugcugugggggcgagaaagcgccuauuucuguggagggguuauuuugugugac
uccgugacccggcacagcgugccguguggcagacccccuaaaaaggcuguuaaagcuuggcaaacucuggcagcaga
cgaugaaaugaugaugacaggagaagggaucugcaugaagagucacacgcuggaaccgaguggguaucuuucag
agcugugcaaggcagugaaucaagguaugaaaccguaggaacuuccaucauguuauggccaugacuacucugcu
agcaguguuaaaucauucagcuaccugagagggggcccuauaacucucucacggcuaaccugaauggacuacgacaua
gucuaguccgccaagAUGUUUCUGCUCACAACCAACGCACUAUGUUUGUUUCCUCGUGCUGCUCUUUGGUAAG
UUCUCAGUGUGUAACUUCACAACACGAACCCAGUUGCCUCCAGCUUAUACCAACUCAUUUACUCGCGGAGUAUAUU
AUC³CGAUAAGGUCUUUAGAAGUAGCGUGUUGCACUCUACACAGGAUCUGUUCUUGCCCUUCUUUAGUAACGUUACC
UGGUUUAUGCAUAUACAUGUGAGCGGAACAAAUGGAACAAAAGAUUUGCCAAUCCAGUGCUUCCAUUUAAUGAUGG
GGUUUACUUUGCCAGUACCGAAAAAGUCAAAACAUAAUCCGGGGUGGAUCUUUGGAACCACUUUGGACUCUAAGACAC
AGUCUCUCCUCAUAGUAACAACGCCACCAUGUUGUCAUAAAAGUAUGCGAAUUUCAGUUUUGCAACGAUCCCUU
CUCGGGGUGUAUUACCAUAAGAAUAAUAAAUCCUGGAUGGAGUCUGAGUUCGGGUUUUAUGUAGUGCUAAUAAUUG
CACUUUCGAUACGUGUCCCAACCAUCCUCAUGGACCUUGAGGGCAAACAGGGGAUUUUAAAAACUUGCGCGAAU
UUGUCUUUAAGAAUAUCGACGGAUACUUUAAGAUCUAUAGUAAACACACUCCUAUCAACCUCGUUCGGGGCCUUC³CCCAA
GGCUUUUCUGCUCUCGAACCCCUCGUAGACUUGCCAAUUGGGAUAAUUAUCACUCGCUUCAAACUUUGCACAU³CAGCUA
CCUGACACCCGGCGACUCUUCUUCUGGUUGGACCGCGCGCGCGUGCCUAUUAUGUUGGUUACCUUCAGCCACGAACAU
UCUUGCUCAAGUAUAACGAGAAUGGCACCAUUAACCGACGCGUGCAUUGUGCAUUGGAUCCCUUGUCUGAAACAAAAUGU
ACCUUGAAGUCCUUUACCGUAGAGAAAGGCAUAUACAGACUCCAACUUCGAGUUCAGCCUACAGAAUCCAUGUGAG
AUUUCCCAACAUCACAAACCUCUGCCCUUUCGGUGAAGUAUUUAUGCUACACGCUUCGCUUCAGUCUAUGCCUGGAAUA
GGAAGCGCAUAUCAAUUGCGUGGCCGAUUAUUCAGUCCUCUAUAAUAGCGCAUCCUUCAGUACUUUCAAGUGCUACGGC
GUUUCCCCCACCAAACUCAUUAUGCUUCACCAACGUCUAUGCUGACAGUUUGUCAUACGAGGCGACGAAGUACG
CCAGAUUGCCCCCGGGCAGACAGGUAAAUUGCUGAUUAUAAUUAUAAACUCCAGAUAGCUUUAUGGAUGCGUCAUAG
CCUGGAAUCCAACAUCUUGAUUCCAAGGUUGGUGGGAUUUAUAAUUAACCUUUAUCGACUGUUCAGAAAGAGUAACUUG
AAACCAUUUGAGAGAGACAUUCCACCGAGAUUUACCGGAGGCGAGUACUCCUUGUAACGGCGUUAAGGGAUUUAACUG
CUAUUUUCCUUUGCAUCCUAUGGCUUUAACCAACAUACGGGGUUGGCUAUAACCCUAUCGAGUGGUUGUCCUGAGCU
UUGAACUUUUGCACGCUCCCGCCACAGUCUGCGGACCAAAAAGAGUACAAAUUUUGUCAAGAAUAAGUGCGUAAAUUUC
AAUUUCAAUGGCCUUACAGGAACAGGCGUGCUGACUGAGUCAACAAAGAAUUCUGCCAUUUCAGCAGUUUGGGCGGGA
UAUAGCAGACACAACUGACGUGUACGCGAUCCUCAGACUUGGAGAUUUUGGACAUACUCCUGUUCUUCGGAGGGG
UAUCUGUCAUACCCCCGGAACUAAUACAUCAAAUCAGGUCGUGUGUUGUACCAAGGCGUCAACUGCACAGAAAGUCCCC
GUUGCUAUACACGCAGACCAGCUCACCCCCACAUGGCGGGUGUACUACUUGGCUCAAACGUUUCCAGACCAGAGCUGG
GUGCUUGAUCGGUGCUGAACACGUAAACAAUAGCUAUGAAUGCGAUUUCCCAUCGGUGCCGGGAUCUGCGCUAGCUAUC
AGACACAGACCAAUUC³CCCCGGCGAGCACGAUCUGUAGCAUCCAGUCUAUUUAUUGCCUACACUAUGUCAUUGGGCGUG
GAGAAUAGCGUCGCAUAUUCAAUAAUUCUAUUGCAUACCCACCAACUUCACAAUCUCCGUAACUACAGAAUACUUC
AGUUUCCAUGACAAAGACAUCAUGGAUUGUACAAUGUAUUAUGCGGAGAUUCCACAGAAUGUCAAUUGCUCUUGC
AGUACGGCUCUUCUGCACCCAGCUCACAGGGCCCUACAGGUUUGCUGUGCAACAGGACAAGAACACACAAGAAGUC
UUCGCCCAAGUCAACAGAUUAACAAAACUCCUCCCAUAAAGGAUUUUGGGCGCUUCAAACUUUAGUCAGAUCCUCCAGA

[illegible]

SEQ ID NO: 28- Full-length VEEV+ B.1.1.7-PP-D614G Antigen Encoding RNA Sequence

a
u
a
g
g
c
g
g
c
g
c
a
u
g
a
g
a
g
a
g
c
c
c
a
g
a
c
c
a
a
u
u
a
c
c
u
a
c
c
c
a
a
a
a
u
g
g
a
g
a
a
g
u
a
c
a
c
g
u
g
a
c
a
u
c
g
a
g
g
a
a
g
a
c
a
g
c
c
c
a
u
u
c
c
u
c
a
g
a
g
c
u
u
u
g
c
a
g
c
g
g
a
g
c
u
u
c
c
c
g
c
a
g
u
u
u
g
a
g
g
u
a
g
a
a
g
c
c
a
a
g
c
a
g
g
u
c
a
c
u
g
a
u
a
a
u
g
a
c
c
a
u
g
c
c
a
g
a
g
c
g
c
g
c
c
c
g
c
a
g
a
a
u
g
a
u
u
c
u
a
a
g
c
a
c
a
g
u
a
c
a
u
g
u
a
u
c
u
g
u
c
c
g
a
u
g
a
g
a
u
g
u
g
c
g
g
a
a
u
c
c
g
g
a
c
a
g
a
a
a
a
c
u
g
u
a
a
g
g
a
a
u
a
a
c
u
g
a
u
a
a
g
g
a
a
u
g
g
a
c
a
a
a
a
u
g
a
a
g
g
a
g
c
u
g
g
c
c
g
c
c
g
c
c
g
u
c
a
u
g
a
g
c
g
a
c
c
c
u
g
a
c
c
u
g
g
a
a
a
c
u
g
a
g
a
c
u
a
u
g
u
g
c
c
u
c
c
a
c
g
a
c
g
a
c
g
a
g
u
c
g
u
g
c
g
c
u
a
c
g
a
a
g
g
g
c
a
a
g
u
c
g
c
g
u
u
u
a
c
c
a
g
g
a
u
g
u
a
a
c
g
c
g
g
u
u
g
a
c
g
g
a
c
c
g
a
c
a
a
g
u
c
u
c
u
a
u
c
c
a
a
g
c
c
a
a
u
c
u
a
c
c
a
a
c
u
g
g
g
c
c
g
a
c
g
a
a
a
c
c
g
u
g
u
u
a
a
c
g
g
c
u
g
u
a
a
c
g
g
c
u
a
c
g
g
u
a
a
c
a
u
a
g
g
c
c
u
a
u
g
c
u
a
c
g
a
u
g
c
a
c
c
g
c
g
a
g
g
g
a
u
u
c
u
g
u
g
c
u
g
c
a
a
a
g
u
g
a
c
a
g
a
c
a
u
u
g
g
a
a
c
g
g
g
g
a
g
a
g
g
g
u
c
u
c
u
u
u
c
c
c
g
u
g
c
a
c
g
u
a
u
g
u
g
c
c
a
g
c
u
a
c
a
u
u
g
u
g
u
g
a
c
c
a
a
u
g
a
c
u
g
g
c
a
c
u
g
g
c
a
c
a
g
a
u
g
u
c
a
g
u
g
c
g
g
a
c
g
a
c
g
c
g
c
a
a
a
a
a
c
u
g
c
u
g
g
u
u
g
g
g
c
u
c
a
a
c
c
a
g
c
g
u
a
u
a
g
u
c
g
u
c
a
a
c
g
g
u
c
a
c
c
c
c
a
g
a
g
a
a
c
c
c
a
a
u
a
c
c
a
u
g
a
a
a
a
u
u
a
c
c
u
u
u
g
c
c
c
c
g
u
a
g
u
g
g
c
c
c
a
g
g
c
a
u
u
u
g
c
u
a
g
g
u
g
g
g
c
a
a
a
g

gaauuaaggaagaucaagaagauaaaggccacuaggacuacgagauagacaguuagucaugggguguuguugggc
uuuuagaaggcacaagauaacaucuaauuuuaagcgcccgauacccaaaccuaucaaaagugaacagcgauuuucc
acucauucgugcugcccaggauaggcaguaacacauuggagaucgggcugagaacaagaucaggaaaauguuagag
gagcacaaggagccgucaccucucauuaccgcccaggagcguacaagaagcuaagugcgagccgaugaggcuaagga
ggugcgugaagccgaggaguugcgcgagcucuaaccaccuuuggcgagcugauguugaggagcccacucuggaggcgag
acgucgacuugauguuacaagaggcugggggccggcucaguggagacaccucguggcuugauaaagguuaccagcuac
gauggcgaggacaagaucggcucuuacgcugugcuuucuccgagggcugua cucaagagugaaaauuuauucugcau
ccaccucucgcugaacaagucuaugugauaacacacucuggccgaaaaggggcguaaugccguggaaccuauaccag
guaaaaguaguggugccagagggaugcauaccguccaggacuuucaagcucugagugaaagugccaccauugug
uacaacgaacgugaguucguaaaacagguaccugcaccuauugccacacauaggaggagcgcgugaacacugaugaga
auuuuacaaaacugucaagcccagcgagcagcgagcggaauaccguacgacaucgacaggaaaacagugcguaaga
aagaacuagucacuggggcuagggcuacagggcgagcuggggaucuccuccuuccauggaauucgcccuaacgagagucug
agaacacgacccagccgcuccuuaccaaguaccaaccuagggguguauggcgugccaggauccaggcaagucuggcau
cauuuuuagcgagucacccaaaaaagaucauguggugagcgccaagaaagaaaaacugugcagaaauuaaagggagcg
ucaagaaaaugaaagggcuggagcucaaugccagaacuguggacucagugcucuugaauuggaugcaaacaccccgua
gagacccuguaauuagcgaagcuuuugcuugucaugcagguacucucagagcgcucauagccauuaaagaccuaa
aaaggcgagugcucugcggggaucuccaaaacagugcgguuuuuuaacauaugugccugaaagugcauuuuuaccacg
agauuugcacacaagucuuaccacaaaagcaucucucgcccguugcacuaaaucugugacuucggucgucucaaccuug
uuuuacgacaaaaaaugagaacgacgaauccgaaagagacuaagauugugauugacacuaccggcgauaccaaaacc
uaagcaggacgaucucauucucacuuguuuucagaggggugggugaagcaguugcaaaugauuacaaaggcaacgaaa
uaaugacggcgagcugccucuaagggcgagaccguaaagguguguaugccguucgguaacaaggugaauaaaauccu
cuguaacgacccaccucagaacauuguaacguccuacugacccgcagggagaccgcaucguguggaaaaacacuagc
cgcgacccauuggauaaaaacacugacugccaaguaccuggggaauuucacugccacgauagaggaguggcaagcag
agcaugaugccaucaugaggcacacuuggagagacccggacccuaccgacgucuccagaauaaggcaaacgugugu
ugggccaaggcuuugagugccggugcugaagaccgugggcauagacauagaccacugaacaauuggaacaacuguggaaua
uuuugaaaaggacaaagcucacucagcagagauaguauugaaccaacuaugcgugaggguucuuuggacucgaucugg
acuccggucuauuuucugcacccacuguuccguuaucacauuaggaauaaucacugggaauaacucccgucgcccuaac
auguacggggcugaauaaagaagugguccgucagcucucucgcagguaccacaacugccucgggcaguugccacugg
aagagucuaugacaugaacacugguacacugcgcauuuauaugauccgcgcauaaaaccuaguaccuguaaacagaagac
ugccuacugcuuuguccuccaccuauaagaacacccacagagugacuauuucuaucgucagcaaauguaggggc
agaacuguccuggugugcggggaaaaguuguccguccaggcaaaaugguugacugguugucagaccggccugaggc
uaccuucagagcucggcuggaauuaggaucuccaggugaugugcccaauaagacauaaauuuuguuaauugugagga
ccccauuaauaauaccuacacuaucagcagugugaagaccuagccauuaagcuuagcauguugaccaagaaagcuugu
cugcaucugaaucccgcggaaccugugcagcauagguuauugguuacgcugacagggccagcgaaagcaucauugg
ugcuauagcgcggcagauucaaguuuucccgguauugcaaacggaaauccucacuugaagagacggaauguucguuuug
uauucauuggguacgaucgcaaggcccguaacgacacauccuuaacaagcuuucuaacccuugaccaacauuuuauaca
ggauccagacuccacgaagccggauugcaccucuaucacauugggugcgagggggaauugccacggccaccgaagg
agugauuuuaaaugcugcuacacagcaaggacaaaccuggcgaggggugugcgagcguguaaagaaaaucccg
aaagcuucgauuuacagccgaucgaaggaagaaaagcgcgacuggucaaaaggugcagcuaaaacauuacauuacugcc
guaggacccaaacuacaacaaaguuucggaggguugaaggugacaaacaguuggcagaggcuuagaguccaucgcuaa

gauugucaacgauaacaauuacaagucaguagcgauuccacuguuguccaccggcaucuuuuccgggaacaaagauc
 gacuaaccccauauugaaccauuugcugacagcuuagacaccacugaugcagauguagccauauacugcaggagc
 aagaaugggaaaugacucucaaggaagcaguggcuaggagagaagcaguggaggagauaugcauauccgacgcacuc
 uucagugacagaaccugaugcagagcuggugagggugcauccgaagaguucuuuggcuggaagggaagggcuacagca
 caagcgauuggcaaaaacuuucucauauuuggaagggaccaaguuucaccaggcgcccaaggauauagcagaaaauuau
 gccauguggcccguugcaacggaggccaauagcagguaugcauguauauccucgggagaaagcaugagcaguauuag
 gucgaaaugccccgucgaagagucggaagccuccacaccaccuagcagcugccuugcuugugcauccaugccauga
 cuccagaaagaguacagcgccuaaaagccucacgucaccagaacaaauuacugugugcucauccuuuccauugccgaag
 uauagaauacugggugugcagaagauccaugcuccagccuauauuguuucacccgaaagugccugcguaauuucac
 uccaaggaaguauucuguggaaacaccaccgguaagcagagacuccggagccaucggcagagaaccaauccaagagg
 ggacaccugaacaaccaccacuuauaacggaggauagagaccaggacuagaaacggcugagccgaucacucgaagag
 gaagaagaggauagcauauuugcugucagauggcccgacccaccaggugcugcaagucgaggcagacaauucacgg
 gccgcccucuguaucugcucacuccugguccauuccucaugcauccgacuuugauguggacaguuuauccauacuug
 acacccuggaggaggagcugagcgugacccagcgggcaacgucagccgagacuaacucuuacuucgcaaagaguauaggag
 uuuucuggcgcgaccggugccugcgccucgaacaguuuucaggaacccuccacaucccgccuccgacacagaacacc
 gucacuugcaccacagcagggccugcucgagaaccagccuaguuuuccaccccgccaggcgugaauaggggugaucacua
 gagaggagcucgagggcgcuaccccgucacgcacuccuagcaggucggucucgagaaccagccuggucuccaaacccg
 ccaggcguaauuaggggugauuacaagagaggaguuugaggcgucuguaagcaacaacaauagacgguuugaugcggg
 ugcauacacuuuuccuccgacaccggucaaggggcauuuacaacaaaaucaguaaggcaaacggugcuauccgaag
 ugguguuaggagaggaccgaauuggagauuucguaugccccgcccucgaccaagaaaaagaagaauuacucgcaag
 aauuacaguuuuauccacaccugcuaacagaaagcagauaccaguccaggaagguggagaacaugaaagccauaac
 agcuagacguauuucugcaaggccuagggcauuauuugaaggcagaaggaaaagguggagugcuaaccgaaccucgcauc
 cuguuccuuuguaucacucuguguaaccgugccuuuucacggcccaaggucgcaguggaagccuguaacgccaug
 uugaaagagaaacuuuccgacuguggcuucuuacuguaauuauuccagaguaacgaugccuauuuggacaugguugacgg
 agcuucaugcugcuuagacacugccaguuuuugcccugcaaaagcugcgagcuuuccaaagaaacacuccuauuugg
 aaccacacauacgaucggcagugccuucagcgauccagaacacgcuccagaaacguccuggcagcugccacaaaaaga
 auuugcaaugucacgcaaaugagagaauugcccguauggauucggcgccuuuauguggaauugcuucaagaaaua
 ugcguguaauaaugaaauuugggaaacguuuuaagaaaaccccaucaggcuuacugaagaaaacgugguaauuaca
 uuaccaaaauuaaaggacacaaaagcugcugcucuuuugcgaagacacauauuugaauugugcaggacauacca
 auggacaggguuuguauggacuuaaagagagacgugaaagugacuccaggaacaaaacauacugaagaacggcccaa
 gguaacaggugauccaggcugccgaucccgcuagcaacagcguauucugugcggaauccaccgagagcugguuaggagau
 uaaauugcgguccugcuuccggaacauuacacucguuugauaugucggcugaagacuuugacgcuaauuauagccgag
 cacuuccagccuggggauugugucuggaaacugacaucgcgucguuugauaaaagugaggacgacgccauggcucu
 gaccgcuuaauugauucuggaagacuuagguguggacgcagagcuguuagcgcugaauaggcgccguuucggcgaaa
 uuucaucaauacauuugcccacuaaaaacuaauuuuaauucggagccaugaugaaucuggaauuguccucacacug
 uuugugaacacagucuuuaacauuguaauucgcaagcagagugugagagaaacggcuuacccggaucaccaugugcagc
 auucauuggagauagacaauaucgugaaaggagucaaaucggacaaaauuauuggcagacaggugcgccaccugguuga
 auuuggaagucagaauuauagugcugugguggggcgagaaagcgccuauuuucuguggaggguuuuuuuugugac
 uccgugacccggcacagcgugccguguggcagacccccuaaaaaggcuguuuuagcuugggcaaacucuggcagcaga
 cgaugaaacaugaugacagggagaaggccauugcaugaagagucacacacgcuggaaccgaguggguauucuuucag

agcugugcaaggcaguagaaucaagguaugaaaccguaggaacuuccaucauaguuauaggccaugacuaacucuaagcu
agcaguguaaaaucauucagcuaccugagagggggcccccuaaacucucuaacggcuaaccugaauaggacuacgacaua
gucuaguccgcgaagAUGUUUCUGCUCACAACCAAACGCACUAUGUUUGUUUUCCUCGUGCUCUCCCUUUGGUAAG
UUCUCAGUGUGUAAACCUGACAACACGAACCCAGUUGCCUCCAGCUUAUACCAACUCAUUUACUCGCGGAGUAUAUU
AUCCCGAUAAGGUCUUUAGAAGUAGCGUGUUGCACUCUACACAGGAUCUGUUCUUGCCCCUUCUUUAGUAACGUUACC
UGGUUUCAUGCAUAUAAGCGGAACAAUUGGAACAAAAGAUUUGACAAUCCAGUGCUUCCAUUUAAUGAUGGGGUUA
CUUUGCCAGUACCGAAAAGUCAAAACAUAAUCCGGGGGUGGAUCUUUGGAACCACUUUGGACUCUAAGACACAGUCUC
UCCUCAUAGUAACAACGCCACCAAGUUGUCAUAAAAGUAUGCGAAUUCAGUUUUGCAACGAUCCCUUUCUCGGG
GUGUACCAUAAGAUAUAUAAUCCUGGAUGGAGUCUGAGUUCGGGUUUAUAGUAGUGCUAAUAAUUGCACUUUCGA
AUACGUGUCCCAACCAUCCUCAUGGACCUUGAGGGCAAACAGGGGAUUUUAAAAACUUGCGCGAAUUUGUCUUUA
AGAAUAUCGACGGAUACUUUAAGAUUCUAVAGUAAACACACUCCUAUCAACCUUCGUUCCGGGAUCUCCCCAAGGCUUU
UCUGCUCUCGAACCCUCUGUAGACUUGCCAAUUGGGGAUAAUAUCACUCGCUUCAAACUUUGCUUGCCCUCCACAG
GAGCUACCUGACACCCGGCGACUCUUCUUCUGGUUGGACCGCCGGCGCCGCGUGCCUAUUAUGUUGGUUACCUUCAGC
CACGAACAUUCUUGCUCAGUAUAACGAGAAUGGCACCAUUAACCGACGCCGUCGAUUGUGCAUUGGAUCCCUUGUCU
GAAACAAAUGUACCUUGAAGUCCUUUACCGUAGAGAAAGGCAUAUACAGACUUCCAACUUCGAGUUCAGCCUAC
AGAAUCCAUUGUGAGAUUUCCCAACAUCAAAACCUCUGCCCUUUCGGUGAAGUAUUUAUGCUACACGCUUCGCUU
CAGUCUAUGCCUGGAUAGGAAGCGCAUAUCAAUUGCGUGGCCGAUUAUUCAGUCCUCUAUAUAGCGCAUCCUUC
AGUACUUUCAAGUGCUACGGCGUUUCCCCACCAAACUCAUUGAUUCUUGCUUACCAACGUCUAUGCUGACAGUUU
UGUCAUACGAGGGCAGCAAGUACGCCAGAUUGCCCCGGGCAGACAGGUAAAAUUGCUGAUUAUAUUAUAAACUCC
CAGAUAGACUUUACUGGAUGCGUCAUAGCCUGGAUUCCAACAUCUUGAUUCCAAGGUUGGUGGGAAUUAUAUUAAC
CUUUAUCGACUGUUCAGAAAGAGUAACUUGAAACCAUUGAGAGAGACAUAUCCACCGAGAUUUACCAGGCGAGCAG
UACUCCUUGUAACGGCGUUGAGGGAUUUAACUGCUAUUUUCCUUUGCAAUCCUAUGGCUUUAACCAACAUAACGGGG
UUGGCUAUCAACCCUAUCGAGUGGUUGUCCUGAGCUUUGAACUUVUUGCACGCUCCCGCCACAGUCUGCGGACCAAAA
AAGAGUACAAAUCUUGUCAAGAAUAAGUGCGUAAAUUCAAUUUCAAUGGCCUUAACAGGAACAGGCGUGCUGACUGA
GUCAAACAAGAAGUUCUGCCAUUUACGAGUUUGGGCGGGGAUAUAGACGACACAACUGACGCUGUACGCGAUCCUC
AGACUUUGGAGAUUCUUGGACAUACUCCUGUUCUUCGGAGGGGAUUCUGUAUCACCCCCGGAACUAAUACAUA
AAUCAGGUCGCGUGUGUACCAAGGCGUCAACUGCACAGAAGUCCCCGUUGCUAUACACGCAGAUACGCUACCCCC
CACAUUGGCGGGUGUACUACUUGGCUAAACGUAUUCCAGACCAGAGCUGGGUGCUUGAUCCGUGCUGAACACGUAA
ACAAUAGCUAUGAAUGCGAUUUCCCAUCGGUGCCGGGAUCUGCGCUAGCUAUCAGACACAGACCAAUCCCAUCGG
CGAGCACGAUCUGUAGCAUCCAGUCUAUUAUUGCCUACACUAUGUCAUUGGGCGCCGAGAAUAGCGUCGCAUUAUC
AAAUAUUUCAUUGCAAUACCCCAACUUCACAAUCUCCGUAACUACAGAAUACUUCCAGUUUCCAUGACAAAGA
CAUCAGUGGAUUGUACAUAUGUAUAUUAUGCGGAGAUUCCACAGAAUGUUAUUAUUGCUUUGCAGUACGGCUCCUUC
UGCACCCAGCUAACAGGGCCCUACAGGUUUGCUGUGCAACAGGACAAGAACACACAAGAAGUCUUCGCCCAAGU
CAAACAGAUUAACAAACUCCUCCCAUAAAGGAUUUUGGCGGCUUCAAACUUUAGUCAGAUCCUCCAGACCCUUCAA
AACC AUUCUAAACGAUCAUUUAUUGAAGAUUCUGCUGUUAACAAGGUCACUCUUGCCGAUGCUGGAUUCAUUAAGCAA
UACGGUGACUGCCUUGGUGAUUAUUGCUGCCCGAGAUUCGAUCUGUGCCCAGAAAUUAACGGGCUACUGUACUCCC
UCCACUGCUCACAGACGAAUUAUUGCACAGUACACAAGUGCCCUGUUGGCAGGCACAAUCACUAGCGGCGUGGACCU
UUGGCGCAGGUGCAGCACUCCAAUACCUUUUGCCAUGCAGAUUGGCCUAUCGGUUUAUUGGGAUAGGCGUGACUCAA
AAUGUCCUCUACGAAAACCAAAGUUGAUAGCUAACCAAUUCAUUCAGCAAUCGGGAAGAUACAGGAUUCACUGUC
UAGUACUGCUAGUGCCCUUGGUAAGCUGCAGGACGUUGUCAACCAGAAUGCUCAAGCUCUGAAUACAUUGGUUAAGC

[illegible]

SEQ ID NO: 29- Full-length VEEV+ Delta.AY1-S2P-wtFur Antigen Encoding RNA Sequence

a
a u a g g c g g c g c a u g a g a g a a g c c c a g a c c a u u a c c u a c c c a a a a u g g a g a a g u a c a c g u u g a c a u c g a g g a g a a g a c
a g c c c a u u c c u c a g a g c u u u g c a g c g g a g c u u c c c g c a g u u u g a g g u a g a a g c c a a g c a g g u c a c u g a u a a u g a c c a
u g c u a a u g c c a g a g c g u u u u c g c a u c u g g c u u c a a a a c u g a u c g a a a c g g a g g u g g a c c c a u c c g a c a c g a u c c u u g
a c a u u g g a a g u g c g c c c g c c c g c a g a a u g u a u u c u a a g c a c a g u a u c a u u g u a u c u g u c c g a u g a g a u g u g c g g a a
g a u c c g g a c a g a u u g u a u a a g u a u g c a a c u a a g c u g a a g a a a a c u g u a a g g a a a u a a c u g a u a a g g a a u u g g a c a a
g a a a a u g a a g g a g c u g g c c g c c g u c a u g a g c g a c c c u g a c c u g g a a a c u g a g a c u a u g u g c c u c c a c g a c g a c g a g u
c g u g u c g c u a c g a a g g g c a a g u c g c u g u u u a c c a g g a u g u a u a c g c g g u u g a c g g a c c g a c a a g u c u c u a u c a c c a a
g c c a a u a a g g g a g u u a g a g u c g c c u a c u g g a u a g g c u u u g a c a c c a c c c c u u u u a u g u u a a g a a c u u g g c u g g a g c
a u a u c c a u c a u a c u c u a c c a a c u g g g c c g a c g a a a c c g u g u u a a c g g c u c g u a a c a u a g g c c u a u g c a g c u c u g a c g
u u a u g g a g c g g u c a c g u a g a g g g a u g u c c a u u c u u a g a a a g a g u a u u u g a a c c a u c c a a c a a u g u u c u a u u c u c u
g u u g g c u c g a c c a u c u a c c a c g a g a a g a g g g a c u u a c u g a g g a g c u g g c a c c u g c c g u c u g u a u u u c a c u u a c g u g g
c a a g c a a a u u a c a c a u g u c g g u g u g a g a c u a u a g u u a g u u g c g a c g g g u a c g u c g u u a a a a g a a u a g c u a u c a g u c
c a g g c c u g u a u g g g a a g c c u u c a g g c u a u g c u g c u a c g a u g c a c c g c g a g g g a u u c u u g u g c u g c a a a g u g a c a g a c
a c a u u g a a c g g g g a g a g g g u c u c u u u u c c c g u g u g c a c g u a u g u g c c a g c u a c a u u g u g u g a c c a a a u g a c u g g c a u
a c u g g c a a c a g a u g u c a g u g c g g a c g a c g c g c a a a a a c u g c u g g u u g g g c u c a a c c a g c g u a u a g u c g u c a a c g g u c
g c a c c c a g a g a a a c a c c a a u a c c a u g a a a a a u a c c u u u u g c c c g u a g u g g c c c a g g c a u u u g c u a g g u g g g c a a a g
g a a u a u a a g g a a g a u c a a g a a g a u g a a a g g c c a c u a g g a c u a c g a g a u a g a c a g u u a g u c a u g g g g u g u u g u u g g g c
u u u u a g a a g g c a c a a g a u a a c a u c u a u u u a u a a g c g c c c g g a u a c c c a a a c c a u c a u c a a a g u g a a c a g c g a u u u c c
a c u c a u u c g u g c u g c c c a g g a u a g g c a g u a a c a c a u u g g a g a u c g g g c u g a g a a c a g a a u c a g g a a a u g u u a g a g
g a g c a c a a g g a g c c g u c a c c u c u c a u u a c c g c c g a g g a c g u a c a a g a a g c u a a g u g c g c a g c c g a u g a g g c u a a g g a
g g u g c g u g a a g c c g a g g a g u u g c g c g c a g c u c u a c c a c c u u u g g c a g c u g a u g u g a g g a g c c c a c u c u g g a g g c a g
a c g u c g a c u u g a u g u a c a a g a g g c u g g g g c c g g c u c a g u g g a g a c a c c u c g u g g c u u g a u a a a g g u a c c a g c u a c

gauggcgaggacaagaucggcucuuacgcugugcuuucuccgcaggcugua cucaagagugaaaaauaucuugcau
ccaccucucgcugaacaagucuaugugauaacacacucuggccgaaaaggcguaaugccguggaaccauaccaug
guaaaguaguggugccagagggacaugcaauacccguccaggacuuucaagcucugagugaaagugccaccauugug
uacaacgaacgugaguucguaaaacagguaccugcaccuauuugccacacauggaggagcgcugaacacugaugaaga
auuuuacaaaacugucaagcccagcgagcacgacggcgaaauaccugua cga caucgacaggaaacagugcguaaga
aagaacuaugucacugggcuagggcucacaggcgagcugggugauccuccuuccaugaaauccgcuacgagagucug
agaacacgaccagccgcuccuuaccaaguaccaaccauagggguguauggcgugccaggauccaggcaagucuggcau
cauuaaaagcgcgagucacccaaaaagaucuaguggugagcgccaagaaagaaaacugugcagaaauuaaagggacg
ucaagaaaugaaagggcuggacgucaauggccagaacuguggacucagugcucuugaauuggaugcaaacaccccgua
gagaccuguaauaugacgaagcuuuugcuugucaugcagguacucucagagcgcucauagccauuaagaccuaa
aaaggcgagugcucugcggggauccaaaacagugcgguuuuuuuuacauaugugccugaaagugcauuuuuacccacg
agauuugcacacaagucuuaccacaaaagcaucucucgcccguugcacuaaaucugugacuuccggucgucuaaccuug
uuuucgacaaaaaaugagaacgacgaauccgaaagagacuaagaauugugauugacacuaccggcgauaccaccc
uaagcaggacgaucucacuuucacuuuuucagaggggugggugaagcaguugcaauuagauuacaaaggcaacgaaa
uaaugacggcgagcugccucuaagggcgacccguaaagguguguaugccguucgguaacaaggugaauaaaauccu
cuguaacgacccaccucagaacauuguaacguccuacugacccgcacggaggaccgcaucguguggaaaacacuagc
cgcgaccccauggauaaaaacacugacugccaaguacccugggaaauuacacugccacgauagaggaguggcaagcag
agcaugaugccaucaugaggcacaucuuggagagaccggacccuaccgacgucuccagaauaaggcaaacgugugu
ugggccaaggcuuugugccggugcugaagaccguggcuaugacacugaccaugaacaauuggaacaacuguggauua
uuuugaaacggacaaagcucacucagcagagauaguauugaaccaacuaugcgugagguucuuuggacucgaucugg
acuccggucuauuucugcaccacuguccguuauccauuaggaauaauacacugggaaacuccccgucgcccuaac
auguacgggugaaauaagaagugguccgucagcucucucgcagguacccaacacugccucgggcaguugccacugg
aagagucuaugacaugaacacugguacacugcgcaauuauugauccgcgcauaaacuaguaccuguaaacagaagac
ugccuacugcuuuguccuccaccauaaagaacacccacagagugacuuuuuucuuuacuuugcagcaaaauugaagggc
agaacuguccgugugugcggggaaaaguuuguccgucccaggcaaaaugguugacugguugucagaccggccugaggc
uaccuucagagcucggcuggauuuaggcaucccaggugaugugcccaauaugaacauaauuuuguaauugugagga
cccauuaaaauaccaucacuaucagcagugugaagaccaugccauuaagcuuagcauguugaccaagaaagcuugu
cugcaucugaaucccgcggaaccugugucagcauagguuauugguacgcugacagggccagcgaaagcaucauugg
ugcuauagcgcggcaguucaaguuuuccggguaugcaaacggaaauccucauuugaagagacggaaguucuguuug
uauucauuggguacgaucgcaaggcccguacgcacaauccuuaacaagcuuucuaaaccuugaccaacauuuuaca
ggauccagacuccacgaagccggaugugcaccucuaucuuugugcgaggggaaauugccacggccaccgaagg
agugauuaauaaugcugcuacacagcaaaaggacaaacuggcggaggggugugcgagcguguaaagaaaauccgg
aaagcuucgaaauuacagccgaucgaaguaggaaaagcgcgacuggucaaaggugcagcuaaaacauaucuucaugcc
guaggacaaaacuucaacaaaguuucggaggguugaaggugacaaacaguuggcagaggcuuagaguccaucgcuaa
gauugucaacgaauaacaauuacaagucaguagcgauuccacuguuuguccaccggcaucuuuuccgggaacaaagauc
gacuaaccccauacuuugaaccauuugcugacagcuuugacaccacugaugcagauguagccauuaucugcagggac
aagaaugggaaaugacucucaaggaagcaguggcuaggagagaagcaguggaggagauaugcauauccgacgcacuc
uucagugacagaaccugaugcagagcugugagggugcauccgaagaguucuuuggcuggaagggaagggcuacagca
caagcgauuggcaaaaacuuucuaauuuuggaagggaccaaguucaccaggcgcccaaggauauagcagaaaauau
gccauugggcccguugcaacggaggccaauagcagguaugcauguaauucccgagaaagcaugagcaguauuag

gucgaaaugccccgucgaagagucggaagccuccacaccaccuagcacgcugccuugcuugugcauccaugccauga
 cuccagaaagaguacagcgccuaaaagccuacguccagaacaaauuacugugugcucauccuuuccauugccgaag
 uauagaauacacuggugugcagaagaauccaugcuccagccuauauuguucucacccgaaagugccugcguaauuua
 uccaaggaagauaucuguggaaacaccacccgguagacgagacuccggagccaucggcagagaaccaauccacagagg
 ggacaccugaacaaccaccacuuauaacggaggaugagaccaggacuagaaaggccugagccgaucacucgaagag
 gaagaagaggauagcauaaguuugcugucagauggcccgaccaccaggugcugcaagucgaggcagacaauacagg
 gccgccucuguaucuaugcuaucuccuguccauuccuacugcauccgacuuugauguggacaguuuauccauacuug
 acaccucggaggaggagcuagcgugaccagcggggcaacgucagccgagacuaacucuuacuucgcaaagaguauggag
 uuucuggcgcgaccggugccugcgccucgaacaguuucaggaaccuccacaucggcuccgcgcacaagaacacc
 gucacuugcaccacagcagggccugcucgagaaccagccuaguuccaccccgccaggcgugaauaggugauacua
 gagaggagcucgaggcgcuuaccccgucacgcacuccuagcaggucggucucgagaaccagccugucuccaaccgg
 ccaggcguaaaauaggugauuacaagagaggaguuugaggcgucguagcaacaacaauagacgguuugaugcggg
 ugcuaucacuuuuccuccgacaccggucaagggcauuuacaacaaaaucaguaaggcaaacggugcuauccgaag
 ugguguuggagaggaccgaauuggagauuucguaugcccgcgccucgaccaagaaaaagaagaauuacuacgcaag
 aauuacaguuuuauccacaccugcuaacagaagcagauaccaguccaggaagguggagaacaugaaagccauaac
 agcuagacguauucugcaaggccuagggcauuauuugaaggcagaaggaaaaguggagugcuaccgaaccucgcauc
 cuguuccuuuguaucuaucugugaaaccgugccuuuuaagcccaaggucgaguggaaggccuguaacgccaug
 uugaaagagaacuuuccgacuguggcuuuacuguaauuuccagaguacgaugccuauuuggacaugguugacgg
 agcuucaugcugcuuagacacugccaguuuuugcccgcaagcugcgagcuuuccaaagaaacacuccuauuugg
 aaccacaaucgaucggcagugccuucagcgauccagaacacgcuccagaacguccuggcagcugccacaaaaaga
 aaugcgaugucacgcaauagagagaauugcccguauggauucggcgccuuuauguggaauugcuucaagaaaua
 ugcguguaauaaugaaauuugggaaacguuuuaagaaaaaccccaucaggcuuacugaagaaaacgugguaauuua
 uuaccaaauuaaaaggaccaaagcugcugcucuuuugcgaaagacacauaauuugaauauguugcaggacauacca
 auggacagguuuguaauaggacuuuaagagagacgugaaagugacuccaggaaacaaaacauacugaagaacggcccaa
 gguacaggugauccaggcugccgaucggcuagcaacagcguaucugugcggaauccaccgagagcugguuaggagau
 uaaaugcgguuccugcuuccgaacauuacacuguuugauaugucggcugaagacuuugacgcuauuauagccgag
 cacuuccagccuggggauuguguucuggaaacugacaucgcgucguuuugauaaaagugaggacgacgccauggcucu
 gaccgcuuaaauugauucuggaagacuuaagguguggacgcagagcuguugacgcugauugaggcgccuuucggcgaaa
 uuucaucaauacauuugcccauaaaacuaauuuuaauucggagccaugaugaaucuggaauuguccucacacug
 uuuguaacacagucuuuaacauuguaaucgcaagcagaguguugagagaaaggcuuaaccggaucaaccaugucagc
 auucauuggagauagacaauaucgugaaaggagucuaauucggacaaauuaauggcagacaggugcgccaccugguuga
 auauuggaagucagaauuauagauugcugugggcgagaaagcgccuuuuucuguggaggguuuuuuuugugugac
 uccgugaccggcacagcgugccguguggcagacccccuaaaaaggcguuuaagcuuggcaaacuccuggcagcaga
 cgauagaacauagaugacaggagaaggcauugcaugaagagucacacgcuggaaccgaguggguaauucuuucag
 agcugugcaaggcagugaaucaagguaugaaaccguaggaaucuccaucauaguuauuggccaugacuacucuaugcu
 agcaguguuuuaucauucagcuaccugagagggggcccuauaacucucuaacggcuaccugaauaggacuaacgacaua
 gucuaguccgccaag**AUGUUUCUGUCACAAACCAACGCACUAUGUUUGUUUCCUCGUGCUGCUCUUUUUGGUAAG**
UUCUCAGUGUGUAAACUGAGAACACGAACCCAGUUGCCUCCAGCUUAUACCAACUCAUUUACUCGCGGAGUAUAUU
AUCCCGAUAAGGUCUUUAGAAGUAGCGUGUUGCACUCUACACAGGAUCUGUUCUUGCCCUUCUUUAGUAACGUUACC
UGGUUUAUGCAAUACAUGUGAGCGGAACAAAUGGAACAAAAGAUUUGACAAUCCAGUGCUUCCAUUUAAUGAUGG

GGUUUACUUUGCCAGUAUCGAAAAGUCAAAACAUAAUCCGGGGGUGGAUCUUUGGAACCACUUUGGACUCUAAGACAC
AGUCUCUCCUCAUAGUAAACAACGCCACCAUGUUGUCAUAAAAGUAUGCGAAUUUCAGUUUUGCAACGAUCCCUUU
CUCGACGUGUAUUACCAUAAGAAUAAUAAAUCUGGAUGGAGUCUGGGUUUAUAGUAGUGCUAAUAAUUGCACUUU
CGAAUACGUGUCCCAACCAUUCUUCUAGGACCUUGAGGGCAAACAGGGGAAUUUAAAAACUUGCGCGAAUUUGUCU
UUAAGAAUAUCGACGGGAUACUUUAAGAUCAUAGUAAACACACUCCUAUCAACCUCGUUCGGGAUCUUCCTCAAGGC
UUUUCUGCUCUCGAACCCUCUGAGACUUGCCAAUUGGGAUAAAUACACUCGCUUCAAACUUUGCUUGGCCUCCA
CAGGAGCUACCUGACACCCGGCGACUCUUCUUCUGGUUUGACC GCCGGCGCCGCGUGCCUAUUUGUUGGUUACCUUC
AGCCACGAACAUUCUUGCUCAGUAUAACGAGAAUGGCACCAUUAACCGACGCCGUCGAUUGUGCAUUGGAUCCCUUG
UCUGAAACAAAUGUACCUUGAAGUCCUUUACCGUAGAGAAAGGCAUUAACAGACUCCAACUUCGAGUUCAGCC
UACAGAAUCCAUCGUACGAUUUCCCAACAUACAAACCUCUGCCCUUUCGGUGAAGUAUUUAAUGCUACACGCUUCG
CUUCAGUCUAUGCCUGGAUAGGAAGCGCAUAUCAAAUUGCGUGGCCGAUUAUUCAGUCCUCUAUAAUAGCGCAUCC
UUCAGUACUUUCAAGUGCUACGGCGUUUCCCCACCAAACUCAUGAUUUUGCUUCACCAACGUCUAUGCUGACAG
UUUUGUCAUACGAGGCGACGAAGUACGCCAGAUUGCCCCGGGCAGACAGGUAAUAUUGCUGAUUAUAAUUAUAAAC
UCCCGAUAGACUUUACUGGAUGCGUCAUAGCCUGGAUUCCAACAAUCUAGAUUCCAAGGUUGGUGGGAAUUAUAAU
UACCGUUAUCGACUGUUCAGAAAGAGUAACUUGAAACCAUUGAGAGAGACAUUCCACCGAGAUUUAACAGGCAGG
CAGUAAGCCUUGUAACGGCGUUGAGGGAAUUAACUGCUAUUUUCCUUGCAAUCCUAUGGCUUUAACCAACAAACG
GGGUUGGCUAUCAACCCUAUCGAGUGGUUGUCCUCAGCUUUGAACUUUUGCACGCUCCCGCCACAGUCUGCGGACCA
AAAAAGAGUACAAUUCUUGUCAAGAAUAAGUGCGUAAAUUCAAUUUCAAUGGCCUUACAGGAACAGGCUGCUGAC
UGAGUCAAAACAAGAAUUUCUGCCAUUCAGCAGUUUGGGCGGGAUUAUAGCAGACACAACUGACGCGUACGCGAUC
CUCAGACUUUGGAGAUUCUUGGACAUACUCCUGUUCUUCGGAGGGGUAUCUGUCAUACCCCCGGAACUAAUACA
UCAAAUACAGGUCGCGUGUGUACCAAGGUGUCAACUGCACAGAAGUCCCCGUUGCUAUACACGCAGACCAGCUCAC
CCCCACAUGGGCGGUGUACUCAACUGGCUCAACGUAUUCAGACCAGAGCUGGGUGCUUGAUCGGUGCUGAACACG
UGAACAAUAGCUAUGAAUGCGAUAUUCCCAUCGEUGCCGGGAUCUGCGCUAGCUAUCAGACACAGACCAAUUCCCGC
AGGCGGGCUCGCUUGUAGCAUCCAGUCUAUUUUGCCUACACUAUGUCAUUGGGCGCCGAGAAUAGCGUCGCAUA
UUCAAAUAAUUCUAUUGCAAUACCCACCAACUUCACAAUUCCGUAACUACAGAAUACUUCAGUUUCCAUGACAA
AGACAUCAGUGGAUUGUACAAUGUAUAUUGCGGAGAUUCCACAGAAUGUUCAAAUUUGCUCUUGCAGUACGGCUCC
UUCUGCACCCAGCUCACAGGGCACUACAGGUUUGCUGUCGAACAGGACAAGAACACACAAGAAGUCUUCGCCCA
AGUCAAAACAGAUUAUACAAACUCCUCCCAUAAAGGAUUUUGGCGGCUUCAACUUUAGUCAGAUCCUCCAGACCCUU
CAAAACCAUCUAAACGAUCAUUUAUUGAAGAUUCGUGUUAACAAGGUCACUCUUGCCGAUGCUGGAUUCAUUAAG
CAAUACGGUGACUGCCUUGGUGAUUAUUGCUGCCCAGAUUCGAUCUGUGCCCAGAAAUUCAACGGGCUCACUGUACU
CCUUCACUGCUCACAGACGAAUUGAUUGCACAGUACACAAGUGCCUGUUGGCAGGCACAAUCACUAGCGGCUUGGA
CCUUUGGCGCAGGUGCAGCACUCCAAUACCUUUUGCCAUGCAGAUUGCCUUAUCGGUUUAUUGGGAUAGGCGUGACU
CAAAAUGUCCUCUACGAAAACCAAAAGUUGAUAGCUAACCAAUUCAUUCAGCAAUCGGGAAGAUACAGGAUUCACU
GUCUAGUACUGCUAGUGCCCUUGGUAAGCUGCAGAACGUUGUCAACCAGAAUGCUCUAGCUCUGAAUACAUUGGUUA
AGCAGCUCUCUAGUAAUUUUGGGGCAUCUCUUCAGUACUUAUUGAUUAUUUGAGCCGAUUGGACCCACCUGAAGCU
GAAGUACAGAUUCGACAGGCUGAUAAACAGGCCGGCUCCAAUCCUCCAAACAUACGUGACACAACUACAUCGCGC
AGCCGAAUCCGAGCCAGCGCUAACCUGGCAGCUACCAAGAUGUCAGAAUGCGUUCUGGGCCAGAGUAAACGCGUAG
AUUUCUGCGGGAAAGGUACCACCUGAUUGCCUUUCCCAAUUCUGCACCUCACGGGGUGCUCUUUUUGCAUGUAACA
UACGUACCCGCACAAGAGAAGAAUUUACUACCGCUCUGCCAUCUGUCAUGACGGGAAAGCUCAUUUUCCUCGCGA
AGGUGUGUUUGUAUCUAAUUGGUACACAUUGGUUUUGCACACAGCGGAUUUCUAUGAACCCAGAUCAUUAACACUG

[illegible]

SEQ ID NO: 30- Full-length VEEV+ AY1-S2P-wtFur-newKozak Antigen Encoding RNA Sequence

a u a g g c g g c g c a u g a g a g a a g c c c a g a c c a a u u a c c u a c c a a a a u g g a g a a g u u c a c g u u g a c a u c g a g g a a g a c
a g c c c a u u c c u c a g a g c u u u g c a g c g g a g c u u c c c g c a g u u u g a g g u a g a a g c c a a g c a g g u c a c u g a u a a u g a c c a
u g c u a a u g c c a g a g c g u u u u c g c a u c u g g c u u c a a a a c u g a u c g a a a c g g a g g u g g a c c c a u c c g a c a c g a u c c u u g
a c a u u g g a a g u g c g c c c g c c c g c a g a a u g u a u u c u a a g c a c a g u a u c a u u g u a u c u g u c c g a u g a g a u g u g c g g a a
g a u c c g g a c a g a u u g u a u a a g u a u g c a a c u a a g c u g a a g a a a a c u g u a a g g a a a u a c u g a u a a g g a a u u g g a c a a
g a a a u g a a g g a g a c u g g c c g c c g u c a u g a g c g a c c c u g a c c u g g a a a c u g a g a c u a u g u g c c u c c a c g a c g a c g a g u
c g u g u c g c u a c g a a g g g c a a g u c g c g u u u a c c a g g a u g u a u a c g c g g u u g a c g g a c c g a c a a g u c u c u a u c a c c a a
g c c a a u a a g g g a g u u a g a g u c g c c u a c u g g a u a g g c u u u g a c a c c a c c c c u u u u a u g u u a a g a a c u u g g c u g g a g c
a u a u c c a u c a u a c u c u a c c a a c u g g g c c g a c g a a a c c g u g u u a a c g g c u c g u a a c a u a g g c c u a u g c a g c u c u g a c g
u u a u g g a g c g g u c a c g u a g a g g g a u g u c c a u u c u u a g a a a g a a g u a u u u g a a a c c a u c c a a c a a u g u u c u a u u c u c u
g u u g g c u c g a c c a u c u a c c a c g a g a a g a g g g a c u u a c u g a g g a g c u g g c a c c u g c c g u c u g a u u u c a c u u a c g u g g
c a a g c a a a u u a c a c a u g u c g g u g u g a g a c u a u a g u u a g u u g c g a c g g g u a c g u c g u u a a a a g a a u a g c u a u c a g u c
c a g g c c u g u a u g g g a a g c c u u c a g g c u a u g c u g c u a c g a u g c a c c g c g a g g g a u u c u u g u g c u g c a a a g u g a c a g a c
a c a u u g a a c g g g g a g a g g g u c u c u u u u c c c g u g u g c a c g u a u g u g c c a g c u a c a u u g u g u g a c c a a u g a c u g g c a u
a c u g g c a a c a g a u g u c a g u g c g g a c g a c g c g c a a a a c u g c u g g u u g g g c u c a a c c a g c g u a u a g u c g u c a a c g g u c
g c a c c c a g a g a a a c a c c a a u a c c a u g a a a a u u a c c u u u u g c c c g u a g u g g c c c a g g c a u u u g c u a g g u g g g c a a a g
g a a u a u a a g g a a g a u c a a g a a g a u g a a a g g c c a c u a g g a c u a c g a g a u a g a c a g u u a g u c a u g g g g u g u u g u u g g g c
u u u u a g a a g g c a c a a g a u a c a u c u a u u u a u a a g c g c c c g g a u a c c c a a a c c a u c a u c a a a g u g a a c a g c g a u u u c c
a c u c a u u c g u g c u g c c c a g g a u a g g c a g u a a c a c a u u g g a g a u c g g g c u g a g a a c a a g a u c a g g a a a a g u u a g a g
g a g c a c a a g g a g c c g u c a c c u c u c a u u a c c g c c g a g g a c g u a c a a g a a g c u a a g u g c g c a g c c g a u g a g g c u a a g g a
g g u g c g u g a a g c c g a g g a g u u g c g c g c a g c u c u a c c a c c u u u g g c a g c u g a u g u g a g g a g c c c a c u c u g g a g g c a g
a c g u c g a c u u g a u g u a c a a g a g g c u g g g g c c g g c u c a g u g g a g a c a c c u c g u g g c u u g a u a a a g g u a c c a g c u a c
g a u g g c g a g g a c a a g a u c g g c u c u u a c g c u g u g c u u u c u c c g c a g g c u g u a c u c a a g a g u g a a a a u u a u c u u g c a u
c c a c c c u c u c g c u g a a c a a g u c a u a g u g a u a a c a c a c u c u g g c c g a a a a g g g c g u u a u g c c g u g g a a c c a u a c c a u g
g u a a a g u a g u g g u g c c a g a g g g a c a u g c a a u a c c c g u c c a g g a c u u u c a a g c u c u g a g u g a a a g u g c c a c c a u u g u g
u a c a a c g a a c g u g a g u u c g u a a a c a g g u a c c u g c a c c a u a u u g c c a c a c a u g g a g g a g c g c u g a a c a c u g a u g a a g a
a u a u u a c a a a c u g u c a a g c c c a g c g a g c a c g a c g g c g a a u a c c u g u a c g a c a u c g a c a g g a a a c a g u c g u c a a g a
a a g a a c u a g u c a c u g g g c u a g g g c u c a c a g g c g a g c u g g u g g a u c c u c c c u u c c a u g a a u u c g c c u a c g a g a g u c u g

agaacacgaccagccgcuccuuaccaaguaccaaccgauagggguguauggcgugccaggauaggcaagucuggcau
cauuaaaagcgagucacccaaaaagaucuaguggugagcgccaagaagaaaaacugugcagaaauuaagggacg
ucaagaaaugaaagggcgaggacgucaaugccagaaacuguggacucagugcucuugauggaugcaaacaccccgua
gagaccucuguaauugacgaagcuuugcuugucaugcagguacucucagagcgcucauagccauuaaagaccuaa
aaaggcgagugcucugcggggaucccaaacagugcgguuuuuuaacaugaugugccugaaagugcauuuuuaaccag
agauuugcacacaagucuccacaaaagcaucucucgcccguugcacuaaaucugugacuucggugcucucaaccuug
uuuuacgacaaaaaaugagaacgacgaauccgaaagagacuaagaauugugaugacacuaccggcaguaaccaaacc
uaagcaggacgaucucauucucacuuuuucagaggggugggugaagcaguugcaaaauagauuacaaaggcaacgaaa
uaaugacggcgagcugccucucaagggcgagaccguaaagguguguaugccguucgguaacaaggugaauaaaauccu
cuguaacgacccaccucagaacaugugaacguccuacugacccgcacggaggaccgcaucguguggaaaaacacuagc
cgcgacccauggauaaaaacacugacugccaaguacccugggaaauuacacugccacgauagaggaguggcaagcag
agcaugaugccaucaugaggcacaucuuggagagaccggaccuaccgacgucuccagaauaaggcaaacgugugu
ugggccaaggcuuagugccggugcugaagaccgcuggcauagacauagaccacugaacaauaggaaacacuguggauua
uuuugaaaaggacaaaagcucacucagcagagauagauugaaccaacuaugcgugaggguucuuuggacucgcaucugg
acuccggucuauuuucugcaccacuguuuccguuaucacauuaggaauaacacugggauaacuccccgucgcuuac
auguacggggcugaauaaagaagugggucgucagcucucucgcagguacccaacaacugccucgggcaguugccacugg
aagagucuaugacaugaacacugguacacugcgcauuuagauccgcgcauaaaaccuaguaccuguaaacagaaagac
ugccucaugcuuaguccuccacauaauagaacacccacagagugacuuaucuaucgucagcaaaauagaagggc
agaacuguccuggugugcggggaaaaguuguccguccaggcaaaaugguugacugguugucagaccggccugaggc
uaccuucagagcucggcuggauuuaggcaucccaggugaugugcccaauaugacauaauuuuguuaauugugagga
cccauauaaaauacauacacuaucagcagugugaagaccuagccauuaagcuuagcauguugaccaagaaagcuugu
cugcaucugaaucccgcggaaccugugucagcauagguuaugguuacgcugacagggccagcgaaagcaucauugg
ugcuauagcgcgggcaguucaaguuuucccgguaugcaaaccgaaauccucacuaugaagagacgggauguucuguuug
uaaucauuggguacgaucgcaaggcccguaacgacaaauccuuaacaagcuuucuaacccuagaccaacauuuauacaggu
uccagacuccacgaagccggauugcaccucacuaucauguggugcgaggggaaauugccacggccaccgaaggagugau
uaauaaugcugcuaacagcaaaaggacaaccuggcgaggggugugcgagcguguaaagaaaaucccggaagcuucg
auuuacagccgaucgaaguaggaaaagcgcgacuggucaaaaggugcagcuuaacauaucuauugccguaggaccaaac
uuaacaaaguuucggagguugaaggugacaaacaguuggcagaggcuuaugaguccaucgcuagauugucaacgauaa
cauuuacaagucaguagcgauuccacuguuuccacccggcaucuuuuccgggaaacaaagaucgacuaacccaaucauuga
accauuugcugacagcuuagacaccacugaugcagauguagccauauacugcagggacaagaaugggaaaugacucuc
aagggaagcaguggcuaggagagaagcaguggaggagauugcauauccgacgacucucagugacagaaccugaugcaga
gcuggugaggguugcauccgaagaguuuuuugcuggaaggaagggcuacagcacagcgauugcacaacuuuucuaauu
uggaagggaaccaaguuuaccaggcgggccaaggauauagcagaaauuaugccauguggcccgugcaaccggaggccaau
gagcagguaugcauguauauccucggagaaagcaugagcagauuagguugcaaaugccccgucgaagagucggaagccuc
cacaccaaccuagcacgcugccuugcuugugcauccaugccaugacuccagaaagaguacagcgccuaaaagccucacguc
cagaacaaauuacugugugcucacuuuuccauugccgaagauuagaauacacugguugcagaaagauccaauugcuccag
ccuauauuguucacaccgaaagugccugcguaauuacauccaaggaagauucuguggaaacaccaccgguagacgagac
uccggagccauccggcagagaaccaauccacagaggggacaccugaaacaccaccauuuaaccgaggauagacaccagga
cuagaacgcugagccgaucacuaucgaagaggaagaagaggauagcauaguuugcugucagauggcccgaccaccag
gugcugcaagucgaggcagacauucacggggccgcccucuguaucuaugcuaucuccugguccaauuccuauugcauccgacuu

ugauguggacaguuuauccauacuugacacccuggagggagcuagcgugaccagcggggcaacgucagccgagacuaacu
 cuuacuucgcaaagaguauggaguuucuggcgcgaccggugccugcgccucgaaacaguuucaggaaccuccacauccc
 gcuccgcgcacagaacaccgucacuugcaccagcagggccugcucgagaaccagccuaguuuccaccccgccaggcg
 gaaauaggugaucacuagagaggagcucgagggcgcuaccccgucacgcacuccuagcagguccgucgagaaaccagcc
 uggucuccaaccgcccaggcguaauaggugauuacaagagaggaguuugaggcgucguagcacaacaacaauagcgg
 uuugaugcgggugcauacauuuucccgacacccggucaaggggcauuuacaacaaaaucaguaaggcaaacggugcu
 auccgaaguggugugaggagagccgaauuggagauuucguaugcccgcgccucgaccaagaaaaagaaauuacua
 gcaagaaauuacaguuauuuccacaccugcuaacagaagcagauaccaguccaggaagguggagaaacauaagccaua
 acagcuagacguauucugcaaggccuagggcauuuuugaaggcagaaggaaaugggagugcuaccgaaccugcaucu
 guuccuuuguaaucaucuagugugaaccgugccuuuuaagccccaaggucgaguggaaggccuguaacgccauguugaa
 agagaacuuccgacuguggcuucuuacuguaauuuccagaguaacgaugccuauuuggacaugguugacggagcuuau
 gcugcuuagacacugccaguuuuugcccgcaaaagcugcgagcuuuccaaagaaacacuccuauuuggaaccacaaua
 cgauccggcagugccuucagcgauccagaacacgcuccagaacguccuggcagcugccacaaaaagaaauugcaaugcac
 gcaauagagagaauugcccguaauuggauucggcgccuuuaauugggaaugcuucaagaaauaugcguguaauaagaau
 auugggaaacguuuuaagaaaaccccaucaggcuuacugaagaaaacgugguaauuacauuaccaaaauuaaggacca
 aaagcugcugcucuuuuugcgaagacacauauuugaauauguugcaggacauaccaauggacaggguuuguaauaggacuu
 aaagagagacgugaaagugacuccaggaacaaaacauacugaagaacggcccaagguaacaggugauccaggcugccgauc
 cgcuaagcaacagcguaucugugcggaauccaccgagagcugguuaggagauuaauugcgguccugcuuccgaacauuau
 acacuguuugauaugucggcugaagacuugacgcuaauuagccgagcacuuccagccuggggaaugugucuggaac
 ugacauccgugcguuugauaaaagugaggacgacgccauggcucugaccgcuuaaugauucuggaagacuuaaggugugg
 acgcagagcugugacgcugauugaggcgccuuucggcgaaauuucacauuacauuugccacuaaaacuaaaauuaa
 uucggagccaugaugaaucuggaauuuccucacacuguuugugaacacagucuuuaacauuguaaucgcaagcagagu
 guugagagaacggcuacccggaucccaugugcagcauucuuaggagaucaauaucgugaaaggagucuuuacgggaca
 auuuuauuggcagacaggugcgccaccugguugaauauggaagucagaauuauagauugcugugggggcgagaaagcgccu
 uauuucugugggaggguuuauuuugugugacuccgugaccggcacagcgugccguguggcagaccccuuaaaaggcuguu
 uaagcuuggcgaaccucuggcagcagacgaugaaacauaugauagacaggagaagggaauugcaugaagagucacacgc
 ggaaccgaguggguauucuuucagagcugugcaaggcagugaaaucaagguuagaaaccguaggaaacuuccaucauagu
 auggccaugacuacucuaagcuagcaguguaaaucuuucagcuaccugagagggggcccuuaaacucucuaacggcuacc
 ugaauaggacuacgacauagucuaugccgcccaccAUGUUUCUGUCUACAACCAAACGCACUAUGUUUGUUUCCUCGU
GCUGCUCUUUGGUAAGUUCUCAGUGUGUAAACUGAGAACACGAACCCAGUUGCCUCCAGCUUAUACCAACUCAUUUA
 CUCGCGGAGUAUAUUAUCCCGAUAAAGGUCUUUAGAAGUAGCGUGUUGCACUCUACACAGGAUCUGUUCUUGCCCUUCUUU
 AGUAACGUUACCUGGUUUCUAGCAAUACUUGAGCGGAACAAUUGGAACAAAAAGAUUUGACAUAUCCAGUGCUUCCA
 UAAUGAUGGGGUUUACUUUGCCAGUAUCGAAAAGUCAAAACUAUUAUCCGGGGUGGAUCUUUGGAACCACUUUGGACUCUA
 AGACACAGUCUCUCCUCAUAGUAAACAACGCCACCAUUGUUGCAUAAAAGUAUGCGAAUUCAGUUUGCAACGAUCCC
 UUUUCGACGUGUAUUAACUAAGAAUAAUAAUCCUGGAUGGAGUCUGGGGUUUUAUAGUAGUGCUAAUAAUUGCACUUU
 CGAAUACGUGUCCCAACCAUUCUUAUGGACCUUGAGGGCAACAGGGGAAUUUUAAAAACUUGCGCGAAUUGUCUUUA
 AGAAUAVCGACGGAUACUUUAAGAUUCUAVAGUAAACACACUCCUAUCAACCUCGUUCGGGAUCUCCCCAAGGCUUUUCU
 GCUCUCGAACCCUCUGUAGACUUGCCAAUUGGGAUAAUUAUCACUCGCUUUCAAACUUUGCUUGCCUCCACAGGAGCUA
 CCUGACACCCGGCGACUCUUCUUCUGGUUUGACCGCGCGGCGCGCUGCCUAUUAUGUUGGUUACCUUCAGCCACGAACAU
 UCUUGCUCAAGUAUAACGAGAAUGGCACCAUUAACGACGCCGUCGAUUGGCAUUGGAUCCCUUGUCUGAAACAAAAUGU

[illegible]

aaaaaaaaaaaaaa

SEQ ID NO: 31- Full-length VEEV+ Omicron- B.1.1.529 Antigen Encoding RNA Sequence

auaggcggcgcaugagagaagcccagaccauuuaccccaaaauggagaaaguucacguugacaucgaggaaga
cagcccauuccucagagcuuugcagcggagcuucccgaguuugagguagaagccaagcaggucacugauaauagac
caugcuaauugccagagcguuuucgcaucuggcucaaaacugaucgaaacggagguggacccaucggacacgaucc
uugacauuggaagugcgcgcgcgcgcagaauguauucuaagcacaaguaucauuguaucugucgggaugagaugugc
ggaagauccggacagauuguaaaguauugcaacuaagcugaagaaaaacuguaaggaaauaacuguaaaggaaauug
gacaagaaaaugaaggagcuggccgcgcgucaugagcgacccugaccuggaaacugagacuaugugccuccacgacg
acgagucgugucgcuacgaagggcaagucgcuguuuaccaggauuguauacgcggguugacggaccgacaagucucua
ucaccaagccaauaaggaguuagagucgccuacuggauaggcuuugacaccacccuuuuuanguuuuagaacauug
gcugggagcauauccaucauacucuaaccaacuggggccgacgaaacccguguaacggcucguaacauaggccuauugca
gcucugacguuauggagcggucacguagagggauguccauucuuagaagaaguauuugaaaccauccaacaugu
ucuauucucuguuuggcucgaccaucuaaccacgagaagagggacuuacugaggagcuggcaccugccgucuguaauu
cacuuacguggcaagcaaaaauacacaugucggugugagacuaauaguauugcgacggguacgucguuaaaagaa
uagcuauacaguccaggccuguaugggaagccuucaggcuauugcugcuacgaugcacccgagggauucuuugugcug
caaagugacagacacauugaacggggagagggucucuuuucccgugugcagcuauugugccagcuacauugugugac
caauugacuggcauacuggcaacagauugcagugcggacgacgcgcgcaaaaacugcugguuggggcucaaccagcgua
uagucgucaacggugcgcacccagagaaacaccauacauagaaaaauuaccuuuugcccguauguggccaggcauu
ugcuaggugggcaaaggaaauaauaggaagaucaagaagaugaaaggccacuaggacuacgagauagacaguauaguc
auggggugugugugggcuuuuagaaggcacaagauaacaucuaauuuauaagcgcccggauacccaaaccaucauca
aagugaacagcgauuuccacucauucgugcugcccaggauaggcaguaacacauuggagauccgggcugagaacaag
aauacaggaaaauguuagaggagcacaaggagccgucaccucucauuaaccgcccaggagcguacaagaagcuagugc
gcagccgagugaggcuaggagggugcgugaagccgaggaguuugcgcgagcucuaaccacuuuggcagcugauguug
aggagcccacucuggaggcagacgucgacuuagauguuacaagaggcuggggccggcucaguggagacaccucgugg
cuugauaaagguuaccagcuacgauggcgaggacaagaucggcucuuacgcugugcuuuucuccgagggcuguaucuc
aagagugaaaaauuauucuuugcauccaccucucgcugaacaagucuaugugauaacaacacucugggccgaaaagggc
guuaugccguggaaccauacauagguaaaaguaguggugccagagggaucgaaauaccguccaggacuuucaagc
ucugagugaaagugccaccauuguguacaacgaacgugaguuuguaaacagguaccugcaccuauuugccacacau
ggaggagcgcuagaacacugaugaagaauuuacaaaacugucaagcccagcgagcacgacggcgaaauaccguuacg
acaucgacaggaaacagugcgucaagaagaacuagucacugggcuagggcucacaggcgagcuggggauccucc
cuuccaугaaauucgcuacgagagucugagaacacgaccagccgucuuuacaauguaccaaccuauaggggugua
ggcgugccaggauacaggcaagucuggcaucauuuuuagcgagucacccaaaaagaucauguggugagcgccaaga
aagaaaaacugugcagaaauuaaagggacgucaagaaaaugaaagggcuggacgucaaugccagaacuguggacuc
agugcucuuugaauuggaugcaaacaccccguagagaccucguauauugacgaagcuuuugcuugucaugcagguacu
cucagagcgcucauagccauuaaagaccuaaaaaaggcagugcucugcggggaucccaaacagugcgguuuuuuuu
acaugaugugccugaaagugcauuuuuaccacgagauuugcacacaagucuuccacaaaagcaucucucgcccguug
cacuaaaucugugacuucggugcucucaaccuuguuuuacgacaaaaaaugagaacgacgaauccgaaagagacu
aagauugugauugacacuaccggcaguaccaaaccuaagcaggacgaucucauucucacuuguuucagagggguggg
ugaagcaguugcaaaugauuacaaaggcaacgaaauaagacggcagcugccucucaagggcugacccguaaagg

uguguaugccguucgguacaaggugaauugaaaauccucuguacgcacccaccucagaacaugugaacguccuacug
acccgcacggaggaccgcacugugggaaaacacuagccggcgacccauggauaaaaacacugacugccaaguacc
cugggaaauucacugccacgauagaggaguggcaagcagagcaugaugccaugaugaggcacaucuuggagagacc
ggacccuaccgacgucuuccagaauaaggcaaacgugugugggccaaggcuuagugccggugcugaagaccgcu
ggcauagacaugaccacugaacaauuggaacaacuguggaauuuugaaaacggacaaaagcucacucagcagagauag
uauugaaccaacuaugcgugagguucuuuggacucgaucuggacuccgggucuaauuuucugcaccacuguuccguu
auccauuaggaauaauacacugggauaacuccccgucgccaacaugaucgggcugaauaaagaagugguuccgucag
cucucucgcagguacccacaacugccucgggcaguugccacuggaagagucuaugacaugaacacugguacacugc
gcaauuagauccgcgcauaaacuaguaccuguaaacagaagacugccuauugcuuaguccuccaccauaauga
acaccacagagugacuauuucuaucugcagcaaaugaagggcagaacuguccuggugggcggggaaaaguug
uccgucccaggcaaaaugguugacugguugcagaccggccugaggcuaccuucagagcucggcuggauuuaggca
ucccaggugaugugcccaaauaugacaauauuuuguaauugugaggaccccauauaaaauaccauacuaucagca
gugugaagaccaugccaauaagcuuagcauguugaccaagaaagcuugucugcaucugaaucccgggcggaaccugu
gucagcauagguuauaggguuacgcugacagggccagcgaaagcaucauuggugcuauagcgcggcaguucaaguuuu
cccggguaugcaaacggaaauccucacuugaagagacgggaaguucuguuuguaaucauuggguacgaucgcaaggc
ccguacgcacaauccuuaacaagcuuucuaacaaccuugaccaacauuuauacagguuccagacuccacgaagccgga
ugugcaccucuaucuaugugugcgagggggaauuugccacggccaccgaaggagugauuuauaaugcugcuaaca
gcaaaggacaaccugggcgaggggugugcgagcguguaaagaaauucccggaagcuucgaaauuacagccgau
cgaaguaggaaaagcgcgacuggucaaaggugcagcuaaacauaucuaucaugccguaggaccaaacuuaacaaa
guuucggagguugaaggugacaaacaguuggcagaggcuuauagauccaucgcuagaauugucaacgaaacaaau
acaagucaguagcgauuccacuguuuguccaccggcaucuuuuccgggaacaaagaucgacuaacccaaucauugaa
ccaauugcugacagcuuagacaccacugaugcagaugagccauauacugcagggacaagaaaugggaaaugacu
cucaagggaagcaguggcuaggagagaagcaguggaggagauaugcauauccgacgcacucucagugacagaaccug
augcagagcugggugaggugcuaucgaagaguucuuuggcuggaagggaaggccuacagcacaagcgauaggcaaaac
uuucuaauuuuggaagggaaccaaguucaccaggcgcccaaggauauagcagaaauuaugccaugugggcccggu
gcaacggaggccaaugagcagguauugcaugauauucccgagaaagcaugagcagauuaggucgaaaugccccg
ucgaagagucggaagccuccacaccaccuagcacgcugccuugcuugugcauccaugccaugacuccagaaagagu
acagcgccuaaaaagccucacguccagaacaaauuacugugugcucuaucuuuccauugccgaagauagaaucau
ggugugcagaagaucuaugcucccagccuauauuguucacacgaaagugccugcguaauuaucauccaagggaagu
aucucguggaaacaccaccgguaagacgagacuccggagccaucggcagagaaccaauccacagaggggacaccuga
acaaccaccacuuauaaccgagggaugagaccaggacuagaacgccugagccgaucauacgaagaggaagaagag
gauagcauaaguuugcugucagauggcccgacccaccaggugcugcaagucgaggcagacaauuacggggccgccc
cuguaucuaugcuaucuccugguccauuccuauugcauuccgacuugauguggacaguuuauccauacuugacacccu
ggaggggagcuagcgugaccagcggggcaacgucagccgagacuaacucuuacuucgcaagagauaggaguuuucug
gcgcgaccggugccugcgccucgaacagauuucaggaaccuccacaucccgucuccgcgacagaacaccgucac
uugcaccacagcagggccugcucgagaaccagccuaguuuuccaccccgccaggcgugaauaggggugaucauagaga
ggagcucgaggcgcuuaccccgucacgcacuccuagcaggucggucucgagaaccagccuggucuccaaccggcca
ggcguaauuaggggugauuacaagagaggaguugaggcgucguagcacaacaacaauagcgguuugaugcgggug
cauacauuuuuccuccgacaccggucaaggggcauuuacaacaaaaucaguaaggcaaacggugcuauccgaagu
gguguuggagaggaccgaauuggagauuucgaaugcccccgccucgaccaagaaaaagaagaauuacucgcaag

aaauuacaguuuuuuccacaccugcuaacagaagcagauaccaguccaggaagguggagaaacaugaaagccauaa
cagcuagacguauucugcaaggccuagggcauuuuuugaaggcagaaggaaaaguggagugcuaccgaaccugca
uccuguuuccuuuguaaucaucuagugugaaccgugccuuuucagcccaaggucgcaguggaagccuguaacgcc
auguugaaagagaaacuuuccgacugugggcuucuuacuguaauuuccagagauacgaugccuauuuggacaugguug
acggagcucuacugcugcuuagacacugccaguuuuugcccugcgaagcugcgcagcuuuccaaagaaacacuccua
uuuggaaccacaaucgaucggcagugccuucagcgauccagaacacgcuccagaacguccuggcagcugccaca
aaaagaaauugcaaugucacgcaaaugagagaauugcccguauuggauucggcgccuuuaauguggaaugcuuca
agaaauaugcguguaauaauagaauuugggaaacguuuuaagaaaaccccaucaggcguuacugaagaaaacguggu
aaauuacauuaccaaaauaaaaggacaaaagcugcugcucuuuuugcgaagacacauauuugaauauguugcag
gacauaccaauggacagguuuguaauggacuuaaagagagacgugaaagugacuccaggaacaaaaacauacugaag
aacggcccaagguacaggugauccaggcugccgcuagcaacagcguaucugugcggaauccaccgagagcgu
gguuaggagauuuuuuugcgguccugcuuccgaacauuacacuguuugauaugucggcgugaagacuugacgcu
auuauagccgagcacuuccagccuggggaugugugucuggaaacugacaucgcgucguuugauaaaagugaggacg
acggcauggcucugaccgcguuaaugauucuggaagacuaggugugggacgcagagcugugacgcugauugaggc
ggcuuucggcgaaaauuacaucauacauuugcccacuaaaacuaauuuuuuuuucgggagccaugaugaaaucugga
auguuccucacacuguuugugaacacagucuuuaacauuguaauucgcaagcagagugugagagaacggcuaaccg
gaucaccaugugcagcauucuuuggagauagacaauaucgugaaaggagucaaaucggacaaaauuauuggcagacag
gugcgccaccugguugaauauggaagucaagauuauagaugcugugguggggcgagaaagcgccuuuuuucugugga
ggguuuuuuuugugugacuccgugaccggcacagcgugccguguggcagacccccuaaaaaggcuguuuuagcuug
gcaaaccucuggcagcagacgaugaacaugaugaugacaggagaaggggcauugcaugaagagucaacacgcuggaa
ccgagugggguauucuuucagagcugugcaaggcaguagaaucaagguauagaaaccguaggaacuuccaucauaguu
augggcaugacuacucuaugcuagcaguguaaaucuuucagcuaccugagagggggccccuauaacucucuaacggcu
aaccugaauaggacuacgacauagucuaaguccgcCGCCACCAUGUUUCUGUUGACGACCAAGCGAACGAUGUUCGUU
UUCUUGGUGCUUUUGCCACUUGUCAGUUCCCAGUGCGUCAUUCUGACGACACGAACACAGCUGCCUCCUGCGUACA
CUAACAGUUUUACGCGAGGAGUGUAUUACCCUGACAAAGUUUUCCGCUCUAGUGUCCUCCAUAAGCACACAGGACUU
GUUUUCUCCCCUUCUUUUCCAACGUUACGUGGUUCCAUGUGAUUAGUGGAACUAACGGUACUAAAAGAUUCGACAAU
CCAGUAUUGCCUUUCAACGAUGGGGUCUAUUUCGCGUCCAUCGAGAAUCAAUAUCAUUCGCGGUUGGAUUUUUG
GAACGACACUCGAUUCAAAGACGCAAUCCCUCUUAUUGUCAACAACGCCACUAACGUAGUCAUUAAGGUUUUGA
GUUCCAGUUUUUGAAUGAUCCUUUUUUGACCACAAGAAUAACAAGAGCUGGAUGGAAAGCGAGUUCAGAGUGUAU
AGCUCUGCAAACAACUGUACUUUUUGAAUACGUGAGUCAACCUUCCUUAUGGACCUUGAAGGUAAACAGGGUAACU
UUAAGAAUUUGCGCGAAUUUGUUUUCAAAAACAUUGAUGGUUACUUUAAAUCUAUAGUAAGCACACUCCUAUCAU
UGUAAGAGAGCCGGAGGACCUUCCACAGGGUUUAGUGCGCUCGAGCCCCUCGUUGACCUGCCCAUUGGGAUCAAC
AUAACUCGAUUCCAAACAUUGCUCGCCCUUCAUCGGUCCUAUCUGACUCCCGGUGACUCCUCUAGCGGAUGGACGG
CAGGUGCCGCCGCAUACUACGUGGGGUACCUUCAACCUCGGACAUUUUUGUUGAAUACAAGAGAAUGGCACUAU
AACUGACGCGGUUGAUUGCGCGCUCGACCCAUUGUCCGAAACUAAGUGUACUUUGAAGUCAUUUACAGUGGAGAAA
GGAUUAUUAUCAGACUAGCAAUUUUCGGGUACAGCCCACGGAGUCUAUCGUACGGUUUCCUAACAUCACGAAUCUGU
GCCCUUUUGAUGAGGUCUUUUAUGCAACACGGUUCGCCUCCGUUAUGCGUGGAUAGAAAGCGCAUCUCAAAUUG
UGUAGCUGAUUAUUCGUACUUUACAACUUGGCCCCCGUUCUUCACAUUUAAUGUGCUACGGUGUAAGCCCUACUAAA
CUGAACGAUUUGUGUUUACCAACGUCUAUGCAGAUAGCUUUUGUUAUUCGAGGCGAUGAGGUACGCCAGAUUGCGC
CUGGUCAAACGGGUAAUAUCGCCGACUACAAUUAUAAAUGCCAGACGAUUUUACUGGUUGUGUCAUCGCUUGGAA

[illegible]

[00182] While preferred embodiments of the present disclosure have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the disclosure. It should be understood that various alternatives to the embodiments of the disclosure described herein may be employed in practicing the disclosure. It is intended that the following claims define the scope of the disclosure and that methods and structures within the scope of these claims and their equivalents be covered thereby.

CLAIMS

What is claimed is:

1. A composition comprising:
 - a lipid carrier, wherein the lipid carrier comprises:
 - liquid oil; and
 - surfactants, wherein the surfactants comprise:
 - a cationic lipid;
 - a hydrophilic surfactant; and
 - a hydrophobic surfactant; and
 - at least one nucleic acid, wherein the at least one nucleic acid comprises a sequence at least 85% identical to SEQ ID NOS: 1 to 7.
2. The composition of claim 1, wherein the nucleic acid comprises a sequence at least 85% identical to the sequence SEQ ID NO: 4, optionally at least 85% identical to the sequence SEQ ID NO: 27.
3. The composition of claim 1, wherein the nucleic acid comprises a sequence region that is SEQ ID NO: 4, optionally SEQ ID NO: 27.
4. The composition of any one of claims 1 to 3, wherein the nucleic acid is in complex with the lipid carrier.
5. The composition of any one of claims 1 to 4, wherein, the nucleic acid further encodes for an RNA polymerase.
6. The composition of claim 5, wherein the RNA polymerase is a Venezuelan equine encephalitis virus (VEEV) RNA polymerase.
7. The composition of claim 5, wherein is the nucleic acid coding the RNA polymerase comprises the nucleic acid sequence of SEQ ID NO: 20.
8. The composition of any one of claims 1 to 7, wherein the liquid oil is α -tocopherol, coconut oil, grapeseed oil, lauroyl polyoxylglyceride, mineral oil, monoacylglycerol, palmkernel oil, olive oil, paraffin oil, peanut oil, propolis, squalene, squalane, soy lecithin, soybean oil, sunflower oil, a triglyceride, or vitamin E.
9. The composition of claim 8, wherein the triglyceride is capric triglyceride, caprylic triglyceride, a caprylic and capric triglyceride, a triglyceride ester, or myristic acid triglycerin.
10. The composition of any one of claims 1 to 9, wherein the cationic lipid is 1,2-dioleoyloxy-3 (trimethylammonium)propane (DOTAP), 3β -[N— (N',N'-dimethylaminoethane) carbamoyl]cholesterol (DC Cholesterol), dimethyldioctadecylammonium (DDA); 1,2-

dimyristoyl 3-trimethylammoniumpropane(DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), N-[1-(2,3-dioleoyloxy)propyl]N,N,N-trimethylammonium, chloride (DOTMA), N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), and 1,2- dilinoleyloxy-3-dimethylaminopropane (DLinDMA), 1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), 306Oi10, tetrakis(8-methylnonyl) 3,3',3'',3'''-(((methylazanediyl) bis(propane-3,1 diyl))bis(azanetriyl))tetrapropionate, 9A1P9, decyl (2-(dioctylammonio)ethyl) phosphate; A2-Iso5-2DC18, ethyl 5,5-di((Z)-heptadec-8-en-1-yl)-1-(3-(pyrrolidin-1-yl)propyl)-2,5-dihydro-1H-imidazole-2-carboxylate; ALC-0315, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); ALC-0159, 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide; β -sitosterol, (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5R)-5-ethyl-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; BAME-O16B, bis(2-(dodecylsulfanyl)ethyl) 3,3'-((3-methyl-9-oxo-10-oxa-13,14-dithia-3,6-diazahexacosyl)azanediyl)dipropionate; BHEM-Cholesterol, 2-((((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)amino)-N,N-bis(2-hydroxyethyl)-N-methylethan-1-aminium bromide; cKK-E12, 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione; DC-Cholesterol, 3 β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol; DLin-MC3-DMA, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino) butanoate; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOSPA, 2,3-dioleoyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; ePC, ethylphosphatidylcholine; FTT5, hexa(octan-3-yl) 9,9',9'',9''',9''''-(((benzene-1,3,5-tricarbonyl)tris(azanediyl)) tris (propane-3,1-diyl)) tris(azanetriyl))hexanonanoate; Lipid H (SM-102), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino) octanoate; OF-Deg-Lin, (((3,6-dioxopiperazine-2,5-diyl)bis(butane-4, 1-diyl))bis(azanetriyl))tetrakis(ethane-2,1-diyl) (9Z,9'Z,9''Z,9'''Z,12Z,12'Z,12''Z,12'''Z)-tetrakis (octadeca-9,12-dienoate); PEG2000-DMG, (R)-2,3-bis(myristoyloxy)propyl-1-(methoxy poly(ethylene glycol)2000) carbamate; TT3, or N1,N3,N5-tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide.

11. The composition of any one of claims 1 to 10, wherein the lipid carrier comprises a

hydrophobic core.

12. The composition of any one of claims 1 to 11, wherein the lipid carrier comprises an inorganic particle.

13. The composition of claim 12, wherein the inorganic particle is within the hydrophobic core.

14. The composition of claim 12 or claim 13, wherein the inorganic particle comprises a metal.

15. The composition of claim 14, wherein the metal comprises a metal salt, a metal oxide, a metal hydroxide, or a metal phosphate.

16. The composition of claim 15, wherein the metal oxide comprises aluminum oxide, aluminum oxyhydroxide, iron oxide, titanium dioxide, or silicon dioxide.

17. The composition of any one of claims 1 to 16, wherein the hydrophobic surfactant is sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, or sorbitan trioleate.

18. The composition of any one of claims 1 to 17, wherein the hydrophilic surfactant is a polysorbate.

19. A composition comprising:

a lipid carrier, wherein the lipid carrier comprises:

liquid oil; and

surfactants, wherein the surfactants comprise:

a cationic lipid;

a hydrophilic surfactant; and

a hydrophobic surfactant; and

at least one nucleic acid, wherein the nucleic acid comprises a sequence encoding for a SARS-CoV-2 omicron variant spike protein antigen or functional variant thereof.

20. The composition of claim 19, wherein the SARS-CoV-2 omicron variant spike protein antigen or functional variant thereof comprises the stem helix of the SARS-CoV-2 omicron variant spike protein antigen.

21. The composition of claim 20, wherein the stem helix of the SARS-CoV-2 omicron variant spike protein antigen comprises an amino acid sequence at least 85% identical to SEQ ID NO: 19.

22. The composition of any one of claims 19 to 21, wherein the nucleic acid encoding for the SARS-CoV-2 omicron variant spike protein antigen comprises a polynucleotide sequence

at least 85% identical to SEQ ID NO: 8, optionally at least 85% identical to the sequence SEQ ID NO: 31.

23. The composition of any one of claims 19 to 22, wherein the SARS-CoV-2 omicron variant spike protein comprises an amino acid sequence at least 85% identical to SEQ ID NO: 16.

24. The composition of any one of claims 19 to 23, wherein the nucleic acid is in complex with the lipid carrier.

25. The composition of any one of claims 19 to 24, wherein the nucleic acid further encodes for an RNA polymerase.

26. The composition of claim 25, wherein the RNA polymerase is a Venezuelan equine encephalitis virus (VEEV) RNA polymerase.

27. The composition of claim 25, wherein is the nucleic acid encoding for the RNA polymerase comprises the nucleic acid sequence of SEQ ID NO: 20.

28. The composition of any one of claims 19 to 27, wherein the liquid oil is α -tocopherol, coconut oil, grapeseed oil, lauroyl polyoxylglyceride, mineral oil, monoacylglycerol, palmkernel oil, olive oil, paraffin oil, peanut oil, propolis, squalene, squalane, soy lecithin, soybean oil, sunflower oil, a triglyceride, or vitamin E.

29. The composition of claim 28, wherein the triglyceride is capric triglyceride, caprylic triglyceride, a caprylic and capric triglyceride, a triglyceride ester, or myristic acid triglycerin.

30. The composition of any one of claims 19 to 29, wherein the cationic lipid is 1,2-dioleoyloxy-3 (trimethylammonium)propane (DOTAP), 3β -[N—(N',N'-dimethylaminoethane) carbamoyl]cholesterol (DC Cholesterol), dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl 3-trimethylammoniumpropane(DMTAP),dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), N-[1-(2,3-dioleoyloxy)propyl]N,N,N-trimethylammonium, chloride (DOTMA), N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), and 1,2- dilinoleyloxy-3-dimethylaminopropane (DLinDMA),1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), 306Oi10, tetrakis(8-methylnonyl) 3,3',3'',3'''-(((methylazanediyl) bis(propane-3,1 diyl))bis (azanetriyl))tetrapropionate, 9A1P9, decyl (2-(dioctylammonio)ethyl) phosphate; A2-Iso5-2DC18, ethyl 5,5-di((Z)-heptadec-8-en-1-yl)-1-(3-(pyrrolidin-1-yl)propyl)-2,5-dihydro-1H-imidazole-2-carboxylate; ALC-0315, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-

hexyldecanoate); ALC-0159, 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide; β -sitosterol, (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5R)-5-ethyl-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; BAME-O16B, bis(2-(dodecylsulfanyl)ethyl) 3,3'-((3-methyl-9-oxo-10-oxa-13,14-dithia-3,6-diazahexacosyl)azanediyl)dipropionate; BHEM-Cholesterol, 2-((((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)amino)-N,N-bis(2-hydroxyethyl)-N-methylethan-1-aminium bromide; cKK-E12, 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione; DC-Cholesterol, 3 β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol; DLin-MC3-DMA, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino) butanoate; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOSPA, 2,3-dioleyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; ePC, ethylphosphatidylcholine; FTT5, hexa(octan-3-yl) 9,9',9'',9''',9''''-(((benzene-1,3,5-tricarbonyl)tris(azanediyl)) tris (propane-3,1-diyl)) tris(azanetriyl))hexanonanoate; Lipid H (SM-102), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino) octanoate; OF-Deg-Lin, (((3,6-dioxopiperazine-2,5-diyl)bis(butane-4, 1-diyl))bis(azanetriyl))tetrakis(ethane-2,1-diyl) (9Z,9'Z,9''Z,9'''Z,12Z,12'Z,12''Z,12'''Z)-tetrakis (octadeca-9,12-dienoate); PEG2000-DMG, (R)-2,3-bis(myristoyloxy)propyl-1-(methoxy poly(ethylene glycol)2000) carbamate; TT3, or N1,N3,N5-tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide.

31. The composition of any one of claims 19 to 30, wherein the lipid carrier comprises a hydrophobic core.

32. The composition of any one of claims 19 to 31, wherein the lipid carrier comprises an inorganic particle.

33. The composition of claim 32, wherein the inorganic particle is within the hydrophobic core.

34. The composition of claim 32 or claim 33, wherein the inorganic particle comprises a metal.

35. The composition of claim 34, wherein the metal comprises a metal salt, a metal oxide, a metal hydroxide, or a metal phosphate.

36. The composition of claim 35, wherein the metal oxide comprises aluminum oxide, aluminum oxyhydroxide, iron oxide, titanium dioxide, or silicon dioxide.

37. The composition of any one of claims 19 to 36, wherein the hydrophobic surfactant is sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, or sorbitan trioleate.

38. The composition of any one of claims 19 to 37, wherein the hydrophilic surfactant is a polysorbate.

39. A composition comprising:

a lipid carrier, wherein the lipid carrier comprises:

liquid oil; and

surfactants, wherein the surfactants comprise:

a cationic lipid;

a hydrophilic surfactant; and

a hydrophobic surfactant; and

at least one nucleic acid, wherein the nucleic acid comprises a sequence encoding for a S2 protein region, optionally a stem helix region, of SARS-CoV-2 spike protein antigen or functional variant thereof.

40. The composition of claim 39, wherein the SARS-CoV-2 spike protein antigen is derived from an alpha variant of SARS-CoV-2, a beta variant of SARS-CoV-2, a delta variant of SARS-CoV-2, a gamma variant of SARS-CoV-2, a mu variant of SARS-CoV-2, or an omicron variant of SARS-CoV-2.

41. The composition of claim 40, wherein the stem helix of the SARS-CoV-2 spike protein antigen comprises an amino acid sequence at least 85% identical to SEQ ID NO: 18 or at least 85% identical to SEQ ID NO: 19.

42. The composition of any one of claims 39 to 41, wherein the nucleic acid is in complex with the lipid carrier.

43. The composition of any one of claims 39 to 41, wherein, the nucleic acid further encodes for an RNA polymerase.

44. The composition of claim 43, wherein the RNA polymerase is a Venezuelan equine encephalitis virus (VEEV) RNA polymerase.

45. The composition of claim 43, wherein is the nucleic acid encoding for the RNA polymerase comprises the nucleic acid sequence of SEQ ID NO: 20.

46. The composition of any one of claims 39 to 45, wherein the liquid oil is α -tocopherol, coconut oil, grapeseed oil, lauroyl polyoxylglyceride, mineral oil, monoacylglycerol, palmkernel oil, olive oil, paraffin oil, peanut oil, propolis, squalene, squalane, soy lecithin, soybean oil,

sunflower oil, a triglyceride, or vitamin E.

47. The composition of claim 30, wherein the triglyceride is capric triglyceride, caprylic triglyceride, a caprylic and capric triglyceride, a triglyceride ester, or myristic acid triglycerin.

48. The composition of any one of claims 39 to 47, wherein the cationic lipid is 1,2-dioleoyloxy-3 (trimethylammonium)propane (DOTAP), 3β -[N— (N',N'-dimethylaminoethane) carbamoyl]cholesterol (DC Cholesterol), dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl 3-trimethylammoniumpropane(DMTAP),dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), N-[1-(2,3-dioleoyloxy)propyl]N,N,N-trimethylammonium, chloride (DOTMA), N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), and 1,2- dilinoleyloxy-3-dimethylaminopropane (DLinDMA),1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), 306Oi10, tetrakis(8-methylnonyl) 3,3',3'',3'''-(((methylazanediy) bis(propane-3,1 diyl))bis (azanetriyl))tetrapropionate, 9A1P9, decyl (2-(dioctylammonio)ethyl) phosphate; A2-Iso5-2DC18, ethyl 5,5-di((Z)-heptadec-8-en-1-yl)-1-(3-(pyrrolidin-1-yl)propyl)-2,5-dihydro-1H-imidazole-2-carboxylate; ALC-0315, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); ALC-0159, 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide; β -sitosterol, (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5R)-5-ethyl-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; BAME-O16B, bis(2-(dodecylsulfanyl)ethyl) 3,3'-((3-methyl-9-oxo-10-oxa-13,14-dithia-3,6-diazahexacosyl)azanediyl)dipropionate; BHEM-Cholesterol, 2-((((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)amino)-N,N-bis(2-hydroxyethyl)-N-methylethan-1-aminium bromide; cKK-E12, 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione; DC-Cholesterol, 3β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol; DLin-MC3-DMA, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino) butanoate; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOSPA, 2,3-dioleoyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; ePC, ethylphosphatidylcholine; FTT5, hexa(octan-3-yl) 9,9',9'',9''',9''''-(((benzene-1,3,5-tricarbonyl)tris(azanediyl)) tris (propane-3,1-diyl)) tris(azanetriyl))hexanonanoate; Lipid H (SM-102), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-

6-(undecyloxy)hexyl)amino) octanoate; OF-Deg-Lin, (((3,6-dioxopiperazine-2,5-diyl)bis(butane-4, 1-diyl))bis(azanetriyl))tetrakis(ethane-2,1-diyl) (9Z,9'Z,9''Z,9'''Z,12Z,12'Z,12''Z,12'''Z)-tetrakis (octadeca-9,12-dienoate); PEG2000-DMG, (R)-2,3-bis(myristoyloxy)propyl-1-(methoxy poly(ethylene glycol)2000) carbamate; TT3, or N1,N3,N5-tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide.

49. The composition of any one of claims 39 to 48, wherein the lipid carrier comprises a hydrophobic core.

50. The composition of any one of claims 39 to 49, wherein the lipid carrier comprises an inorganic particle.

51. The composition of claim 50, wherein the inorganic particle is within the hydrophobic core.

52. The composition of claim 50 or claim 51, wherein the inorganic particle comprises a metal.

53. The composition of claim 52, wherein the metal comprises a metal salt, a metal oxide, a metal hydroxide, or a metal phosphate.

54. The composition of claim 53, wherein the metal oxide comprises aluminum oxide, aluminum oxyhydroxide, iron oxide, titanium dioxide, or silicon dioxide.

55. The composition of any one of claims 39 to 54, wherein the hydrophobic surfactant is sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, or sorbitan trioleate.

56. The composition of any one of claims 39 to 55, wherein the hydrophilic surfactant is a polysorbate.

57. A composition comprising:

a lipid carrier, wherein the lipid carrier comprises:

liquid oil;

an inorganic nanoparticle, wherein the inorganic nanoparticle comprises iron oxide present in an amount of about 0.2 mg/ml 12 nm iron oxide; and

surfactants, wherein the surfactants comprise a cationic lipid; and

at least one nucleic acid, wherein the nucleic acid comprises a sequence encoding for a SARS-CoV-2 spike protein antigen sequence or functional variant thereof.

58. The composition of claim 57, wherein the lipid carrier further comprises:

about 30 mg/mL DOTAP chloride;

about 37.5 mg/mL squalene;

about 37 mg/ml sorbitan monostearate;
 about 37 mg/ml polysorbate 80; and
 about 10 mM sodium citrate.

59. The composition of claim 57 or claim 58, wherein the lipid carrier comprises a hydrophobic core.

60. The composition of any one of claims 57 to 59, wherein the iron oxide comprises oleic acid-coated iron oxide.

61. The composition of claim 60, wherein the oleic acid-coated iron oxide nanoparticles are within the hydrophobic core.

62. The composition of any one of claims 57 to 61, wherein the liquid oil is α -tocopherol, coconut oil, grapeseed oil, lauroyl polyoxylglyceride, mineral oil, monoacylglycerol, palmkernel oil, olive oil, paraffin oil, peanut oil, propolis, squalene, squalane, soy lecithin, soybean oil, sunflower oil, a triglyceride, or vitamin E.

63. The composition of claim 62, wherein the triglyceride is capric triglyceride, caprylic triglyceride, a caprylic and capric triglyceride, a triglyceride ester, or myristic acid triglycerin.

64. The composition of any one of claims 57 to 63, wherein the cationic lipid is 1,2-dioleoyloxy-3 (trimethylammonium)propane (DOTAP), 3 β -[N— (N',N'-dimethylaminoethane) carbamoyl]cholesterol (DC Cholesterol), dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl 3-trimethylammoniumpropane(DMTAP),dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP), distearoyltrimethylammonium propane (DSTAP), N-[1-(2,3-dioleoyloxy)propyl]N,N,N-trimethylammonium, chloride (DOTMA), N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), and 1,2- dilinoleyloxy-3-dimethylaminopropane (DLinDMA),1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), 306Oi10, tetrakis(8-methylnonyl) 3,3',3'',3'''-(((methylazanediyl) bis(propane-3,1 diyl))bis (azanetriyl))tetrapropionate, 9A1P9, decyl (2-(dioctylammonio)ethyl) phosphate; A2-Iso5-2DC18, ethyl 5,5-di((Z)-heptadec-8-en-1-yl)-1-(3-(pyrrolidin-1-yl)propyl)-2,5-dihydro-1H-imidazole-2-carboxylate; ALC-0315, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); ALC-0159, 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide; β -sitosterol, (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5R)-5-ethyl-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; BAME-O16B, bis(2-(dodecyldisulfanyl)ethyl) 3,3'-((3-methyl-9-oxo-10-oxa-13,14-dithia-

3,6-diazaheacosyl)azanediyldipropionate; BHEM-Cholesterol, 2-(((3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)amino)-N,N-bis(2-hydroxyethyl)-N-methylethan-1-aminium bromide; cKK-E12, 3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione; DC-Cholesterol, 3 β -[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol; DLin-MC3-DMA, (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino) butanoate; DOPE, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; DOSPA, 2,3-dioleoyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; ePC, ethylphosphatidylcholine; FTT5, hexa(octan-3-yl) 9,9',9'',9''',9''''-(((benzene-1,3,5-tricarbonyl)tris(azanediylyl)) tris (propane-3,1-diyl)) tris(azanetriyl))hexanonanoate; Lipid H (SM-102), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino) octanoate; OF-Deg-Lin, (((3,6-dioxopiperazine-2,5-diyl)bis(butane-4, 1-diyl))bis(azanetriyl))tetrakis(ethane-2,1-diyl) (9Z,9'Z,9''Z,9'''Z,12Z,12'Z,12''Z,12'''Z)-tetrakis(octadeca-9,12-dienoate); PEG2000-DMG, (R)-2,3-bis(myristoyloxy)propyl-1-(methoxy poly(ethylene glycol)2000) carbamate; TT3, or N1,N3,N5-tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide.

65. The composition of any one of claims 57 to 64, wherein the nucleic acid is in complex with the lipid carrier.

66. The composition of any one of claims 57 to 65, wherein the SARS-CoV-2 spike protein antigen is derived from an alpha variant of SARS-CoV-2, a beta variant of SARS-CoV-2, a delta variant of SARS-CoV-2, a gamma variant of SARS-CoV-2, a mu variant of SARS-CoV-2, or an omicron variant of SARS-CoV-2.

67. The composition of any one of claims 57 to 66, wherein the SARS-CoV-2 spike protein is derived from a variant of SARS-CoV-2 comprising an amino acid substitution of D614G.

68. The composition of any one of claims 57 to 67, wherein the nucleic acid comprises a sequence as set forth in one of SEQ ID NOS: 1-8.

69. The composition of any one of claims 57 to 68, wherein the SARS-CoV-2 spike protein antigen sequence or functional variant thereof has an amino acid sequence as set forth in one of SEQ ID NOS: 9-16.

70. The composition of any one of claims 57 to 69, wherein the nucleic acid further encodes for an RNA polymerase.

71. The composition of claim 70, wherein the RNA polymerase is a Venezuelan equine encephalitis virus (VEEV) RNA polymerase.

72. The composition of claim 70, wherein is the nucleic acid encoding for the RNA polymerase comprises the nucleic acid sequence of SEQ ID NO: 20.

73. A composition comprising:

a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising:

about 30 mg/mL DOTAP chloride

about 37.5 mg/ml squalene;

about 37 mg/ml sorbitan monostearate;

about 37 mg/ml polysorbate 80;

about 10 mM sodium citrate; and

about 0.2 mg Fe/ml 12 nm oleic acid-coated iron oxide nanoparticles; and

b) at least one nucleic acid, wherein the at least one nucleic acid comprises a sequence encoding for a SARS-CoV-2 spike protein antigen sequence or functional variant thereof.

74. The composition of claim 73, further comprising sucrose, optionally, wherein the sucrose is present in an amount of about 50 mg.

75. The composition of claim 73 or claim 74, wherein the nucleic acid is in complex with the lipid carrier.

76. The composition of any one of claims 73 to 75, wherein the SARS-CoV-2 spike protein antigen is derived from an alpha variant of SARS-CoV-2, a beta variant of SARS-CoV-2, a delta variant of SARS-CoV-2, a gamma variant of SARS-CoV-2, a mu variant of SARS-CoV-2, or an omicron variant of SARS-CoV-2.

77. The composition of any one of claims 73 to 76, wherein the SARS-CoV-2 spike protein is derived from a variant of SARS-CoV-2 comprising an amino acid substitution of D614G.

78. The composition of any one of claims 73 to 77, wherein the nucleic acid comprises a sequence as set forth in one of SEQ ID NOS: 1-8.

79. The composition of any one of claims 73 to 78, wherein the SARS-CoV-2 spike protein antigen sequence or functional variant thereof has an amino acid sequence as set forth in one of SEQ ID NOS: 9-16.

80. The composition of any one of claims 73 to 79, wherein the nucleic acid further encodes for an RNA polymerase.

81. The composition of claim 80, wherein the RNA polymerase is a Venezuelan equine

encephalitis virus (VEEV) RNA polymerase.

82. The composition of claim 80, wherein the nucleic acid encoding for the RNA polymerase comprises the nucleic acid sequence of SEQ ID NO: 20.

83. The composition of any one of claims 73 to 82, wherein the lipid carrier comprises a hydrophobic core.

84. The composition of claim 83, wherein the oleic acid-coated iron oxide nanoparticles are within the hydrophobic core.

85. A composition comprising:

a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising:

DOTAP chloride present in an amount of about 0.75 mg;

squalene present in an amount of about 0.94 mg;

sorbitan monostearate present in an amount of about 0.93 mg;

polysorbate 80 present in an amount of about 0.93 mg;

citric acid monohydrate present in an amount of about 1.05 mg; and

oleic acid-coated iron oxide nanoparticles present in an amount of about 0.005 mg; and

b) at least one nucleic acid, wherein the at least one nucleic acid comprises a sequence encoding for a SARS-CoV-2 spike protein antigen sequence or functional variant thereof.

86. The composition of claim 85, wherein the at least one nucleic acid sequence is present in an amount of up to about 100 micrograms (μg).

87. The composition of claim 85, wherein the at least one nucleic acid sequence is present in an amount of up to about 25 μg .

88. The composition of claim 85, further comprising sucrose, optionally, wherein the sucrose is present in an amount of about 50 milligrams (mg).

89. The composition of any one of claims 85 to 88, wherein the nucleic acid is in complex with the lipid carrier.

90. The composition of any one of claims 85 to 89, wherein the SARS-CoV-2 spike protein antigen is derived from an alpha variant of SARS-CoV-2, a beta variant of SARS-CoV-2, a delta variant of SARS-CoV-2, a gamma variant of SARS-CoV-2, a mu variant of SARS-CoV-2, or an omicron variant of SARS-CoV-2.

91. The composition of any one of claims 85 to 90, wherein the SARS-CoV-2 spike protein is derived from a variant of SARS-CoV-2 comprising an amino acid substitution of D614G.

92. The composition of any one of claims 85 to 91, wherein the nucleic acid comprises a sequence as set forth in one of SEQ ID NOS: 1-8.

93. The composition of any one of claims 85 to 92, wherein the SARS-CoV-2 spike protein antigen sequence or functional variant thereof has an amino acid sequence as set forth in one of SEQ ID NOS: 9-16.

94. The composition of any one of claims 85 to 93, wherein the nucleic acid further encodes for an RNA polymerase.

95. The composition of claim 94, wherein the RNA polymerase is a Venezuelan equine encephalitis virus (VEEV) RNA polymerase.

96. The composition of claim 94, wherein is the nucleic acid encoding for the RNA polymerase comprises the nucleic acid sequence of SEQ ID NO: 20.

97. The composition of any one of claims 85 to 96, wherein the lipid carrier comprises a hydrophobic core.

98. The composition of claim 97, wherein the oleic acid-coated iron oxide nanoparticles are within the hydrophobic core.

99. The composition of any one of claims 1 to 98, wherein the composition is lyophilized.

100. A suspension comprising the composition of any one of claims 1 to 99.

101. A pharmaceutical composition comprising the composition of any one of claims 1 to 99, and a pharmaceutically acceptable excipient.

102. A method of generating an immune response in a subject, the method comprising:
administering to a subject the composition of any one of claims 1 to 99, thereby generating an immune response to an antigen.

103. The method of claim 102, comprising, wherein the composition is administered to the subject by two doses.

104. The method of claim 102, wherein the second dose is administered at about 28 days after the first dose.

105. The method of claim 102, further comprising administering a third dose of the composition to said subject.

106. The method of any one of claims 102 to 105, wherein 5 µg of the composition is administered to the subject.

107. The method of any one of claims 102 to 105, wherein 10 µg of the composition is administered to said subject.

108. The method of any one of claims 102 to 105, wherein 25 µg of the composition is administered to said subject.

109. The method of any one of claims 102 to 108, wherein the composition is administered intramuscularly or intranasally.

110. The method of any one of claims 102 to 109, wherein the subject is a human.

111. The method of any one of claims 102 to 110, wherein the subject has or is suspected of having a viral infection.

112. The method of claim 111, wherein the viral infection is a coronavirus infection.

113. The method of claim 112, wherein the coronavirus infection is caused by a SARS-CoV-2 virus or a variant thereof.

114. The method of any one of claims 102 to 113, wherein the antigen is a SARS-CoV-2 spike protein or a fragment thereof.

115. The method of any one of claims 102 to 114, wherein the immune response comprises increasing the titer of neutralizing antibodies to the antigen as compared to a subject that has not been administered the composition.

116. The method of any one of claims 102 to 115, wherein the immune response comprises increasing the amount of CD4+ and/or CD8+ positive T-cells as compared to a subject that has not been administered the composition.

117. The method of any one of claims 102 to 116, wherein the subject is immunocompromised or immunosuppressed.

118. A method of augmenting an immune response in a subject, the method comprising:
administering to a subject the composition of any one of claims 1 to 99, thereby augmenting an immune response to an antigen.

119. A method of treating a coronavirus infection, the method comprising: administering to a subject the composition of any one of claims 1 to 99, thereby treating the coronavirus infection.

120. The method of claim 119, wherein the coronavirus infection is caused by a SARS-CoV-2 virus or a variant thereof.

121. The method of claim 119 or claim 120, wherein the subject is a human.

122. The method of any one of claims 119 to 121, wherein the subject is immunocompromised or immunosuppressed.

123. The method of any one of claims 119 to 122, wherein the composition is administered intramuscularly or intranasally.

124. A kit comprising a composition comprising:

- a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids; and
- b) at least one nucleic acid sequence, wherein the nucleic acid sequence comprises a sequence capable of expressing an antigen, wherein the antigen is a SARS-CoV-2 spike protein.

125. The kit of claim 124, further comprising one or more surfactants.

126. A dried composition comprising:

- a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, one or more inorganic nanoparticles and one or more lipids;
- b) at least one nucleic acid sequence, which comprises a sequence which encodes a sequence capable of expressing an antigen, wherein the antigen is a SARS-CoV-2 spike protein; and
- c) at least one cryoprotectant.

127. A pharmaceutical composition comprising the composition of claim 126 reconstituted in a suitable diluent; and a pharmaceutically acceptable carrier.

128. A dried composition comprising:

- a) a lipid carrier, wherein the lipid carrier is a nanoemulsion comprising a hydrophobic core, and one or more lipids;
- b) at least one nucleic acid that comprises a sequence which encodes a sequence capable of expressing an antigen, optionally wherein the antigen is a SARS-CoV-2 spike protein or a functional variant thereof; and
- c) at least one sugar present in amount of (i) at least about 50% by weight of the dried composition, or (ii) present in an amount of least about 50 mg.

129. The composition of claim 128, wherein the composition is lyophilized.

130. The composition of claim 128, wherein the composition is thermally stable at about 25 degrees Celsius.

131. The composition of claim 128, wherein the composition is thermally stable at about 45 degrees Celsius.

132. The composition of claim 128, wherein the composition is thermally stable at about -20 degrees Celsius.

133. The composition of claim 128, wherein the composition is thermally stable at about 2 degrees Celsius to about 8 degrees Celsius.

134. The composition of claim 128, wherein the composition is thermally stable for at least 1 week, at least 2 weeks, and/or at least 1 month.

135. The composition of claim 128, wherein the hydrophobic core comprises an oil.

136. The composition of claim 135, wherein the oil comprises at least one of α -tocopherol, lauroyl polyoxylglyceride, monoacylglycerol, propolis, squalene, mineral oil, grapeseed oil, olive oil, paraffin oil, peanut oil, soybean oil, sunflower oil, soy lecithin, triglyceride, vitamin E, a caprylic/capric triglyceride, a triglyceride ester of saturated coconut/palmkernel oil derived caprylic and capric fatty acids and plant derived glycerol, dihydroisqualene (DHIS), farnesene and squalane.

137. The composition of claim 128, wherein the one or more lipids is selected from the group consisting of cationic lipids, anionic lipids, neutral lipids, and any combinations thereof.

138. The composition of claim 137, wherein the one or more lipids comprises a cationic lipid.

139. The composition of claim 138, wherein the cationic lipid is selected from the group consisting of 1,2-dioleoyloxy-3-(trimethylammonium)propane (DOTAP); 3β -[N-(N',N'-dimethylaminoethane)-carbonyl]cholesterol (DC Cholesterol); dimethyldioctadecylammonium (DDA); 1,2-dimyristoyl-3-trimethylammoniumpropane (DMTAP), dipalmitoyl(C16:0)trimethyl ammonium propane (DPTAP); distearoyltrimethylammonium propane (DSTAP); N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA); N,N-dioleoyl-N,N-dimethylammonium chloride (DODAC); 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC); 1,2-dioleoyl-3-dimethylammonium-propane (DODAP); and 1,2-dilinoleyloxy-3-dimethylaminopropane (DLin-DMA); 1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl) (2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediyl)bis(dodecan-2-ol) (C12-200), 1,2-dioleoyl-*sn*-glycero-3-phosphoethanolamine (DOPE); *N*-decyl-*N,N*-dimethyldecyl-1-aminium bromide (DDAB); 2,3-dioleoyloxy-*N*-[2-(sperminecarboxamido)ethyl]-*N,N*-dimethyl-1-propanaminium trifluoroacetate (DOSPA); ethylphosphatidylcholine (ePC); and any combinations thereof.

140. The composition of claim 128, wherein the lipid carrier comprises at least one surfactant.

141. The composition of claim 140, wherein the at least one surfactant is selected from the group consisting of a hydrophobic surfactant, a hydrophilic surfactant, and any combinations thereof.

142. The composition of claim 141, wherein the hydrophobic surfactant comprises a sorbitan ester selected from the group consisting of sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, and sorbitan trioleate; and the hydrophilic surfactant comprises a polysorbate.

143. The composition of claim 128, wherein the lipid carrier has a z-average hydrodynamic diameter ranging from about 40 nm to about 150 nm, with an average polydispersity index ranging from about 0.1 to about 0.4.

144. The composition of claim 128, wherein the one or more nucleic acid is a DNA.

145. The composition of claim 128, wherein the one or more nucleic acid is a RNA.

146. The composition of claim 145, wherein the RNA is a self-replicating RNA.

147. The composition of claim 128, wherein the one or more nucleic acid is incorporated or complexed with the lipid carrier to form a lipid carrier-nucleic acid complex.

148. The composition of claim 147, wherein the lipid carrier-nucleic acid complex is formed via non-covalent interactions or via reversible covalent interactions.

149. The composition of claim 128, wherein a molar ratio of the lipid carrier to the one or more nucleic acids, characterized by the nitrogen-to-phosphate (N:P) molar ratio, ranges from about 1:1 to about 150:1.

150. The composition of any one of claims 128 to 149, wherein the at least one sugar is selected from the group consisting of sucrose, maltose, trehalose, mannitol, glucose, and any combinations thereof.

151. The composition of any one of claims 128 to 149, wherein the at least one sugar is present in an amount of at least about 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 or more mg.

152. The composition of claim 128, wherein the at least one sugar is present in an amount of 50 mg to 250 mg.

153. The composition of claim 128, wherein the at least one sugar is present in an amount of at least about 250 mg.

154. The composition of any one of claims 128 to 149, wherein the sugar is present in amount of the composition by weight of at least 50, 55, 60, 65, 70, 75, 80, 85, 90, 95% or more.

155. The composition of claim 85, wherein the sugar is present in amount of the composition by weight of 80 to 98%, optionally 94 to 96%.

156. The composition of claim 128, wherein the sugar is present in amount of the composition by weight of about 95%.

157. The composition of any one of claims 128 to 156, wherein the at least one sugar comprises sucrose.

158. The composition of any one of claims 128 to 156, wherein the hydrophobic core comprises one or more inorganic nanoparticles.

159. The composition of claim 158, wherein the one or more inorganic nanoparticles is selected from the group consisting of a metal salt, metal oxide, metal hydroxide, metal phosphate, and any combinations thereof.

160. The composition of any one of claims 128 to 159, wherein the at least one nucleic acid comprises a sequence at least 85% identical to SEQ ID NOS: 1-8.

161. A composition for prophylaxis of SARS-CoV-2 comprising:

- a) a sorbitan fatty acid ester;
- b) an ethoxylated sorbitan ester;
- c) a cationic lipid;
- d) an immune stimulant; and
- e) at least one RNA encoding for a SARS-CoV-2 spike protein antigen or

functional fragment thereof.

162. A composition, wherein the composition comprises:

- a first nucleic acid comprising a sequence encoding for an RNA-dependent RNA polymerase; and
- a second nucleic acid comprising a sequence encoding for a SARS-CoV-2 omicron antigen sequence.

163. The composition of claim 162, wherein the first nucleic acid and second nucleic acid are present on a shared nucleic acid.

164. The composition of claim 162, wherein the first nucleic acid and second nucleic acid are present on separate nucleic acids.

165. The composition of claim 162, wherein the RNA-dependent RNA polymerase comprises a VEEV RNA polymerase.

166. The composition of any one of claims 162 to 165, further comprising a nanoparticle carrier system.

167. The composition of claim 166, wherein the nanoparticle carrier system comprises a cationic lipid and a hydrophobic core.

168. The composition of claim 167, wherein the hydrophobic core comprises an inorganic nanoparticle.

169. The composition of any one of claims 162 to 168, wherein the first nucleic acid and/or second nucleic acid comprises RNA.

170. The composition of any one of claims 162 to 168, wherein the second nucleic acid comprises a sequence at least 85% identical to SEQ ID NO: 8.

171. A composition, wherein the composition comprises:
a first nucleic acid comprising a sequence encoding for an RNA-dependent RNA polymerase; and
a second nucleic acid comprising a sequence encoding for a SARS-CoV-2 spike S2 sequence region, optionally a stem helix region.

172. The composition of claim 171, wherein the first nucleic acid and second nucleic acid are present on a shared nucleic acid.

173. The composition of claim 171, wherein the first nucleic acid and second nucleic acid are present on separate nucleic acids.

174. The composition of claim 171, wherein the RNA-dependent RNA polymerase comprises a VEEV RNA polymerase.

175. The composition of any one of claims 171 to 174, further comprising a nanoparticle carrier system.


176. The composition of claim 175, wherein the nanoparticle carrier system comprises a cationic lipid and a hydrophobic core.


177. The composition of claim 176, wherein the hydrophobic core comprises an inorganic nanoparticle.



178. The composition of any one of claims 171 to 177, wherein the first nucleic acid and/or second nucleic acid comprises RNA.


179. The composition of any one of claims 171 to 177, wherein the second nucleic acid comprises a sequence at least 85% identical to SEQ ID NO: 18.


180. The composition of any one of claims 171 to 177, wherein the second nucleic acid comprises a sequence at least 85% identical to SEQ ID NO: 19.


**FIG. 1**


**FIG. 2**


*FIG. 3A**FIG. 3B*



*FIG. 3C*

*FIG. 4A*

*FIG. 4B*

*FIG. 5A*

*FIG. 5B*

*FIG. 6A**FIG. 6B*

10/15




FIG. 7A











FIG. 7B


*FIG. 7C**FIG. 7D*

12/15

*FIG. 7E**FIG. 7F*

*FIG. 8*

*FIG. 9A**FIG. 9B*

*FIG. 10*

SEQ ID NO: 1: A.1 spike

Native

sp	S1	S2	TM	CD
B.1 spike				
sp	*D614G		TM	CD

SEQ ID NO: 2: A.1 pre-fusion stabilized spike

Pre-Fusion

sp	S1	S2 **KV995PP	TM	CD
B.1 pre-fusion stabilized spike				
sp	*D614G **KV995PP		TM	CD
SEQ ID NO: 5: B.1.1.7 pre-fusion stabilized spike				
sp	*A570D *N501Y *D614G *P681H *T716I	*S982A **KV995PP	TM	CD
SEQ ID NO: 4: B.1.351 pre-fusion stabilized spike				
sp	*L18F *D80A *D215G Δ242-244 *R246I *K417N *E484K *N501Y *D614G *A701V	**KV995PP	TM	CD

FIG. 1